2002

AIDS Healthcare Foundation Awards 2002 'Heart of Stone' to British Pharmaceutical Giant GlaxoSmithKline: PRNewswire - December 31, 2002; LOS ANGELES, Dec. 31 /PRNewswire/ -- The US largest AIDS organization today awarded its 2002 Heart of Stone to British pharmaceutical giant GlaxoSmithKline for putting profit above human decency while 8,500 die every day of AIDS. AHF -- which provides medical care to uninsured AIDS patients from California to
Healthy Love or Destructive Obsession? Author of New Book Honored as a 2002 'Visionary': PRNewswire - December 28, 2002; CHICAGO, Dec. 28 /PRNewswire/ -- John D. Moore, a 32-year old therapist and professor of health sciences at American Public University announced today that Liberation Publications has identified him as a 2002 Visionary for his work in the social services field as it relates to HIV/AIDS. Moore is the author of a newly r
HIV/AIDS Specialist Regulation Approved by State of California: Landmark Bill Mandating HMO Access to HIV/AIDS Specialists to Take Effect Mid-January: PRNewswire - December 24, 2002; -- AB 2168 (Gallegos, D, Los Angeles, 2000) Requires Standing Referrals, State, Community & Medical Groups Worked Together to Craft Definition of Specialist LOS ANGELES, Dec. 24 /PRNewswire/ -- Groundbreaking legislation ordering California HMOs to provide standing referrals to AIDS specialists for patients infecte
Showtime Networks Presents WHAT'S GOING ON? : New Documentary Family Series From RCN Entertainment, in Association with The United Nations, to Focus on Issues Through a Child's Eyes: PRNewswire - December 23, 2002; -- Celebrity-hosted 10-Part Series of Specials to Begin Airing On SHOWTIME January 19, 2003 -- Danny Glover to Host Premiere Episode on HIV/AIDS Epidemic: Angelina Jolie, Jeff Bridges, Laurence Fishburne & Michael Douglas Serve As Episode Hosts -- Nicole Silver and Orly Wiseman to Executive Produce Series NEW YORK,
Roche's COBAS Ampliscreen System Tests Receive FDA Approval -- FDA Approves the COBAS AmpliScreen(TM) HCV Test, Version 2.0 and the COBAS AmpliScreen(TM) HIV-1 Test, Version 1.5: PRNewswire - December 23, 2002; INDIANAPOLIS, Dec. 23 /PRNewswire/ -- Following recent news of the U.S. Food and Drug Administration s ( FDA ) clearance of Roche Diagnostics COBAS AmpliScreen System for the blood banking industry, Roche is now pleased to announce FDA approval of the first two tests which are designed for use with this System -- the C
AIDS Healthcare Foundation Urges Stepped Up Involvement by US in Global AIDS Fight: Nation's Largest AIDS Organization Expresses Optimism About Likely Senate Majority Leader: PRNewswire - December 21, 2002; AIDS Healthcare Foundation Praises Physician/Senator s Medical Relief Work in Africa, Recognizes Frist s Leadership Sponsoring First US Global AIDS Funding Legislation LOS ANGELES, Dec. 21 /PRNewswire/ -- AIDS Healthcare Foundation, (AHF) the nation s largest AIDS organization which operates free AIDS clinics in the
Bristol-Myers Squibb Submits New Drug Application for Investigational Protease Inhibitior Atazanavir for Treatment of HIV Infection: PRNewswire - December 20, 2002; PRINCETON, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for atazanavir, an investigational protease inhibitor under development for the treatment of HIV/AIDS in combination
Vertex Pharmaceuticals Announces Submission of NDA/MAA Filings in U.S. And Europe for GW433908 for Treatment of HIV Infection: PRNewswire - December 20, 2002; CAMBRIDGE, Mass., Dec. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that GlaxoSmithKline (GSK) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for marketing approval of GW433908 (also known as 908 or VX-175), an investigation
Additional Artists Answer Nelson Mandela's Call to Perform at Historic Human Rights Concert: Dave Stewart, Yusuf Islam, Bono, Queen, Macy Gray, Nelly Furtado, Coldplay, Shaggy, Eve, Ludacris and More Scheduled: PRNewswire - December 19, 2002; Nelson Mandela to Host Extraordinary Event: People s Concert to Take Place Simultaneously at South Africa s Green Point Stadium in Conjunction With Concert at Robben Island NEW YORK, Dec. 19 /PRNewswire/ -- Some of the world s most celebrated recording artists have come together to answer Nelson Mandela s SOS to eradic
Mental Health, HIV Patients Oppose Plan Being Considered by Governor Hodges To Cut Access to Medicaid Drugs: Patient - Physician Relationship Threatened by State Action: PRNewswire - December 19, 2002; COLUMBIA, S.C., Dec. 19 /PRNewswire/ -- It s Christmas time at the State Capital in Columbia, but several South Carolina patient groups are not in a holiday mood. A new state Medicaid drug plan -- being considered by outgoing Governor Hodges -- has South Carolina patient advocates very concerned. The prescription drug
Nation's Largest AIDS Organization Files for Preliminary Injunction Against Glaxo in AZT Patent Piracy Lawsuit: AHF's Anti-Trust Complaint Seeks to Overturn Glaxo Patent on AZT, Combivir & Trizivir AHF Cites Fraud During Patent Process as Reason to Invalidate GSK's Patents: PRNewswire - December 19, 2002; LOS ANGELES, Dec. 19 /PRNewswire/ -- The largest AIDS organization in the United States today announced that it has filed a motion for a Preliminary Injunction against GlaxoSmithKline (GSK) and related companies in its federal anti-trust complaint against the British-owned pharmaceutical giant. AIDS Healthcare Foundat
Groundbreaking Celebrity Event Will Help Fight Mother-to-Child HIV Transmission in India: - Richard Gere and Parmeshwar Godrej Bring Indian Celebrities Together to Host Fundraising and Awareness Building Event Benefiting Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - December 19, 2002; MUMBAI, India , Dec. 19 /PRNewswire/ -- In the first-ever event of its kind, leading Indian celebrities will gather in Mumbai, India on December 20 to raise awareness of India s HIV/AIDS epidemic, and to lend their support to efforts to reduce mother-to-child transmission of the virus. The event, A Time for Heroes Ind
The Immune Response Corporation Granted Patent in South Africa for Novel Formulation of REMUNE(R): Vaccine Formulation Using REMUNE(R) and Immunostimulatory Sequence Aimed at Preventive Applications: PRNewswire - December 19, 2002; CARLSBAD, Calif., Dec. 19 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today it has been granted Republic of South Africa Patent Number 2001/8559 entitled HIV Immunogenic Compositions and Methods for its latest vaccine development utilizing a novel formulation of REMUNE(R) in conce
Update on the Manufacture of Investigational HIV Drug FUZEON: First commercial scale production successfully completed: PRNewswire - December 18, 2002; NUTLEY, N.J., and DURHAM, N.C., Dec. 18 /PRNewswire-FirstCall/ -- As part of the stated commitment to keep interested parties informed on the development of their investigational HIV drug, Roche and Trimeris now have enough data from the first three months of experience of the commercial manufacturing process of FUZEON
Primagen's Mitox Tests for Mitochondrial Toxicity Highlighted In Presentations at the HIV-1 DART Conference: PRNewswire - December 18, 2002; AMSTERDAM, Netherlands , Dec. 18 /PRNewswire/ -- Primagen today presented new pre-clinical data on its proprietary Mitox tests at the HIV-1 DART conference in Florida, where frontiers in drug development for antiretroviral therapies are discussed among the worlds best drug developers and scientists. Primagen s Mito
Pharmacor Receives U.S. Patent for anti-HIV Integrase Inhibitor: PRNewswire - December 18, 2002; MONTREAL, Dec. 18 /PRNewswire/ - Pharmacor Inc. has been issued U.S. patent application no. 09/963,329 relating to its antiretroviral program. The small-molecule compounds described in the patent, entitled Aromatic derivatives with HIV integrase inhibitory properties, are novel anti-HIV lead molecules that target a nov
Showtime Networks Greenlights WHAT'S GOING ON?; New Documentary Family Series from RCN Entertainment, in Association with The United Nations, To Focus on Issues Through a Child's Eyes - Celebrity-Hosted 10-Part Series of Specials to Begin Airing On SHOWTIME in January 2003: PRNewswire - December 17, 2002; - Danny Glover to Host Premiere Episode on HIV/AIDS Epidemic - Angelina Jolie, Jeff Bridges, Laurence Fishburne & Michael Douglas Serve As Episode Hosts Nicole Silver and Orly Wiseman to Executive Produce Series NEW YORK, Dec. 17 /PRNewswire/ -- Showtime Networks has reached an agreement with RCN Entertainment to p
Hemispherx Presents New Data from Phase IIB Clinical Trial of RNA-based Ampligen(R) for Structured Treatment Interruption in HIV at DART Conference - Ampligen(R) Study Indicates Prolonged Time Off AIDS Drugs Without Viral Rebound: PRNewswire - December 17, 2002; PHILADELPHIA, Dec. 17 /PRNewswire-FirstCall/ -- Hemispherx Biopharma Inc. (Amex: HEB) today presented new data from a Phase IIB clinical trial of its experimental compound, RNA-based Ampligen(R), on Structured Treatment Interruption (STI) in HIV. Gary Blick, M.D. and Hemispherx s Clinical Director, David Strayer, M.D.,
Congresswoman Hilda Solis to Cut Ribbon as AIDS Healthcare Foundation, Bienestar Human Services Join Forces in Grand Opening of New El Monte HIV/AIDS Healthcare Center: PRNewswire - December 17, 2002; -- Partnership Between Nation s Largest AIDS Organization, Leading Southern California Latino AIDS Social Service Provider Offers Region s HIV/AIDS Patients Improved Access to Quality Care, Services in Greater El Monte EL MONTE, Calif., Dec. 17 /PRNewswire/ -- In an effort to better reach some under-served Los Angeles
Hemispherx Files New US Patent Application on Immune-Based Alternative Treatment to HIV/AIDS: Designed to Protect 'Sanctuary' Regions of the Body Where Virus Hides and Mutates into Drug Resistant Strains.: PRNewswire - December 16, 2002; PHILADELPHIA, Dec. 16 /PRNewswire/ -- Hemispherx Biopharma Inc. (Amex: HEB) has filed a US patent application (US Provisional No. 60/339,390) to develop a new immune-based treatment for HIV/AIDS. All of the approximately 18 existing approved therapies are antiretrovirals, and thus far uniformly directed only at the AID
VaxGen Receives Fast Track Designation from FDA for AIDSVAX B/B and AIDSVAX B/E: Conference Call Scheduled for 11 a.m. Eastern Time, Tuesday, December 17th: PRNewswire - December 16, 2002; BRISBANE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that the U.S. Food and Drug Administration ( FDA ) has designated HIV/AIDS vaccine candidates, AIDSVAX B/B and AIDSVAX B/E (rgp120), Fast Track Products for the prevention of HIV infection. The Fast Track designation will
Press Briefing On Smallpox Vaccination: PRNewswire - December 14, 2002; WASHINGTON, Dec. 14 /PRNewswire/ -- The following is a transcript of remarks by President Bush: GOVERNOR RIDGE: Good afternoon. The President has just outlined the plan to strengthen the security of America by improving significantly our capability to protect Americans in the event of a small pox attack. As he describe
Potential Use of ADVR's Product R to Treat AIDS Is Focus of A&U Magazine Article: International AIDS Publication Profiles Recently Initiated Israeli Clinical Trials: PRNewswire - December 12, 2002; YONKERS, N.Y., Dec. 12 /PRNewswire-FirstCall/ -- Advanced Viral Research Corporation (OTC Bulletin Board: ADVR) today announced that the potential for Company s Product R as treatment for AIDS was the subject of a recent article in A&U Magazine. This global publication is devoted to collecting, archiving, publishin
Joint Statement By the United States and the Republic of Kenya, And Ethiopia: PRNewswire - December 11, 2002; WASHINGTON, Dec. 11 /PRNewswire/ -- At the invitation of President George W. Bush, President Daniel T. Arap Moi of Kenya and Prime Minister Meles Zenawi of Ethiopia met at the White House on Thursday, December 5, 2002. The leaders reaffirmed their strong commitment in the global war on terrorism.
'AmeriCares Action for Africa' Program Calls on Worldwide Support Through Online Donations: PRNewswire - December 11, 2002; NEW CANAAN, Conn., Dec. 11 /PRNewswire/ -- AmeriCares, the international disaster relief agency, today announced the launch of a humanitarian aid and disaster relief effort to deliver medicines and nutritional supplements to hospitals and clinics in southern Africa and Ethiopia . The first in a six- month series of Ame
Results of New PROCRIT(R) Study in Critically Ill Patients Finds Reduction in Red Blood Cell Transfusions: Study Published in The Journal of the American Medical Association: PRNewswire - December 10, 2002; BRIDGEWATER, N.J., Dec. 10 /PRNewswire/ -- Results of a new study published today in The Journal of the American Medical Association found that critically ill patients who received once weekly PROCRIT(R) (Epoetin alfa) were ten percent less likely to receive red blood cell transfusions (RBCs) than patients in the place
Results of New PROCRIT(R) Study in Critically Ill Patients Finds Reduction in Red Blood Cell Transfusions: Study Published in The Journal of the American Medical Association: PRNewswire - December 10, 2002; BRIDGEWATER, N.J., Dec. 10 /PRNewswire/ -- Results of a new study published today in The Journal of the American Medical Association found that critically ill patients who received once weekly PROCRIT(R) (Epoetin alfa) were ten percent less likely to receive red blood cell transfusions (RBCs) than patients in the place
Transgene Signs Vaccine Manufacturing Agreement With International AIDS Vaccine Initiative: PRNewswire - December 10, 2002; STRASBOURG, France , Dec. 10 /PRNewswire-FirstCall/ -- Transgene announced today that it has entered into a collaborative agreement with the International AIDS Vaccine Initiative (IAVI) to manufacture pre-clinical lots of IAVI s constructs for a novel form of vaccine. These constructs, developed at the National Institu
Global Fund Launches Program to Fight AIDS Epidemic in Haiti: Haiti Becomes First Country Outside of Africa to Sign Grant Agreement With Global Fund: PRNewswire - December 9, 2002; WASHINGTON, Dec. 9 /PRNewswire/ -- The Government of Haiti signed this week an agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria, launching a program that will open a pipeline for grants totaling $67 million to the country over the next five years. It is the first such agreement for the Global Fund
Mymetics' Potent In Vitro AIDS Therapy Research Results to Be Presented at 10th Conference on Retroviruses and Opportunistic Infections: PRNewswire - December 9, 2002; ANNAPOLIS, Md., Dec. 9 /PRNewswire-FirstCall/ -- Mymetics Corporation today announced that the Company will present research findings on a new approach to treating HIV and other retroviral diseases at the 10th Conference on Retroviruses and Opportunistic Infections. Mymetics is testing a novel class of anti-retroviral
Mandela SOS Answered By Oprah Winfrey, Archbishop Desmond Tutu And Naomi Campbell: Nelson Mandela Sends Out an SOS on the AIDS Pandemic Across the World Calling for Awareness and Funds to Fight the HIV/AIDS Crisis: PRNewswire - December 6, 2002; Historic Mandela SOS Concert to Take Place on Robben s Island in South Africa on February 2, 2003 CAPE TOWN, South Africa, Dec. 6 /PRNewswire/ -- Nelson Mandela s SOS has been answered. At a launch event today at the National Botanical Gardens in Cape Town, Nelson Mandela, supported by Archbishop Desmond Tutu, Oprah Wi
Reused Medical Devices Pose Health and Safety Risk to Patients Survey Shows Majority of Doctors and Nurses Oppose Practice, Most Consumers Unaware of Practice: PRNewswire - December 5, 2002; MCLEAN, Va., Dec. 5 /PRNewswire/ -- The Center for Patient Advocacy today released a survey of surgeons, operating room nurses and consumers which reveals that health care professionals have grave concerns about the reuse of single use medical devices and their impact on patient health and safety. These devices, such a
Sundance Channel Joins Viacom in Company-Wide AIDS Initiative: Programming Includes Sundance Film Festival Award-Winner 'Silverlake Life: The View from Here': PRNewswire - December 5, 2002; NEW YORK, Dec. 5 /PRNewswire/ -- Sundance Channel joins Viacom in a company-wide initiative to raise awareness about the ongoing global AIDS crisis. As part of its efforts, Sundance Channel will present acclaimed documentary films about living with AIDS on January 13th and 14th. Monte Bramer s Paul Monette: The Brink o
Roche Receives FDA Clearance for the COBAS AmpliScreen System: Significantly Strengthens Roche's Position in the Blood Screening Business: PRNewswire - December 5, 2002; INDIANAPOLIS, Dec. 5 /PRNewswire-FirstCall/ -- Roche Diagnostics (Roche), based in Indianapolis, Ind., is pleased to announce that the U.S. Food and Drug Administration ( FDA ) has granted 510(k) clearance of the company s COBAS AmpliScreen System. The COBAS AmpliScreen System is intended for use in laboratories testin
AZT Scientists Joins GSK Patent Challenge: AIDS Drug's Recognized Co-Inventor, Dr. Hiroaki Mitsuya, Joins AIDS Healthcare Foundation President Michael Weinstein to Denounce Glaxo Patent Piracy: Former NIH Scientist Discovered AZT's Use Against HIV/AIDS: PRNewswire - December 5, 2002; -- Dr. Jerome P. Horwitz, Researcher Who First Discovered AZT in the 1960 s As A Possible Cancer-Fighting Drug Offers Letter Supporting AIDS Group s Effort to Invalidate Patent on AZT, Other HIV Drugs LONDON, Dec. 5 /PRNewswire/ -- The researcher who first demonstrated that the drug AZT (Retrovir(R) or zidovudine) supp
Mymetics Corporation Presents Data on Novel Anti-Retroviral Agents At Scientific Conference: PRNewswire - December 4, 2002; ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) today presented preclinical data at the International Feline Retrovirus Research Symposium demonstrating potent antiviral activity of five candidate compounds against FIV, the feline equivalent of HIV. The Mymetics peptides
FDA Approves Pegasys(R) (peginterferon alfa-2a) in Combination with Copegus(TM) (ribavirin) for the Treatment of Hepatitis C: New Treatment Offers Dosing Regimen Based on Hepatitis C Virus Strain: PRNewswire - December 3, 2002; NUTLEY, N.J., Dec. 3 /PRNewswire/ -- Roche announced today that the U.S. Food and Drug Administration ( FDA ) has approved combination therapy with Pegasys(R) (peginterferon alfa-2a), a pegylated interferon, and Copegus(TM) (ribavirin) for the treatment of adults with chronic hepatitis C who have compensated liver dise
Trinity Companies, Inc. and Freedom from Hunger to Co-Develop Workplace-Based HIV/AIDS Education for Global Industries: PRNewswire - December 3, 2002; CBL Global Corp., Wholly-Owned Subsidiary of Trinity Companies, Inc., To Provide Awareness and Prevention Education Through Major Employers In Mining and Other Global Industries BERKELEY, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Trinity Companies, Inc. ( Trinity Companies ) (OTC: TTYC), a publicly-held Utah Corporation
Genetronics and Chiron Extend Collaborative Agreement to Explore Delivery of HIV Vaccine: PRNewswire - December 3, 2002; SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Genetronics Inc. (Amex: GEB; Toronto) announced today that it has extended a collaborative agreement with Chiron Corporation (Nasdaq: CHIR), Emeryville, CA to conduct additional experiments using Electroporation, Genetronics proprietary technology, to test an HIV DNA vaccine.
World Vision Named Lead Agency in Consortium Awarded $100 Million to Help Prevent Famine in Southern Africa: PRNewswire - December 3, 2002; WASHINGTON, Dec. 3 /PRNewswire/ -- The U.S. government has promised to World Vision and two other humanitarian organizations one of the largest emergency aid grants in history to help address the needs of people starving in southern Africa. The $100 million grant to World Vision, CARE, and Catholic Relief Services will
Mumbai AIDS and Health Education Gets Major Boost: PRNewswire - December 2, 2002; MUMBAI, Dec. 2 /PRNewswire Asia/ -- India s fight against AIDS received additional support today with a sponsorship from global reinsurer Swiss Re, under their Sharing Solutions programme, for an HIV education project in Mumbai. The project will be managed by the NGO PCI (Project Concern International) and locally impl
Healthy Russia 2020 Project Awarded to Consortium Led by Johns Hopkins Center for Communication Programs: Federal Grant of $25 Million Aims to Promote Healthier Russian Lifestyle: PRNewswire - December 2, 2002; BALTIMORE, Dec. 2 /PRNewswire/ -- The U.S. Agency for International Development (USAID) in Russia has awarded a group led by Johns Hopkins Bloomberg School of Public Health Center for Communication Programs (CCP) a $25 million grant to help improve the health of Russians, a population with a sobering health burden that
Romark Laboratories Announces FDA Approval of Drug for Children With Diarrhea Caused by Cryptosporidium and Giardia: First-Ever Cryptosporidium Treatment; First New Giardia Drug in More than 40 Years: PRNewswire - December 2, 2002; TAMPA, Fla., Dec. 2 /PRNewswire/ -- Romark Laboratories announced today that the United States Food and Drug Administration ( FDA ) has approved Alinia(TM) (nitazoxanide) for Oral Suspension for treatment of children with diarrhea caused by Cryptosporidium parvum and Giardia lamblia. Alinia is the first and only drug
Pfizer Inc and The Pfizer Foundation Announce New And Expanded HIV/AIDS Initiatives: Programs Increase Access to Medicines, Build Employee Awareness and Support HIV/AIDS Prevention and Education Organizations: PRNewswire - December 1, 2002; NEW YORK, Dec. 1 /PRNewswire-FirstCall/ -- Pfizer Inc and The Pfizer Foundation today announced new and expanded initiatives designed to address the growing threat to human health posed by the HIV/AIDS pandemic. On the second anniversary of their innovative Diflucan Partnership Program, Pfizer and the South African Min
Baltimore Area Clergy Launch HIV/AIDS Initiative on World AIDS Day: White House HIV/AIDS Policy Director is Guest Speaker: PRNewswire - December 1, 2002; BALTIMORE, Dec. 1 /PRNewswire/ -- Baltimore s interfaith community launched an HIV/AIDS awareness initiative on World AIDS Day, Sunday, December 1 at an ecumenical breakfast held at the New All Saints Roman Catholic Church, 4408 Liberty Heights Avenue. Clergy from across the city came together to pledge their support a
World AIDS Day, 2002: By the President of the United States of America: A Proclamation: PRNewswire - December 1, 2002; WASHINGTON, Dec. 1 /PRNewswire/ -- The following is a proclamation by the President: The HIV/AIDS pandemic has taken the lives of more than 20 million people and is projected to take millions more. On World AIDS Day, countries around the world are united to support the individuals, families, and communities affected by
Larry Kramer: Glaxo Patent on AZT is 'Murder!': Award-Winning Playwright, ACT UP Founder Supports GSK Patent Challenge: Lawsuit Seeks to Invalidate Patent on AZT, Other HIV Drugs.: PRNewswire - November 29, 2002; LOS ANGELES, Nov. 29 /PRNewswire/ -- Larry Kramer, the award-winning playwright and ACT UP (AIDS Coalition to Unleash Power) founder, has lent his powerful voice in support of a lawsuit seeking to invalidate the patent for the life-saving drug AZT (Retrovir(R) or zidovudine), the first AIDS drug. London-based
New Global Online Database of Programs Serving Children Affected By HIV/AIDS Announced by Pendulum Project, Children's AIDS Fund: PRNewswire - November 29, 2002; WASHINGTON, Nov. 29 /PRNewswire/ -- A new online database of programs serving children affected by HIV/AIDS around the world will debut on World AIDS Day December 1, 2002. Database listings will include grassroots programs throughout the world that provide care and support to children affected, infected and orphaned by
SHOWTIME Original Drama 'Behind The Red Door' Starring Kiefer Sutherland, Kyra Sedgwick and Stockard Channing to Air on Sunday, January 12 - SHOWTIME Supports Viacom's HIV/AIDS Initiative With AIDS Themed Film: PRNewswire - November 26, 2002; NEW YORK, Nov. 26 /PRNewswire/ -- SHOWTIME will premiere its latest original picture BEHIND THE RED DOOR on Sunday January 12 at 8:00 PM ET/PT. The film stars Golden Globe(R)-winning actor Kiefer Sutherland ( 24, Lost Boys, Young Guns and the SHOWTIME ORIGINAL PICTURE A Soldier s Sweetheart ), Kyra Sedgwick ( Something
Soft Economy Hardens Hearts for AIDS Crisis: More Americans Blame 'Lack of Money' for Inaction in Fight Against AIDS: PRNewswire - November 26, 2002; SEATTLE, Nov. 26 /PRNewswire/ -- Americans have little interest in helping children overseas orphaned by the AIDS pandemic, according to a national survey commissioned by World Vision, the international Christian humanitarian organization. While 41 percent said they might be open to supporting organizations addressing
Statement of IAVI's Seth Berkley, MD, in Response to the Latest UN HIV/AIDS Statistics: PRNewswire - November 26, 2002; NEW YORK, Nov. 26 /PRNewswire/ -- In advance of World AIDS Day, 1 December, the Joint United Nations Programme on HIV/AIDS and the World Health Organization have released the 2002 statistics on the global epidemic: By the end of this year, 5 million men, women and children worldwide will have become infected with HIV,
FDA Clears Use of GuideLines(TM) 6.0 Rules, Next-Generation Software To Help Predict HIV Drug Resistance - Interpretative Software Compares Results with Latest Medical Information: PRNewswire - November 26, 2002; TARRYTOWN, N.Y., Nov. 26 /PRNewswire/ -- Bayer Corporation, acting through its Diagnostics Business Group, today announced that the U.S. Food and Drug Administration ( FDA ) has granted clearance for GuideLines(TM) 6.0 Rules(1), the next-generation interpretative software used with the TRUGENE(TM) HIV-1 Genotyping Test
ViroLogic Announces Florida Medicaid Program Initiates Coverage Policy for HIV Drug Resistance Testing: Florida Is Second Largest HIV/AIDS Market In U.S.; 47 Out of 50 Medicaid Programs Now Cover Resistance Testing: PRNewswire - November 25, 2002; SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Florida Medicaid Program has initiated a benefit coverage policy for phenotypic and genotypic HIV drug resistance testing effective November 15, 2002. This brings the number of state Medicaid programs
Hemispherx Biopharma Invited to Present New Anti HIV Data at DART Conference: Phase IIB Clinical Trials of Strategic Treatment Intervention : Major Drug Development in Antiretroviral Research (DART) Conference 2002 in Naples, Florida, Tuesday, December 17: PRNewswire - November 25, 2002; PHILADELPHIA, Nov. 25 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (Amex: HEB) announced today that it will present expanded new interim data from the Phase IIB HIV Clinical Trials of its RNA-based Ampligen(R) in Structured Treatment Interruption (STI), at the Drug Development in Antiretroviral Research (DART)
Are women more AIDS-conscious?: PRNewswire - November 25, 2002; - World AIDS day: 1 December 2002 Analysing the sales of a range of items that actively promote AIDS responsibility reveals that women would seem to be more proactive than their male counterparts when considering safe sex. Six times more women than men are buying underwear that has a secret pocket for a condom. The ran
Sir Elton John, Dave Matthews, Michelle Branch and Wyclef Jean Join Missy Elliott and a Host of Celebrities in Levi's(R) 'Staying Alive' Jacket Campaign : World AIDS Day Campaign Includes Specially Designed Levi's Jackets Listed On eBay(R) to Raise Funds and Awareness to Combat HIV/AIDS Globally: PRNewswire - November 22, 2002; SAN FRANCISCO, Nov. 22 /PRNewswire/ -- Several big name recording artists have joined the Levi s(R) Staying Alive Jacket campaign in an effort to raise funds and awareness to combat HIV/AIDS globally. The latest participants in the campaign are Dave Matthews and Michelle Branch. Matthews and Branch join a list of parti
Use of Boosted Saquinavir or Kaletra(TM) Results in HIV Suppression in Most Patients at 24 Weeks: PRNewswire - November 22, 2002; GLASGOW, Scotland, Nov. 22 /PRNewswire-FirstCall/ -- Data from the largest-ever study of boosted protease inhibitors demonstrated that a high proportion of HIV patients taking an investigational boosted saquinavir regimen (saquinavir 1000 mg with ritonavir 100 mg BID) or
GlaxoSmithKline/South Africa Picketed By Hundreds of Treatment Action Campaign (TAC) Activists : AIDS Healthcare Foundation Applauds Action By Advocates, Calls for Stepped Up Activism Against British AIDS Patent Pirates: PRNewswire - November 21, 2002; LOS ANGELES, Nov. 21 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , today applauded two staged protests against British pharmaceutical giant GlaxoSmithKline (GSK)/ South Africa that were spearheaded by South Africa s Treatment Action Campaign (TAC).
BET Plans Special World AIDS Day Programming: Network's Popular News and Music Programming to Provide Public Awareness; Documentaries Will Focus on HIV/AIDS Epidemic Among African-American Population: PRNewswire - November 21, 2002; WASHINGTON, Nov. 21 /PRNewswire/ -- BET today announced its plans to provide special programming to coincide with World AIDS Day, which will be commemorated globally on Sunday, December 1. In keeping with its commitment to provide quality programming from an African-American perspective, BET will televise programs gear
48-Week Results for the SOLO Trial Comparing GW433908/R QD to Nelfinavir BID: Presented at International HIV Meeting: PRNewswire - November 21, 2002; GLASGOW, United Kingdom , Nov. 21 /PRNewswire/ -- Results of the SOLO trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with ritonavir (908/r) QD in antiretroviral therapy-naive
New Study Reports Alarming Rates of HIV and HCV Among African American and Latino American Drug Injectors : Former U.S. Surgeon General, Dr. Joycelyn Elders Backs Needle Exchange Programs to Fight Spread of HIV and Hepatitis C Among Drug Injectors: PRNewswire - November 21, 2002; NEW YORK, Nov. 21 /PRNewswire/ -- A study released this week found among drug injectors, African Americans are five times as likely to get HIV than whites and Latinos are one-and-a-half times as likely. The study also found that 50 to 80 percent of needle drug users become hepatitis C positive within six to 12 months o
FDA Approves Expanded Uses for Gen-Probe's HIV-1/HCV Assay: PRNewswire - November 20, 2002; SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today announced that the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration has granted two new intended uses for Gen-Probe s licensed nucleic acid test (NAT) for the detection of human immunodef
Results of Clinical Trial Show Patients Who Switched from PI-based HIV/AIDS Regimen Maintained HIV Suppression and Improved Triglyceride Levels: PRNewswire - November 20, 2002; GLASGOW, Scotland, Nov. 20 /PRNewswire/ -- A new clinical study found that individuals switching from a protease inhibitor (PI)- based regimen to a PI- sparing, NNRTI-based regimen using VIRAMUNE(R)( nevirapine ), sustained viral suppression and had improved triglyceride levels. Researchers also observed that individu
Chemokine Modulators Likely to Generate Blockbuster Sales Through Use in Multiple Disease Drug Markets: HIV Market To Significantly Benefit From Chemokine Receptor Antagonists, According To New Report From Decision Resources: PRNewswire - November 20, 2002; WALTHAM, Mass., Nov. 20 /PRNewswire/ -- Decision Resources, one of the world s leading research and advisory firms for pharmaceutical and health care issues, forecast today that chemokine modulators are likely to generate blockbuster sales because of their use in multiple disease drug markets. By far the greatest poten
Chiron Signs Multi-Year Agreements with U.S Blood Collection Organizations: PRNewswire - November 19, 2002; EMERYVILLE, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today that multi-year agreements have been signed with the primary blood collection organizations in the U.S. for supply, service and support of Chiron s Procleix(TM) HIV-1/HCV Assay and System. Details of the agreements w
Chiron Signs Multi-Year Agreements with U.S Blood Collection Organizations: PRNewswire - November 19, 2002; EMERYVILLE, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today that multi-year agreements have been signed with the primary blood collection organizations in the U.S. for supply, service and support of Chiron s Procleix(TM) HIV-1/HCV Assay and System. Details of the agreements w
New Survey Finds Students 'Make the Grade' When it Comes to Smarter Sex, But More Education Still Needed: SmarterSex.org, New Sexual Health Site Just for College Students, Created to Fill Knowledge Gaps: PRNewswire - November 18, 2002; DENVER, Nov. 18 /PRNewswire-FirstCall/ -- New research about the sexual activities and attitudes of students ages 18-24 is offering a positive look at what is really happening behind closed doors. The Smarter Sex Survey, an online survey of more than 1,000 students, has surprising results: they take sex and monogamy se
Quest Diagnostics is the First Laboratory to Commercially Offer Improved HIV-1 Viral Load Test From Roche Diagnostics: PRNewswire - November 18, 2002; TETERBORO, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated, (NYSE: DGX), the nation s leading provider of diagnostic testing, information and services, announced today that it is the first reference laboratory to commercially offer Roche Diagnostics new, FDA- approved AMPLICOR HIV-1 MONITOR(R) Te
Second Pivotal Study Demonstrates Benefit of FUZEON(TM) Across Range of Treatment-Experienced HIV Patients - Separate Study Shows Subcutaneous Administration Manageable for Most Patients at 24 Weeks: PRNewswire - November 18, 2002; GLASGOW, Scotland, Nov. 18 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced data from a second pivotal Phase III study (TORO 2) demonstrating that FUZEON(TM) ( enfuvirtide ), in combination with other antiretrovirals, provided benefit to treatment-experienced HIV patients at 24 weeks re
Magic Johnson Brings Message Of Hope To African Americans With HIV: PRNewswire - November 15, 2002; RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire/ -- Earvin Magic Johnson is teaming up with GlaxoSmithKline (GSK) to bring hope, encouragement and awareness about HIV/AIDS to the African-American community, which has experienced a steep rise in the incidence of the disease in the last decade. Johnson and GSK anno
ViroLogic Signs Preferred Provider Agreement and Equity Agreement with Pfizer: PRNewswire - November 14, 2002; SOUTH SAN FRANCISCO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed a preferred provider agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, ViroLogic becomes Pfizer s preferred supplier for HIV resistance testing technology and
ADVR Begins Product R Israeli Clinical Trials; Quintiles Retained to Monitor/Audit Trials, Selikoff Center to Conduct Trials: PRNewswire - November 14, 2002; YONKERS, N.Y., Nov. 14 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it has initiated the single dose safety study which is the first phase of three Product R clinical trials in Israel . The Company also announced that it has retained Quintiles Transnational Cor
Kaleidos Pharma, Inc. Announces Collaboration with the NIH to Investigate The Use of TGF alpha in the Treatment of AIDS: PRNewswire - November 13, 2002; SEATTLE, Nov. 13 /PRNewswire/ -- Kaleidos Pharma, Inc., today announced a collaboration with the Division of AIDS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). Under the terms of the agreement, NIH researchers will conduct a non-human primate study to evaluate the po
Pharmacor Receives U.S. Patent for Next-Generation anti-HIV Protease Inhibitor: PRNewswire - November 13, 2002; MONTREAL, Nov. 13 /PRNewswire/ - Pharmacor Inc. has been issued U.S. patent application no. 10/143,095, relating to its antiretroviral program. The small-molecule compounds described in the patent, entitled Urea derivatives as HIV aspartyl protease inhibitors , are next-generation anti-HIV lead molecules that demonstra
Nation's First Health Care Center Targeted to Injection Drug Users Opens in New York City -Injection Drug Users Account for 30 Percent of All New HIV/AIDS Cases in the U.S.: PRNewswire - November 13, 2002; NEW YORK, Nov. 13 /PRNewswire/ -- Positive Health Project, a New York City syringe exchange program, and Diversified Health Systems Management, Inc., today announced the opening of Positive Health Care, the nation s first comprehensive health care center targeting high-risk clients, including current and former injecti
The Advertising Council and the United Nations Foundation Launch National Campaign to Raise Awareness of the Global AIDS Epidemic: PRNewswire - November 12, 2002; NEW YORK, Nov. 12 /PRNewswire/ -- The United Nations Foundation, in partnership with The Advertising Council, announced the launch of a new public service advertising (PSA) campaign designed to raise national awareness of the global AIDS epidemic and encourage all Americans to get involved in the fight against AIDS.
Gen-Probe Receives FDA Approval for Its Hepatitis C Virus (HCV) Qualitative Assay: PRNewswire - November 8, 2002; -- Most Sensitive Assay to Be Approved for Qualitative Detection Of HCV to Be Marketed by Bayer Diagnostics - SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO), an established leader in molecular diagnostics based on its patented nucleic acid testing (NAT) technologies, today announced t
Preventing HIV Feels Good in New Social Marketing Campaign Targeting Positives: PRNewswire - November 7, 2002; SAN FRANCISCO, Nov. 7 /PRNewswire/ -- I have HIV, and I have sex is the opening line of a bold new installment of the groundbreaking HIV STOPS WITH ME public health prevention campaign. Reaching out to people already infected with HIV, the campaign is due to launch this week on television and in print in San Francisco.
EngenderHealth Awarded HIV/AIDS Health Literacy Grant From The Pfizer Foundation: PRNewswire - November 7, 2002; NEW YORK, Nov. 7 /PRNewswire/ -- EngenderHealth today announced that it has been awarded a $178,266 grant under The Pfizer Foundation s newly introduced International HIV/AIDS Health Literacy Grants program. This grant will enable EngenderHealth to start its project, Building a Common Literacy: Creating Bridges between
FDA Approves New 20-Minute Rapid HIV Test: PRNewswire - November 7, 2002; -- Magic Johnson, Congresswoman Loretta Sanchez, AIDS Healthcare Foundation Applaud Action on Potential Life-saving Tool: Broad Coalition of Public Officials, Health Organizations, AIDS Groups Now Call for Widespread Availability of Test WASHINGTON, Nov. 7 /PRNewswire/ -- Health and Human Services Secretary Tommy Thomp
Ghana Launches National Program to Encourage Compassion and Support For People Living with HIV/AIDS - Muslim and Christian Leaders to Help Implement Phase 2 of Stop AIDS, Love Life: PRNewswire - November 6, 2002; ACCRA, Ghana , Nov. 6 /PRNewswire/ -- Muslim and Christian religious leaders will foster support and compassion for those living with HIV/AIDS under a new program launched today in Ghana, where approximately a half- million people are living with the virus that causes AIDS. Reach Out, Show Compassion for people living
Gates Foundation, BIO Global Health Forum Features International Health Experts: PRNewswire - November 5, 2002; WASHINGTON, Nov. 5 /PRNewswire/ -- The Biotechnology Industry Organization (BIO) today announced that Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and David L. Heymann, MD, executive director of communicable diseases for the World Health Organization (WHO),
NASA's Quest to Determine How Space Affects the Shelf-Life of Medications Is Among the Topics Presented at This Year's Annual Meeting of the American Association of Pharmaceutical Scientists: PRNewswire - November 4, 2002; -- Annual Meeting Makes Its International Debut in Toronto, Ontario, Canada on November 10-14; More than 7,500 Scientists to Attend ARLINGTON, Va., Nov. 4 /PRNewswire/ -- From effects of space on an astronaut s medications to a young scientist s dream of creating a healthier world for all races, the 2002 American Assoc
Brazil Orders Four Million FC Female Condoms - Prevention Program Continues to Expand: PRNewswire - November 4, 2002; CHICAGO, Nov. 4 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it signed a contract with the Ministry of Health of Brazil to provide four million FC Female Condoms for the Ministry s groundbreaking National AIDS Program. Under the terms of the contract, two million u
Coviracil(R) NDA for the Treatment of HIV Disease Accepted by the Food and Drug Administration: PRNewswire - November 4, 2002; DURHAM, N.C., Nov. 4, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that the U.S. Food and Drug Administration ( FDA ) has notified the Company that its New Drug Application (NDA) for marketing approval of Coviracil for the treatment of HIV disease has been accepted for fi
Study Shows New Drug Reduced Morbidity And Mortality Associated With Cryptosporidiosis In Malnourished Children: PRNewswire - November 4, 2002; TAMPA, Fla., Nov. 4 /PRNewswire/ -- A study published in the November 2, 2002 issue of the British journal, The Lancet, showed that a new drug, nitazoxanide, significantly reduced the duration of diarrhea and the rate of death in malnourished children with Cryptosporidium infection. Cryptosporidium is a waterborne prot
Compounds with Potential Use in Treatment of Cancer, HIV and Hepatitis C Donated to University of Arizona Foundation by Procter & Gamble: PRNewswire - November 4, 2002; -- University of Arizona College of Pharmacy, Arizona Cancer Center to Lead Research TUCSON, Ariz., Nov. 4 /PRNewswire/ -- The Procter & Gamble Company (NYSE: PG) today donated to the University of Arizona (UA) Foundation 33 patents and accompanying intellectual property related to a portfolio of compounds that hav
Norzyme(TM) Clinical Trials On HIV-AIDS Patients Underway: National Institutes Of Health (NIH) Grants Of $1.6 Million Funding Study: PRNewswire - November 4, 2002; CHICAGO, Nov. 4 /PRNewswire/ -- Norzyme, Inc., developer of therapeutic drug monitoring technology for use at point-of-care, has launched clinical trials for its Levoprin-ZG(TM) product, developed to aid in the disease management of HIV-AIDS patients. Five universities are participating in the study, titled Measurement
Biosyn, Inc. Announces $10 Million Grant from National Institutes of Health: PRNewswire - November 4, 2002; HUNTINGDON VALLEY, Pa., Nov. 4 /PRNewswire/ -- Biosyn, Inc. announced today that the company, along with five collaborating partners, has been awarded a $10 million grant from the National Institutes of Health (NIH) for the development of a potent HIV-inhibiting compound, Cyanovirin-N, as a microbicide to prevent the s
Bush Administration Awards $12 Million to Provide Permanent Housing and Services to Thousands Living With HIV/AIDS: PRNewswire - October 31, 2002; WASHINGTON, Oct. 31 /PRNewswire/ -- Thousands of people with HIV/AIDS and their families will receive permanent housing and supportive services as a result of $12 million in grants announced today by Housing and Urban Development Secretary Mel Martinez. The renewal grants are part of HUD s Housing Opportunities for Per
L.A. County Supervisor Don Knabe, Congresswoman Jane Harman to Cut Ribbon as AIDS Healthcare Foundation, Pathways Join Forces in Grand Opening of New Redondo Beach HIV/AIDS Healthcare Center: PRNewswire - October 31, 2002; Partnership Between Nation s Largest AIDS Organization, Respected Local Social Service Provider Offers Region s HIV/AIDS Patients Improved Access to Quality Care, Services in South Bay REDONDO BEACH, Calif., Oct. 31 /PRNewswire/ -- In an effort to better reach some under-served Los Angeles County residents with quality
Top Scientists Find Cure For CytRx: PRNewswire - October 30, 2002; LOS ANGELES, Oct. 30 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR) announced today the results of the company s first Scientific Advisory Board (SAB) meeting. The meeting was chaired by Dr. Louis Ignarro, 1998 Nobel Laureate in medicine, and took place on Thursday, October 17th in Los Angeles, California. The SAB of
ChevronTexaco Sponsors 'A Day in the Life of Africa' Project - All Publishing Profits From Book to Support HIV/AIDS Education Fund Programs in Africa: PRNewswire - October 30, 2002; SAN FRANCISCO, Oct. 30 /PRNewswire/ -- ChevronTexaco Corp. (NYSE: CVX) today welcomed the official launch of A Day in the Life of Africa, the latest release in the best-selling A Day in the Life photo documentary series. ChevronTexaco is an underwriting partner of the project -- which includes a book, DVD documentary a
American TeleCare(R), Inc. Announces Partnership with New York City Health & Hospitals Corporation -- HHC Health & Home Care: PRNewswire - October 28, 2002; EDEN PRAIRIE, Minn., Oct. 28 /PRNewswire/ -- American TeleCare, Inc. (ATI) announced today that HHC Health & Home Care, a division of New York City Health & Hospitals Corporation, has implemented the first home telehealth program that targets patients who are HIV positive. In March 2002, HHC purchased 59 of ATI
Life OUTside, America's New, Syndicated, Gay Radio-Newsmagazine, Joins Growing Ranks of Gay Programs Available Via Mainstream Media: PRNewswire - October 28, 2002; -- News, Solid Reporting and Dateline Format Drawing Gay and Straight Listeners Alike To Life OUTside on 70 Radio Stations Nationwide Plus Internet CHICAGO, Oct. 28 /PRNewswire/ -- Once relegated to local community newspapers, during the past decade, gay-themed programming and media have grown exponentially to now reac
Discovery Health Channel Airs Special Programming on World AIDS Day: December 1: PRNewswire - October 28, 2002; -- Actor James Woods Hosts Program Featuring Children Who Relate Their Personal Experiences With HIV/AIDS; Another Examines the Impact of this Devastating Epidemic on Our Society BETHESDA, Md., Oct. 28 /PRNewswire/ -- Although the growth of the ongoing AIDS epidemic has wrought a terrible physical and emotional toll, m
Bill & Melinda Gates Foundation Grant Awarded to Johns Hopkins To Explore Novel Interventions to Control HIV-Related Tuberculosis: PRNewswire - October 28, 2002; SEATTLE and BALTIMORE, Oct 28 /PRNewswire/ -- The Bill & Melinda Gates Foundation will contribute $3 million to the Johns Hopkins University School of Medicine for the development of community-based preventive strategies to control tuberculosis (TB) in areas around the world with severe HIV epidemics. The grant wil
Bill & Melinda Gates Foundation Grant to Evaluate Once-Daily Antiretroviral As a Potential Method of HIV Prevention: PRNewswire - October 28, 2002; SEATTLE and RESEARCH TRIANGLE PARK, N.C., Oct. 28 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today that it has awarded Family Health International (FHI) a $6.5 million, three-year grant for a multinational clinical trial to evaluate an antiretroviral treatment as a novel approach to HIV preventio
Multiple Characteristics of HAART Affect Adherence; Pill Count Has the Greatest Impact on Adherence, Survey Reports: PRNewswire - October 26, 2002; At-A-Glance -- 299 HIV+, treatment-experienced people participated in the survey -- Multiple factors impact a patient s adherence to a HAART treatment regimen exactly as prescribed. -- Total number of pills in a regimen has the greatest impact on adherence of 10 attributes studied in a survey on treatment adherence.
Nationwide Survey Shows 80% of HIV-positive Patients Report Symptoms of Depression and Anxiety: PRNewswire - October 25, 2002; -- HIV Infection, Street Drugs and HIV Medications Cited as Leading Causes - CHICAGO, Oct. 25 /PRNewswire/ -- Key findings of a national physician and patient survey conducted by the International Association of Physicians in AIDS Care (IAPAC) demonstrate a strong link between HIV infection and the mental health of pat
Business, Media, Non-Government Organizations & Charitable Foundations Form Unprecedented Partnership to Make Globally Televised World AIDS Day Concert: PRNewswire - October 25, 2002; -- Sean P. Diddy Combs to Perform in Cape Town & Michelle Branch in Seattle as Part of HIV/AIDS Awareness Concerts To Premiere on MTV Globally as 90-Minute Special on World AIDS Day -- More Than 60 Broadcasters Worldwide Confirmed to Air Concert & Other HIV/AIDS Awareness Programming Rights Free CAPE TOWN,
ALR Technologies Taking Medication Non-Compliance Message to Government and Health Insurance Officials: PRNewswire - October 25, 2002; -- Medication Noncompliance Increases Health Problems and Escalates Healthcare Costs WINSTON-SALEM, N.C., Oct. 25 /PRNewswire-FirstCall/ -- ALR Technologies (OTC Bulletin Board: ALRT), manufacturer of an affordable, easy-to-use medication reminder called the ALRT Med Reminder, announced at a meeting this week in Winsto
New Study Evaluates the Effectiveness of VALTREX(R) Caplets For Suppression Of Genital Herpes In HIV-Infected Persons: PRNewswire - October 25, 2002; - VALTREX Prolonged Length of Time To First Recurrence of Genital Herpes CHICAGO, Oct. 25 /PRNewswire/ -- Twice daily treatment with VALTREX(R) (valacyclovir HCl) caplets is effective in suppressing genital herpes recurrences in HIV-infected patients, according to data presented at the Infectious Diseases Society of Am
New 20-Minute Rapid HIV Test Nears FDA Approval: Broad Coalition of Public Health Officials, Health Organizations, AIDS Groups Call for Widespread Availability of Potential Life-Saving Tool: PRNewswire - October 24, 2002; LOS ANGELES, Oct. 24 /PRNewswire/ -- A broad, growing coalition of public health officials, health organizations, and HIV/AIDS groups are calling for widespread availability of new rapid HIV tests through a waived status under the Clinical Laboratories Improvement Act (CLIA). Supporters include President Bush s Advisor
102.9 WMGK, Philadelphia, Will Exhibit Works of Art Created by Popular Musicians, Singers and Songwriters at The Shops at Liberty Place: PRNewswire - October 23, 2002; -- The Month-Long 102.9 WMGK Classic Rock Art Show and Silent Auction Opens To The Public on Friday, November 15 and Will Benefit the Elizabeth Glaser Pediatric AIDS Foundation PHILADELPHIA, Oct. 23 /PRNewswire/ -- WMGK (102.9FM/Philadelphia) will showcase a never-before seen collection of original art and lithographs,
Zengen, Inc. Announces Investigational New Drug Filing To Treat Vaginal Yeast Infection: PRNewswire - October 23, 2002; -- Company s Proprietary Peptide Technology Offers Potential Alternative to Standard Treatment Regimens WOODLAND HILLS, Calif., Oct. 23 /PRNewswire/ -- Zengen, Inc. announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for CZEN 002, one of the Company
Chiron Corporation Provides Clinical Pipeline Update: Company Announces Discontinuation of SILCAAT and HBV-MF59 Trials And PA-1806 Program: PRNewswire - October 23, 2002; -- Information for SILCAAT Patients and Clinicians Available Toll Free At 1-866-874-3153 EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today decisions on three clinical development programs. Chiron is stopping SILCAAT, a Phase III study for recombinant human interleuk
Delta Dental Plan of Minnesota Study Suggests Regular Dental Visits Benefit Oral Health of HIV Patients; Study is Lead Story in October Issue of JADA: PRNewswire - October 23, 2002; EAGAN, Minn., Oct. 23 /PRNewswire/ -- Regular dental visits may help maintain better oral health in people with the Human Immunodeficiency Virus (HIV), suggests a study conducted by Delta Dental Plan of Minnesota researchers and published as the cover story in the October issue of the Journal of the American Dental Ass
The Only Oral Anabolic Agent Indicated for the Treatment of Involuntary Weight Loss - New 10mg OXANDRIN(R) Tablets Now Available ...: PRNewswire - October 22, 2002; - More Convenient Dosage of OXANDRIN May Enhance Patient Compliance ISELIN, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Today Bio-Technology General Corp. (Nasdaq: BTGC) announced the availability of the new 10mg strength of OXANDRIN(R) (oxandrolone, USP - CIII) a treatment for involuntary weight loss which can be associat
Remarks by the President on Prescription Drugs: PRNewswire - October 21, 2002; WASHINGTON, Oct. 21 /PRNewswire/ -- The following are remarks by the President on Prescription Drugs: The Rose Garden 8:33 A.M. EDT THE PRESIDENT: Good morning. For more than a year, the Federal Trade Commission has investigated delays and abuses in the process of bringing generic drugs to the market. I have reviewed t
Parker Hughes Develops New AIDS Drug; Stampidine Effective Against Drug Resistant HIV: PRNewswire - October 21, 2002; ROSEVILLE, Minn., Oct. 21 /PRNewswire/ -- A new powerful drug against AIDS, known as STAMPIDINE, was developed at the Parker Hughes Center for Clinical Immunology. The effectiveness of this drug was tested first in the test tube against drug-resistant AIDS virus isolates from 29 different HIV- infected individuals. Thi
VaxGen's Phase III Trial in Thailand Clears Final Scheduled Safety Review: PRNewswire - October 21, 2002; BRISBANE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- The independent board that oversees VaxGen , Inc. s clinical trials completed the final safety and conduct review of the company s Phase III trial in Thailand and once again concluded that the study was being conducted appropriately and that VaxGen s AIDS vaccine cand
ViroLogic and Surveillance Data, Inc., Partner to Create New HIV Market Data Products: PRNewswire - October 21, 2002; SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) and Surveillance Data, Inc. (SDI), announced today that the companies have signed an agreement to create a new line of HIV market research products based on data collected through ViroLogic s HIV resistance testing and therapy
Kawasumi America Receives FDA 510 (K) Clearance on Needle Safety Device: PRNewswire - October 18, 2002; - K-Shield Protection Device Provides Cost-Effective Mechanism for OSHA Needle Stick Safety Compliance TAMPA, Fla., Oct. 18 /PRNewswire/ -- Kawasumi Laboratories America, Inc. has received FDA 510 (k) clearance to market a needle safety device to protect oncology clinicians from Huber needle stick injuries incurred whi
The Medical Institute for Sexual Health: Scientific Review of Condom Effectiveness Research Reveals Condoms Provide Inadequate Risk Reduction For Sexually Transmitted Diseases: PRNewswire - October 16, 2002; WASHINGTON, Oct. 16 /PRNewswire/ -- A new scientific report released today reveals that condoms, even when used 100 percent of the time, fail to reduce the risk of some of the most common and potentially dangerous sexually transmitted diseases (STDs) to an acceptable level. Sex, Condoms, and STDs: What We Now Know, rel
Immusol Chief Scientific Officer, Flossie Wong-Staal, Ph.D., Named One of Top 50 Women Scientists: PRNewswire - October 15, 2002; SAN DIEGO, Oct. 15 /PRNewswire/ -- Immusol, The Inverse Genomics(TM) Co., announced that Discover Magazine has recognized Dr. Flossie Wong-Staal, Immusol s Chief Scientific Officer and Vice President of Genomics, as one of 50 most extraordinary women scientists across all disciplines. Selection of the top women scienti
Pharmacor Discovers New Class of Compounds for the Treatment of Drug-Resistant HIV/AIDS: PRNewswire - October 15, 2002; MONTREAL, Oct. 15 /PRNewswire-FirstCall/ - Pharmacor announces the discovery of a new class of drug-like compounds in its battle against drug- resistant HIV. The exceptional characteristic of these compounds is that they are significantly more active against protease-inhibitor (PI) resistant strains than against the co
ALR Technologies Medication Reminders Benefit Treatment for AIDS Patients: PRNewswire - October 15, 2002; WINSTON-SALEM, N.C., Oct. 15 /PRNewswire/ -- Patients undergoing treatment for the HIV virus have benefited from a new medication reminder that prompts them to take their medications on time, as prescribed, according to feedback from physicians who have given reminders to their patients. The positive, anecdotal results
AIDS Healthcare Foundation's Anti-Trust Complaint Amended to Include GSK's Blockbuster AIDS Drugs Combivir & Trizivir; Fraud During Patent Process Used to Procure Invalid Patents on AZT and Other Subsequent HIV Drugs: PRNewswire - October 15, 2002; - Nation s Largest AIDS Organization Discovers Glaxo Smoking Gun: British Drug Maker Lied to Get AZT Patent NEW YORK, Oct. 15 /PRNewswire/ -- The largest AIDS organization in the United States today announced that it has filed an amended federal anti-trust complaint against British-owned G
Global Health Action Makes Inroads Into China: PRNewswire - October 15, 2002; - Global Health Action Collaborates With Chinese Health and Government Agencies to Address Domestic Abuse, HIV/AIDS Infection and Women s Reproductive Health Issues ATLANTA, Oct. 15 /PRNewswire/ -- Global Health Action (GHA), a nonprofit health education and leadership and management development organization headquarte
ADVR's Product R Reverses Cancerous Properties of Human Promyelocytic Leukemia Cells in Laboratory Cultures: PRNewswire - October 11, 2002; - Findings Presented at Meeting of the American Association for Cancer Research Show That Product R Induces Differentiation of a Human Promyelocytic Leukemia Cell Line YONKERS, N.Y., Oct. 11 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that the Company s peptide nuc
ViroLogic Announces Study Published in Journal of AIDS Supports Use Of PhenoSense GT Combination Assay: PRNewswire - October 11, 2002; - 1,400-Patient Sample Study Demonstrates Phenotypic and Genotypic Assays Provide Complementary Information Critical for Optimum Treatment SOUTH SAN FRANCISCO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that study results published in the current issue of the Journal of Acq
FUZEON(TM) Granted Priority Review Status by U.S. FDA - First HIV fusion inhibitor will have a target six month review period -: PRNewswire - October 11, 2002; NUTLEY, N.J. and DURHAM, N.C., October 11 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that the U.S. Food and Drug Administration ( FDA ) has notified the companies that the New Drug Application (NDA) for FUZEON(TM) (generic: enfuvirtide , formerl
Planning Reduces Impact of HIV on Mother and Baby: PRNewswire - October 10, 2002; LAS VEGAS, Oct. 10 /PRNewswire/ -- Women infected with HIV who develop a treatment plan with both their pediatrician and obstetrician during pregnancy reduce the impact of the virus on themselves and their unborn baby, Ronald J. Librizzi, D.O., an osteopathic obstetrician and gynecologist, reported at the American Oste
FDA Grants URRMA Biopharma IDE Approval For Anti-R7V Diagnostic Kit as Determinant For Progressor / Non-Progressor to Aids: PRNewswire - October 10, 2002; MONTREAL, Oct. 10 /PRNewswire/ - URRMA Biopharma Inc. ( URRMA ) is pleased to announce the US Food and Drug Administration ( FDA ) has granted approval of URRMA s Investigational Device Exemption (IDE) application for the Anti-R7V Diagnostic Kit. This is equivalent to a Phase II in the more commonly used terminology pe
Chimerix, Inc. Announces Appointment of Expert In Antiviral Discovery and Development as CEO - Company Currently Developing an Oral Drug for Smallpox Infections -: PRNewswire - October 9, 2002; SAN DIEGO, Oct. 9 /PRNewswire/ -- Chimerix, Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today announced the appointment of George Painter, Ph.D. as company President and CEO. Dr. Painter has twenty-four years of experience in the discovery and develo
Viacom and Kaiser Family Foundation to Launch Comprehensive Media Campaign to Fight HIV/AIDS: PRNewswire - October 9, 2002; - Worldwide Initiative to Foster HIV/AIDS Awareness and Prevention Through PSAs, Television and Radio Programming, and Outdoor, Print and Online Content NEW YORK, Oct. 9 /PRNewswire/ -- Viacom Inc. and the Henry J. Kaiser Family Foundation today announced a comprehensive global media campaign beginning January 6, 2003
Bill Gates to Visit India on HIV/AIDS Mission: PRNewswire - October 6, 2002; SEATTLE, Oct. 6 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced that its co-founder, Bill Gates, will visit India next month to lead a foundation delegation that will see first-hand some of the challenges and exemplary initiatives underway to prevent the transmission of HIV. During his trip, Ga
Gen-Probe Receives Contract Funding From the National Heart, Lung And Blood Institute to Initiate Development of a Nucleic Acid Screening Test for West Nile Virus: PRNewswire - October 3, 2002; SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) an established leader in molecular diagnostics based on its patented nucleic acid testing (NAT) technologies, today announced that it has received $1.0 million from the National Heart, Lung and Blood Institute (NHLBI) of the National Inst
Two Historic HIV/AIDS Awareness Concerts to Take Place in Cape Town with Alicia Keys, & Seattle with Missy Elliott & Dave Matthews to Premiere on MTV Globally as 90-Minute Special on World Aids Day, December 1st: PRNewswire - October 3, 2002; - MTV, Levi s(R) Brand, Bill & Melinda Gates Foundation, Paul G. Allen Charitable Foundation, Population Services International s YouthAIDS & UNAIDS Form Unprecedented HIV/AIDS Awareness Partnership For Youth - All HIV/AIDS Awareness Programming & PSAs Available Rights Free to All Broadcasters Worldwide
U.S. Government Bars Unfair Drug Marketing Practices: AIDS Healthcare Foundation Urges Lower Drug Prices to Reflect Reduced Marketing Costs: PRNewswire - October 2, 2002; - As Government Limits Pharmaceutical Marketing Practices That Skirt Federal Fraud and Abuse Laws, Nation s Largest AIDS Organization Demands That Drug Price Reductions Accompany New Regulations LOS ANGELES, Oct. 2 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest specialized provider of HIV/AIDS m
SLIL Biomedical Announces Publication of Study on Its Proprietary 'Sequential Pathogenesis' Technology in October Issue of Cancer Research: PRNewswire - October 2, 2002; MENLO PARK, Calif., Oct. 2 /PRNewswire/ -- SLIL Biomedical Corp. today announced the publication of seminal Sequential Pathogenesis research, conducted by UCSF scientists, SLIL Biomedical researchers and academic collaborators, in the October issue of Cancer Research. The study found that macrophages, normally key immu
EraGen Biosciences' Nucleic Acid Technology Validated by FDA Approval of Bayer Diagnostics' VERSANT(R) HIV-1 RNA 3.0 Assay: PRNewswire - October 2, 2002; MADISON, Wis., Oct. 2 /PRNewswire/ -- EraGen Biosciences, a growing life science company, commented today on the relationship between its AEGIS(TM) nucleic acid technology and the recent US Food and Drug Administration ( FDA ) approval of Bayer Diagnostics VERSANT(R) HIV-1 RNA 3.0 Assay (bDNA). The Versant(R) Assay ha
Abbott Laboratories' Kaletra(R) (lopinavir/ritonavir) Attains Status As Most-Prescribed Protease Inhibitor for the Treatment of HIV: PRNewswire - October 2, 2002; ABBOTT PARK, Ill., Oct. 2 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) Kaletra (R) ( lopinavir / ritonavir ) has become the most-prescribed protease inhibitor (PI) as part of a treatment regimen for HIV in the
Nastech Reacquires Nascobal(R) (Cyanocobalamin, USP) Gel From Schwarz Pharma And Signs Contract Sales Agreement With Cardinal Health: PRNewswire - October 1, 2002; BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced it has reacquired all product, patent, trademark, licensing and regulatory rights for Nascobal(R) in the United States from Schwarz Pharma. Under terms of the acquisition agreement, Nastech will pay Schwarz a t
Serono Announces Positive Results of Serostim(R) Clinical Trial for Treatment of HIV-Related Metabolic Complication: PRNewswire - September 30, 2002; - Findings Also Suggest Reduction in Cardiovascular Risk Factors Associated with Condition ROCKLAND, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Serono S.A. (virt-x: SEO and NYSE: SRA) announced 24-week results from a completed clinical trial of Serostim(R) [somatropin (rDNA origin) for injection] evaluating the treatmen
VIRACEPT(R) Appears to be Generally Well Tolerated In Hepatitis-C Co-Infected Patients: PRNewswire - September 30, 2002; SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Data presented today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy in San Diego reveal that for patients co-infected with Hepatitis-C (HCV) and HIV, VIRACEPT(R) (nelfinavir mesylate) is generally well tolerated. The retrospective analysis, con
ViroLogic Studies Presented at ICAAC Highlight Benefits Of Its HIV Drug Resistance Technology - Company Also Launches Comprehensive Professional Education Program: PRNewswire - September 30, 2002; SOUTH SAN FRANCISCO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced that results of four studies demonstrating the benefits of its HIV drug resistance products and technologies were presented today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Achillion Pharmaceuticals Presents at ICAAC In Vitro Data Showing Anti-HIV Activity of a New Class of Compounds Against a Novel HIV Target: PRNewswire - September 30, 2002; - Representative Lead Pre-clinical Compound Developed To Combat HIV Drug Resistance Using Novel Target SAN DIEGO, Calif., Sept. 30 /PRNewswire/ -- Achillion Pharmaceuticals announced the development of a new class of compounds that inhibits a broad spectrum of drug-resistant HIV strains by targeting a novel virus prote
Achillion Pharmaceuticals and Beth Israel Deaconess Investigator Present Results of a Phase 1/2 Clinical Trial Demonstrating Potent Antiviral Activity Of New Anti-HBV Agent at ICAAC: PRNewswire - September 28, 2002; SAN DIEGO, Sept. 28 /PRNewswire/ -- Demonstrating encouraging advances in the treatment of chronic hepatitis B virus (HBV) infection, researchers at Beth Israel Deaconess today presented the first clinical data for Beta-L-Fd4C (ACH-126,443), Achillion Pharmaceuticals novel L-nucleoside. In the blinded, placebo controll
Data Show Bristol-Myers Squibb's Investigational Protease Inhibitor Atazanavir Provided Antiviral Effect Comparable to SUSTIVA(R) In Treatment-Naive HIV/AIDS Patients: PRNewswire - September 28, 2002; SAN DIEGO -- A study presented today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, California showed that a regimen containing the investigational protease inhibitor atazanavir provided antiviral effect comparable to a standard-of-care regimen containing SUSTIVA(R) (
New Data Demonstrate Benefit of FUZEON(TM) in Combination Therapy Across Range of Treatment-Experienced HIV Patients - Patients See Improvement Regardless of Treatment History: PRNewswire - September 28, 2002; SAN DIEGO -- Roche and Trimeris (NASDAQ: TRMS) today announced new data from a Phase III pivotal study demonstrating that regardless of patient demographics or treatment history, FUZEON(TM) (generic: enfuvirtide , formerly known as T-20) in combination with other antiretrovirals provided benefit to treatment-experience
GlaxoSmithKline Drug Discovery and Development Award 2002 - Six Researchers Share $500,000 Award for Work on HIV/AIDS Treatment Breakthroughs: PRNewswire - September 27, 2002; SAN DIEGO, Sept. 27 /PRNewswire/ -- Six HIV and AIDS researchers will split $500,000 as this year s recipients of the GlaxoSmithKline (GSK) Drug Discovery and Development Award. The unrestricted research award program is funded by GSK to support independent, innovative and novel research in the development of HIV/AIDS
New Study Evaluates Suppressive Therapy With VALTREX(R) Caplets for the Reduction of Transmission of Genital Herpes: PRNewswire - September 27, 2002; SAN DIEGO -- According to study data presented at the 42nd ICAAC, the Interscience Conference on Antimicrobial Agents and Chemotherapy, once-daily suppressive therapy with VALTREX(R) (valacyclovir HCl) caplets reduced transmission of symptomatic genital herpes (a visible outbreak) by 77 percent in healthy heterosexual
New Protease Inhibitor Held HIV at Undetectable Levels For Four Years: PRNewswire - September 27, 2002; SAN DIEGO -- A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir / ritonavir ( Kaletra (R)) suppressed HIV to undetectable levels and was well tolerated through four years of treatment in patients who had not
Bristol-Myers Squibb Early Access Program Can Provide Investigational Protease Inhibitor Atazanavir for Eligible Patients With HIV: PRNewswire - September 27, 2002; PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE: BMY) has started enrolling patients in an early access program to provide the investigational protease inhibitor, atazanavir, to eligible patients infected with HIV. An early access program (EAP) provides medicines to eligible patients in need of alternative therap
Once-Daily Coviracil(R) Regimen Superior to Zerit(R) in FTC-301 Clinical Trial; Triangle Pharmaceuticals, Inc. Presents Coviracil Data at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): PRNewswire - September 27, 2002; SAN DIEGO -- Triangle Pharmaceuticals, Inc. (NASDAQ: VIRS) presented data at the Late Breaker Session at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which showed that Coviracil (emtricitabine) was statistically superior to Zerit (
Mymetics Corporation Presents Promising New AIDS Therapy Research Results at ICAAC: PRNewswire - September 27, 2002; ANNAPOLIS, Md. -- Mymetics Corporation (BULLETIN BOARD: MYMX) today presented preclinical data at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on two novel gp41-derived peptide candidates that demonstrate potent inhibition of HIV in vitro. Both peptides were developed to disrupt a phenom
New Data Shows Better Lipid Safety Profile of Boosted Saquinavir vs. Boosted Indinavir: PRNewswire - September 27, 2002; SAN DIEGO -- Roche today announced results of two studies examining the lipid safety profile of twice-daily boosted saquinavir (1000 mg saquinavir with 100 mg ritonavir ) for HIV. Data from the first head-to-head study of boosted protease inhibitors (the MaxCmin1 trial) revealed that boosted saq
Phase III, 24-Week Results for the NEAT Trial Comparing GW433908 (908) to Nelfinavir: Presented At ICAAC: PRNewswire - September 27, 2002; SAN DIEGO -- Results of the NEAT trial, an open-label, multi-center study evaluating the safety and efficacy of the investigational protease inhibitor (PI) GW433908 (908) in antiretroviral therapy-naive patients versus nelfinavir (NFV, Viracept (R)), were presented here today at the 42nd Interscience Conference on Anti
The Coca-Cola Africa Foundation and Coca-Cola Bottlers in Africa Create HIV/AIDS Healthcare Program: PRNewswire - September 26, 2002; - Program Designed to Expand Employee Healthcare to Include AIDS Testing And Drug Treatment That Will Start in Southern and Eastern Africa MANZINI, Swaziland , Sept. 26 /PRNewswire/ -- The Coca-Cola Africa Foundation announced today that it is joining with Coca-Cola s 40 bottlers in Africa to help them expand their emp
ViroLogic Announces Significant Presence at 42nd Interscience Conference On Antimicrobial Agents and Chemotherapy: PRNewswire - September 26, 2002; SOUTH SAN FRANCISCO, Calif., Sept. 26 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that four presentations related to its novel drug resistance products and technology will be made at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place at the San Di
PharmAccess International organizes a HIV/AIDS Treatment Program in Collaboration With the Coca-Cola Africa Foundation and Coca-Cola Bottlers in 56 Countries in Africa: PRNewswire - September 26, 2002; - Program designed to Expand Employee Healthcare Include Prevention, AIDS Testing and Drug Treatment that will start in Southern and Eastern Africa AMSTERDAM, Netherlands , Sept. 26 /PRNewswire/ -- PharmAccess International announced today that it will participate in a program to expand employee healthcare in collabora
Inhibitors of HIV Replication Identified Using Ciphergen Biosystems Technology: PRNewswire - September 26, 2002; - Culmination of 16 Year Hunt Suggests New Therapeutic Strategies in AIDS - FREMONT, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH) today announced an important discovery made using their proprietary protein analysis technology: the long-awaited identification of the CD8+ Antiviral
Calypte Biomedical Reports On US Conference on AIDS; Conference Attended by Over 3,500 Healthcare Providers; Pre-IDE Meeting Scheduled October 4th With FDA for Rapid Test: PRNewswire - September 26, 2002; ALAMEDA, Calif. -- Calypte Biomedical Corporation (BULLETIN BOARD: CALY) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, shared information about the benefits and performance of its urine HIV-1 tests at the United States Conference on AIDS (USCA) h
New Software Gives Patients the Tools They Need to Manage Health Conditions Like Diabetes, Asthma, Hypertension and More - Includes First Ever Solution for HIV/Aids Patients: PRNewswire - September 24, 2002; ARLINGTON, Va., Sept. 24 /PRNewswire/ -- FireLogic, Inc. today introduced the next generation of its innovative HealthEngage disease management software. HealthEngage provides an easy to use, yet comprehensive tool for patients to manage their wellbeing from any desktop or handheld computer. Using HealthEngage, patient
Pharmasset, Inc. is a Proud Sponsor of the 2nd Annual Georgia Life Sciences Summit: PRNewswire - September 24, 2002; ATLANTA, Sept. 24 /PRNewswire/ -- Pharmasset, Inc. is pleased to announce its sponsorship of the 2nd annual Georgia Life Sciences Summit -- From Bench to Blockbuster. This event, which is considered the primary gathering of scientists and industry decision makers for Georgia s life sciences community, will take place o
Patent Granted for Preparation of Promising HIV Drug - Chicago-Area Company Advances Calanolide A, Compound Derived From Malaysian Rainforest: PRNewswire - September 24, 2002; WOODRIDGE, Ill., Sept. 24 /PRNewswire/ -- The U.S. Patent and Trademark Office issued a broad patent to Sarawak MediChem Pharmaceuticals of Woodridge, Ill., bolstering the company s proprietary position in the use of calanolides as potential anti-viral drugs, the company announced today. Sarawak MediChem Pharmaceutical
4th Annual AIDS Walk Michigan to be Held on Belle Isle, Sept. 28: PRNewswire - September 23, 2002; DETROIT, Sept. 23 /PRNewswire/ -- The city of Detroit AIDS Walk is a unique collaboration of 25 service organizations in the Detroit area that will host their 4th annual AIDS Walk on Detroit s Belle Isle, Saturday, September 28, 2002. Registration begins at 10 a.m. with the 5K walk scheduled to start at noon come rain
Primagen and Gilead Extend Service Testing Agreement To Use The Retina(TM) Mitox Test For All Samples of Multi-Year Clinical Study: PRNewswire - September 23, 2002; AMSTERDAM, Netherlands , Sept. 23 /PRNewswire/ -- Primagen Holding B.V. announced today that they have extended their service testing agreement with Gilead Sciences , Inc., to measure mitochondrial DNA using the Retina(TM) Mitox test in samples of a multi-year, multi-center phase III clinical study of
Invenux, Inc. Secures Grant From the National Institutes of Health to Initiate A Discovery Program for New Anti-HIV Agents - Second SBIR Phase I Grant for 2002 -: PRNewswire - September 23, 2002; DENVER, Sept. 23 /PRNewswire/ -- Invenux, Inc. announced today that the company was awarded an SBIR grant of $100,000 from the National Institutes of Health to begin a drug-discovery program aimed at producing novel anti-HIV agents. The phase I study will involve the initiation of a program to generate a small molecule
FDA Approves Gilead's Hepsera(TM) for the Treatment of Chronic Hepatitis B: PRNewswire - September 23, 2002; -- First Nucleotide Analogue for the Treatment of Chronic Hepatitis B : Second Novel Gilead Antiviral Approved in Less than One Year - FOSTER CITY, Calif., Sept. 23 /PRNewswire-FirstCall/-- Gilead Sciences (Nasdaq: GILD) today announced that it received U.S. Food and Drug Administration ( F
At UMDNJ-New Jersey Medical School Innovative Autologous Immune Therapy May Be Answer for Treating AIDS Effectively: PRNewswire - September 23, 2002; - Finding Based on Clinical Trial of New Treatment Developed by BDSI - NEWARK, N.J., Sept. 23 /PRNewswire-FirstCall/ -- A clinical trial by researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) has shown a new autologous immunotherapy appears to be safe and effective treatment for controlling HI
Basketball Great 'Magic' Johnson, Jr. to Cut Ribbon & Tour San Francisco AIDS Clinic Named in His Honor: PRNewswire - September 20, 2002; -- State-of-the-Art AIDS Healthcare Foundation Facility Offers San Franciscans Improved Access to Quality Care, Services SAN FRANCISCO, Sept. 20 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest provider of specialized HIV/AIDS medical care, is pleased to announce that basketball legend Earvin Mag
Marketing Authorization Application Submitted In European Union For Fuzeon(TM), First HIV Fusion Inhibitor Under Review - EU Filing Submitted Just Days After U.S. Filing --: PRNewswire - September 20, 2002; NUTLEY, N.J. and DURHAM, N.C., Sept. 20 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced the submission of a Marketing Authorization Application to the European Union (EU) for FUZEON(TM) ( enfuvirtide ), formerly known as T-20, for HIV-1 infection in combination with other antiretrovira
Bid on a Phone Call With the Castaway Voted Off Survivor: Thailand Each Week Or Own a Part of Survivor History: PRNewswire - September 19, 2002; - Survivor Props, Memorabilia, Experience Packages and Castaway Phone Calls To Be Offered on eBay to Benefit the Elizabeth Glaser Pediatric AIDS Foundation SANTA MONICA, Calif., Sept. 19 /PRNewswire/ -- Get ready for a whole new season of Survivor and your chance to own a piece of television history. Ever wondered what
Mymetics Announces Appointment of Senior Management Team and Formation of Its Scientific Advisory Board: PRNewswire - September 19, 2002; ANNAPOLIS, Md., Sept. 19 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX), an international biotechnology firm focused on molecular mimicry and retroviral diseases, announced today the appointment of its senior management team and scientific advisory board. The senior management includes Peter
Calypte's Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States - West Virginia Department of Insurance Amends Rule to Include Urine HIV-1 Antibody Testing: PRNewswire - September 19, 2002; ALAMEDA, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that the West Virginia Office of the Insurance Commissioner has cleared the way f
VaxGen to Present at UBS Warburg Life Sciences Conference on Oct. 8: PRNewswire - September 18, 2002; BRISBANE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- VaxGen , Inc. (Nasdaq: VXGN) is scheduled to present at the UBS Warburg Global Life Sciences Conference at 4 p.m. Eastern time, Oct. 8, 2002 at the Plaza Hotel in New York. Lance K. Gordon, Ph.D., VaxGen s CEO, will represent VaxGen at the conference. Dr. Gordon
Governor Gray Davis Signs Bill AB 2197: - Landmark California AIDS Care Bill Extends Medi-Cal Coverage To HIV Positive, Non-Disabled: PRNewswire - September 18, 2002; - Action on Assemblyman Paul Koretz s (D, West Hollywood) Bill Received Overwhelming Editorial Support From State s Top Newspapers, Called Most Important AIDS Policy Bill Nationwide This Year, By AIDS Healthcare Foundation President Michael Weinstein LOS ANGELES, Sept. 18 /PRNewswire/ -- Honoring a campaign pledge made
Ushercell Leads Microbicide Research with CONRAD - Additional Funding Will Accelerate Results: PRNewswire - September 18, 2002; TORONTO, Sept. 18 /PRNewswire-FirstCall/ -- Polydex Pharmaceuticals Ltd. (Nasdaq: POLXF) announces continued progress in the development of Ushercell, the patented lead development product for Polydex. Ushercell has completed three Phase I/II clinical trials and further Phase I/II clinical trials are ongoing. Ushercell
Triangle Pharmaceuticals Announces Final Settlement Of Patent Disputes Involving Amdoxovir (DAPD): PRNewswire - September 17, 2002; DURHAM, N.C., Sept. 17, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced the final settlement of patent disputes involving Triangle s drug candidate amdoxovir. Amdoxovir is a purine nucleoside analogue for the treatment of HIV disease. Triangle licensed amdoxovir from Emory U
California Representatives Cross Party Lines to Back Increase for AIDS Drugs: PRNewswire - September 17, 2002; - AIDS Healthcare Foundation Praises Thirty California Representatives Joining Mary Bono, Henry Waxman, Doug Ose, and Diane Watson in Effort to Boost AIDS Drug Assistance Program (ADAP) LOS ANGELES, Sept. 17 /PRNewswire/ -- Thirty of California s representatives in Congress today joined across party lines to ask House
Detroit Artists Unite in the Fight Against AIDS at the Eighth Annual 'ART WORKS FOR LIFE' on September 28: PRNewswire - September 17, 2002; FERNDALE, Mich., Sept. 17 /PRNewswire/ -- Over 200 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the eighth annual ART WORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 28, 2002 at the Edsel and Eleanor Ford House in Grosse Pointe Shores to be
DaimlerChrysler Recognized for HIV/AIDS Initiative: PRNewswire - September 17, 2002; WASHINGTON, Sept. 17 /PRNewswire-FirstCall/ -- The Constituency for Africa (CFA) recently presented DaimlerChrysler AG with its Corporate Leadership Award in recognition of the company s commitment to combating the HIV/AIDS Pandemic in Africa. The award was presented at the organization s annual awards ceremony last we
Clothes Minded Teens Open Hearts for AIDS - Tech Pairs With Fashion as Microsoft and Macy's Team Up for Passport 20/02 - Wednesday, September 18, 2002: PRNewswire - September 17, 2002; WHO: Teens will test their tech and fashion flair at Microsoft s Outsmart Encarta and Strike a Pose stages at Macy s Passport 20/02. Teens will model their quest for knowledge by offering smart answers to shock jock Strawberry from WILD 94.9, who will ask some tough trivia questions at the Outsmart Encarta stage.
Bayer Receives FDA Approval for VERSANT(R) HIV bDNA Viral Load System - Assay Generates More Confident Results for Physicians and Patients -: PRNewswire - September 17, 2002; TARRYTOWN, N.Y., Sept. 17 /PRNewswire/ -- Bayer Diagnostics announced today that it received US Food and Drug Administration approval for VERSANT(R) HIV-1 RNA 3.0 Assay (bDNA)*, its nucleic acid probe diagnostic assay for the direct quantification of HIV-1 RNA in the plasma of people living with HIV. VERSANT(R) HIV bDN
Roche and Trimeris Submit New Drug Application for FUZEON(TM), First Fusion Inhibitor to be Reviewed by FDA: PRNewswire - September 17, 2002; NUTLEY, N.J. and DURHAM, N.C., Sept. 17 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for approval to market FUZEON(TM) ( enfuvirtide ), formerly known as T-20.
United States Conference on AIDS this Week in Anaheim, CA - Nation's Largest Gathering of HIV/AIDS Community: PRNewswire - September 16, 2002; WASHINGTON, Sept. 16 /PRNewswire/ -- An unintended casualty of last year s horrific events of September 11 was the cancellation of the 2001 United States Conference on AIDS scheduled to begin just two days later in Miami Beach. For the first time since that fateful day, HIV/AIDS treatment leaders, advocates and front-l
Delmar Learning Releases Latest Editions of OSHA and OBRA Handbooks to Help Health Care Facilities Satisfy Government Standards: PRNewswire - September 16, 2002; ALBANY, N.Y., Sept. 16 /PRNewswire/ -- Delmar Learning, a leader in educational resources for lifelong learning and part of The Thomson Corporation (NYSE: TOC; TSX: TOC), today announced the release of the latest editions of health care facilities handbooks covering OSHA and OBRA guidelines. The third edition of The OS
New PhRMA Survey Finds 249 Medicines in the Pipeline for African Americans: PRNewswire - September 13, 2002; WASHINGTON, Sept. 13 /PRNewswire/ -- Pharmaceutical and biotechnology companies are working on 249 new medicines for diseases that disproportionately afflict African Americans or diseases that are among the top 10 causes of death among African Americans, according to a new survey by the Pharmaceutical Research and Manu
Media Advisory: Dame Elizabeth Taylor Appears One Night Only At Macy's Passport '02 20th Anniversary Gala On Thursday, September 19th in San Francisco - Earvin 'Magic' Johnson Hosts the American Express Cardmember Evening on Friday, September 20th: PRNewswire - September 13, 2002; WHO: DAME ELIZABETH TAYLOR hosts Macy s Passport 20/02 s Gala Evening on September 19, America s premier HIV/AIDS fundraiser and fashion show featuring the best of Macy s fall collections for men, women and children. Presented by American Express, this year the show includes a special performance by classical violinist
Calypte Biomedical to Attend US Conference on AIDS: PRNewswire - September 12, 2002; ALAMEDA, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, said the company will attend the United States Conference on AIDS (USCA) in Anaheim, CA, Sept
Micrologix Expands Pipeline through Acquisition of Antiviral Product & Technology Portfolio - Antiviral Technologies focused on Human Papillomavirus (HPV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): PRNewswire - September 12, 2002; VANCOUVER, Sept. 12 /PRNewswire-FirstCall/ - Micrologix Biotech Inc. (TSX: MBI; US OTC: MGIXF) has acquired a broad portfolio of antiviral technologies and product candidates (the Portfolio ) formerly owned and/or being developed by Origenix Technologies Inc. (the Origenix Intellectual Property ). These technologies an
BioDelivery Sciences International, Inc. Receives NIH Grant to Develop An Oral Prophylactic/Therapeutic HIV Vaccine in Collaboration With Biokeys Pharmaceuticals, Inc.: PRNewswire - September 12, 2002; NEWARK, N.J., Sept. 12 /PRNewswire-FirstCall/ -- BioDelivery Sciences International (Nasdaq: BDSI; BDSIW) announced today that they have received a two year $600,000 National Institutes of Health (NIH) SBIR Grant to develop an oral form of a powerful HIV prophylactic/therapeutic vaccine with their patented Bioral(TM) d
Real People. Real Stories. AIDS Walk Detroit: HIV Positive Man Walks to Reinforce His Passion for Life: PRNewswire - September 10, 2002; ROYAL OAK, Mich., Sept. 10 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2002 campaign, Real People. Real Stories. As part of this campaign, 5 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 15 Walk. They include, Bill, an HIV positive
Euroscreen Awarded US Patent Covering Key HIV Target - CCR5 Chemokine Receptor is a Crucial Target for a Novel Aids Therapy -: PRNewswire - September 10, 2002; BRUSSELS, Belgium , Sept 10 /PRNewswire/ -- Euroscreen s.a., a world leader in G-protein-coupled receptors (GPCRs), today announced the issue of a key US patent in the area of HIV infection. The patent claims a specific GPCR sequence included in the human CCR5 receptor. The CCR5 receptor has a central role in the mecha
The Immune Response Corporation Announces Restructuring and Cost Reductions To Focus Exclusively On REMUNE(R) - Ronald B. Moss M.D. Is Named President: PRNewswire - September 9, 2002; CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Signaling a move to restructure and reposition the Company for potential product commercialization, The Immune Response Corporation (Nasdaq: IMNR) announced today a restructuring program and management changes aimed at reducing costs and refocusing the Company on its
Expanding Multi-Resistant HIV Populationin Need of New Classes of Drugs - Trimeris' T-20 HIV Drug Poised to Address Key Unmet Need in These Patients, According to a New Report from Decision Resources: PRNewswire - September 9, 2002; WALTHAM, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, Inc., one of the world s leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that the expanding multi-resistant HIV population is in need of new classes of drugs. One such drug that could prove valuable to the
US' Largest AIDS Organization Calls Glaxo AIDS Drug Announcement a 'Hollow Gesture': New Price Remains Seven Times Higher Than Generics: PRNewswire - September 6, 2002; - AIDS Healthcare Foundation Says Tragic Glaxo Decision Won t Save Lives, Denounces Cynical P.R. Effort Against Lawsuit LOS ANGELES, Sept. 6 /PRNewswire/ -- The United States largest AIDS organization described yesterday s AIDS drug price reduction announcement by British-owned GlaxoSmithKline a hollow gesture th
Real People. Real Stories. AIDS Walk Detroit; Ferndale Woman Walks to Honor the Memory of Her Father: PRNewswire - September 6, 2002; ROYAL OAK, Mich., Sept. 6 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2002 campaign, Real People. Real Stories. As part of this campaign, 5 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 15 Walk. They include, Yvette, whose father, J
National HIV/AIDS Conference Takes Place in Atlanta, Oct. 11-12: Conference to Unveil Research Results and Focus on Advances and Treatment Options for HIV patients: PRNewswire - September 6, 2002; ATLANTA, Sept. 6 /PRNewswire/ -- Results from the scientific study, HEDS UP (HIV Early Detection Study of Unrecognized Positives), will be unveiled at a national HIV/AIDS Conference on Friday, Oct. 11 and Saturday, Oct. 12 at the Swissotel in Buckhead. The HEDS UP study found that 40 percent of patients diagnosed with
Gen-Probe Announces Results From the Initial Field Evaluation of The TIGRIS(TM) Instrument System for Clinical Diagnostic Testing: PRNewswire - September 5, 2002; SAN DIEGO, Sept. 5 /PRNewswire/ -- Gen-Probe Incorporated, an established leader in molecular diagnostics based on its patented nucleic acid testing ( NAT ) technologies, today announced results from the initial field evaluation (beta trial) of the Company s TIGRIS System for clinical diagnostic testing. Two applicatio
HIV Medication Adherence Worsens Following September 11 Attacks: PRNewswire - September 5, 2002; -Patients taking medications for HIV were more likely to miss doses or take doses later following the events of 9/11, according to a study from the Center for HIV Educational Research and Training (CHEST) published on GayHealth.com NEW YORK, Sept. 5 /PRNewswire/ -- Gay and bisexual men with HIV on HAART (Highly Active
Triangle Pharmaceuticals, Inc. Submits New Drug Application for Coviracil(R) For the Treatment of HIV Disease: PRNewswire - September 4, 2002; DURHAM, N.C., Sept. 4, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for marketing approval of Coviracil for the treatment of HIV disease. Coviracil is a potent, once-a-day Nucleoside Rever
HIV Pioneer Encourages Chinese Health Authorities to Take 'Full Advantage' Of Calypte's HIV-1 Urine Screening Test: PRNewswire - September 3, 2002; ALAMEDA, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that HIV pioneer Professor Luc Montagnier, co-discoverer of HIV-1 and discoverer o
Hemispherx Biopharma Will Be Presenting at The Wall Street Analyst Forum in New York on September 9, 2002: PRNewswire - September 3, 2002; PHILADELPHIA, Sept. 3 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (Amex: HEB), a biopharmaceutical company focused in the experimental-stage development of immune-based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, today announced that Dr. William Carter, Chairman and CE
Innovative Australian HIV Drug Gets Green Light for Further Testing: PRNewswire - September 3, 2002; MELBOURNE, Australia , Sept. 3 /PRNewswire-FirstCall/ -- * Milestone in Australian HIV drug development with new study piggy-backing on current VIR201 treatment trial * Now testing VIR201 as independent therapy without accompanying anti-retroviral medications * New medication may provide relief from rigid routine and p
MTV, Kaiser Family Foundation Win Emmy for 'Be Safe/Fight for Your Rights: Protect Yourself' Campaign: PRNewswire - August 30, 2002; NEW YORK, Aug. 30 /PRNewswire/ -- Last night, MTV: Music Television and the Kaiser Family Foundation accepted a National Emmy Award for Be Safe/Fight for Your Rights: Protect Yourself, a national public education campaign that informs young people about sexual health issues such as HIV/AIDS and STDs via public service
Transplants in HIV Patients Should Proceed, But Drug Interactions Can Be Concern, Concludes Research at International Congress of The Transplantation Society: PRNewswire - August 29, 2002; MIAMI, Aug. 29 /PRNewswire/ -- While historically surgeons have been reluctant to transplant patients with the human immunodeficiency virus (HIV), in recent years, some centers have begun to accept patients with well- controlled HIV as candidates for liver or kidney transplantation. Based on results of three studies fr
The National Academy of Television Arts & Sciences Presents Its 2001 Community Service and PSA Emmy Awards: PRNewswire - August 29, 2002; NEW YORK, Aug. 29 /PRNewswire/ -- Reality TV used to evoke open and honest discussions about race, a campaign that tells the importance adults play in a child s education and an awareness program about HIV and sexual health issues were honored last night as the National Academy of Television Arts & Sciences present
New Approaches Promote Shared Responsibility for Women and Men to Prevent HIV And Unplanned Pregnancy: PRNewswire - August 28, 2002; -Grants Totaling $48 Million to Fund Research and Development of New Approaches To Contraception and Disease Prevention SEATTLE, Aug. 28 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced a series of grants that will combine innovative uses of existing tools with research and development of technol
Governor Signs AB 2064 (Cedillo, D, Los Angeles) - Bill Paves Way for New Approach to HIV Testing: PRNewswire - August 28, 2002; -Law Enables Community-based, Nonprofit Organizations With Demonstrated Expertise to Conduct Counselor Training for State s HIV Testing Programs -AIDS Healthcare Foundation Gears Up to Target Hard-to-Reach Populations in Sex Clubs, Bath Houses and Via Mobile Testing Van -Preliminary July 2002 Alternative Testing Site R
Real People. Real Stories. AIDS Walk Detroit - Allen Park man lost his close friend to AIDS after 5 year battle: PRNewswire - August 28, 2002; ROYAL OAK, Mich., Aug. 28 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2002 campaign, Real People. Real Stories. As part of this campaign, 5 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 15 Walk to be held in Downtown Royal Oak. They
Panacos Pharmaceuticals Awarded $143,000 Grant to Discover Novel Drugs for Respiratory Syncytial Virus Infection: PRNewswire - August 28, 2002; Company Extends Its Fusion Inhibitor Technology to New Viral Target GAITHERSBURG, Md., Aug. 28 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has been awarded a Phase I Small Business Innovative Research (SBIR) Grant of $143,000 by the National Institutes of Health (NIH). The award will help supp
Calypte to Accelerate Development of Rapid HIV Urine Test: Schedules Pre-IDE Meeting With FDA for Early October: PRNewswire - August 27, 2002; ALAMEDA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY) the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced that based upon positive preliminary results which have yielded 100 percent specifi
New AIDS Therapy Research to Be Presented at ICAAC in September: PRNewswire - August 27, 2002; ANNAPOLIS, Md., Aug. 27 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) today announced that the first major poster presentation of the Company s new approach to treating HIV and other retroviral diseases will take place next month at the Interscience Conference on Antimicrobial Agents and Che
bd's mongolian BBQ Celebrates 10 Years; Restaurant Honors Association with AIDS Walk Detroit: PRNewswire - August 26, 2002; ROYAL OAK, Mich., Aug. 26 /PRNewswire/ -- Royal Oak based bd s mongolian barbeque, a chain of restaurants with 28 locations spread across 12 states, celebrated its 10 year anniversary on Thursday, August 22, 2002 with an invitation only party at its Royal Oak establishment. At the event, Billy Downs, owner and founder
Steven Spielberg to Accept HRC National Equality Award: Singer Melissa Etheridge to Present Award at Sixth Annual HRC National Dinner: PRNewswire - August 26, 2002; - Talk Show Host Cristina Saralegui, the Latin Oprah, to Accept HRC Civil Rights Award - Rep. Richard Gephardt, D-Mo., is Featured Speaker WASHINGTON, Aug. 26 /PRNewswire/ -- The Human Rights Campaign proudly announced today that filmmaker Steven Spielberg will accept the 2002 Human Rights Campaign National Equality Aw
Revolutionary Medication Compliance Technology, The Pill Timer(TM), Gives New Hope for People With HIV: PRNewswire - August 23, 2002; MED TIME TECHNOLOGY INTRODUCES THE PILL TIMER Med Time Technology, Inc. s new invention, The Pill Timer, is the only medication monitoring and compliance device that s recommended by pharmacists and meets USP safety standards. This helps individuals who sometimes forget to take their medications. Medicine must be taken
Evotec OAI Grants Licence to Roche Diagnostics: PRNewswire - August 22, 2002; HAMBURG, Germany and ABINGDON, England, Aug. 22 /PRNewswire-FirstCall/ -- Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that it granted a licence to Roche Diagnostics GmbH, the German affil
Roche Molecular Systems Initiates U.S. Clinical Trials Of COBAS AmpliScreen(TM) HBV Test Researchers: Study to Shed New Light on Highly Infectious, Often 'Silent,' Transfusion-Transmitted Virus, Hepatitis B: PRNewswire - August 22, 2002; PLEASANTON, Calif., Aug. 22 /PRNewswire/ -- Roche Molecular Systems, Inc. (Roche) today announced the start of comprehensive clinical trials of its COBAS AmpliScreen(TM) HBV Test. The trials mark an important milestone because, for the first time in the U.S., Roche s PCR nucleic acid amplification technology (NAT) test
Chiron Appoints Jack Goldstein President, Chiron Blood Testing : New Business Unit Head Brings Substantial Operating Experience to Blood Testing Division: PRNewswire - August 22, 2002; EMERYVILLE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today named Jack Goldstein, 55, as president of Chiron s Blood Testing division. Based in Emeryville, Dr. Goldstein will be responsible for the commercial operations of Chiron s blood testing business. He will also serve as a member
Trinity Medical Group USA Announces REMUNE(R) Study Results In Slowing HIV Progression and Overcoming Specific Drug Resistance In Antiretroviral Therapies Two Studies Were Presented at FASEB Conference on Therapeutic and Preventive HIV Vaccines: PRNewswire - August 22, 2002; RANCHO SANTA MARGARITA, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today publicly announced clinical results presented at a scientific conference on therapeutic and preventive HIV vaccines indicating that HIV-positive patients in Thailand taking highly ac
Alonzo Mourning Launches National Campaign to Help Chronically Ill Patients With Anemia: Exhaustion Most Frequent and Significant Symptom Related to Serious Chronic Diseases, According to Harris Interactive Survey: PRNewswire - August 20, 2002; ORTHO BIOTECH TO DISTRIBUTE REBOUND FROM ANEMIA BROCHURE: Pro basketball star Alonzo Mourning and Ortho Biotech Products, L.P. are distributing a free brochure, Rebound from Anemia, to educate and encourage the millions at risk for anemia. For more information about the program, call 1-800-251-0627 or visit www.procrit
ADVR's Product R Subject of Published Study on Clinical Trial For Treatment of HIV/AIDS: Study Concludes Product R Patients Had Increased CD-4 Cell Counts and Weight Gains Compared to Placebo Patients: PRNewswire - August 20, 2002; YONKERS, N.Y., Aug. 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that the results of a randomized, controlled and blinded clinical study of Product R therapy in patients with HIV/AIDS have been published in the July/August 2002 issue of HIV Clinical Trials. This
Students Rally for AIDS Walk Detroit; Grosse Pointe North High School Builds a Team for September 15 Walk: PRNewswire - August 19, 2002; ROYAL OAK, Mich., Aug. 19 /PRNewswire/ -- On Sunday, August 11, 2002, Danielle Dipert, Dan Gilleran and Sara Johnson, team leaders for the Grosse Pointe North High School Walk Team, and approximately 40 other students and teachers gathered for a kick-off rally to begin building their team for AIDS Walk Detroit 2002. Th
FDA Approves Kytril For The Prevention and Treatment of Post-Operative Nausea and Vomiting - Studies Show Kytril Significantly More Effective Than Placebo: PRNewswire - August 19, 2002; NUTLEY, N.J., Aug. 19 /PRNewswire/ -- Roche announced today that the U.S. Food and Drug Administration ( FDA ) granted approval of its antiemetic, Kytril(R) Injection (granisetron hydrochloride) for both the prevention and treatment of post-operative nausea and vomiting (PONV). When used for prevention, Kytril is given
Virax to Develop Hepatitis B Treatment With New York Blood Center: PRNewswire - August 19, 2002; MELBOURNE, Australia , Aug. 19 /PRNewswire-FirstCall/ -- * Virax expands development program into third product area * Prestigious US organisation seeks Virax collaboration * Visit http://www.virax.com.au for more information Virax Holdings Limited (ASX: VHL) announced today that it has signed a development agreement w
Hemispherx Biopharma Receives Letter of Intent for Potential Multimillion-dollar Investment by Royal Family of United Arab Emirates - Understanding Announced at Annual Meeting in Philadelphia: PRNewswire - August 19, 2002; -- Global Technology Expands as Company-held Patents Approach the 400 Mark -- Clinical Trial for HIV and Hepatitis C Set to Start in Spain PHILADELPHIA, Aug. 19 /PRNewswire-FirstCall/ -- Hemispherx Biopharma has received a Letter of Intent for a potential multimillion-dollar investment in the Company by the Royal Famil
First 2003 Nissan 350Z(TM) - VIN #0000001 - to be Available on eBay Motors; All Proceeds Will Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - August 19, 2002; GARDENA, Calif., Aug. 19 /PRNewswire/ -- Nissan North America, Inc., (NNA) today announced that the first 2003 Nissan 350Z(TM), VIN 0000001, will be available for bidding on eBay Motors. Nissan, in conjunction with the Entertainment Industry Foundation, will donate the winning bid amount to the Elizabeth Glaser Pediatr
Roche and Trimeris Open Physician Enrollment For Fuzeon(TM) U.S. Early Access Program: PRNewswire - August 16, 2002; NUTLEY, N.J. and DURHAM, N.C., Aug. 16 /PRNewswire/ -- Responding to patient need, Roche and Trimeris today announced that physician enrollment for the U.S. Early Access Program for Fuzeon(TM)* ( enfuvirtide ), formerly known as T-20, will open on Monday, August 19. This program, running parallel with other controlled
The Immune Response Corporation Announces Results From Trial of REMUNE(R) In Treatment Interruptions for Chronic HIV Infection - Results Indicate Approach Allowed for Extended Periods Off Antiretroviral Therapy: PRNewswire - August 15, 2002; CARLSBAD, Calif., Aug. 15 /PRNewswire-FirstCall/ -- Indicating for the first time in a clinical trial that REMUNE(R) might give relief for HIV- infected patients from the adverse side-effects of antiretroviral therapies, The Immune Response Corporation (Nasdaq: IMNR) announced today results from an ongoing study by the
Calypte Files 10-Q and Submits Financial Certification With the SEC: PRNewswire - August 14, 2002; ALAMEDA, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY) today announced that its Chairman Anthony Cataldo, CEO Nancy Katz, and CFO Richard Brounstein today affirmed the accuracy of Calypte s Form 10-Q for the period ending June 30, 2002 as filed with the Securities a
Gen-Probe Reports Second Quarter 2002 Financial Results - Company recognizes initial commercial revenues in the United States from its HIV-1/HCV blood screening assay: PRNewswire - August 14, 2002; -- Gen-Probe distribution to the shareholders of Chugai expected on or about September 15, 2002; Company expects to begin trading on the Nasdaq National Market(R) under ticker symbol GPRO on September 16, 2002 SAN DIEGO, Aug. 14 /PRNewswire/ -- Gen-Probe Incorporated, an established leader in molecular diagnostics base
Norzyme(TM) Awarded Grant by National Institutes of Health - Million Dollar Grant to Fund Clinical Trials on HIV-AIDS Patients: PRNewswire - August 14, 2002; CHICAGO, Aug. 14 /PRNewswire/ -- Norzyme, Inc., developers of in-vitro diagnostic technology for therapeutic drug monitoring, today announced the National Institutes of Health (NIH) has further recognized the promise of its Levoprin-ZG(TM) product to aid in the disease management of HIV-AIDS patients with the award of
Epimmune Issued Additional Patent for PADRE(R) Technology - Patent Includes Claims Covering Compositions and Methods For Inducing Immune Responses in Humans: PRNewswire - August 13, 2002; SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body s immune system, today announced that the U.S. Patent and Trademark Office recently issued the Company a patent
Data From Cohort Study Showed Better Virologic Response in Regimens Containing SUSTIVA(R) Compared to Viramune(R)-Containing Regimens in HIV Treatment-Naive Patients: PRNewswire - August 12, 2002; PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Data from a large observational cohort study published in the July/August issue of HIV Clinical Trials showed that anti-HIV combination treatment regimens containing SUSTIVA(R) ( efavirenz ) had a better virologic response than regimens containing
Group Led by Johns Hopkins Center for Communication Programs Wins $127 Million for Global Health Communication Project - Award Will Fund Programs to Combat Public Health Threats Such as HIV/AIDS: PRNewswire - August 9, 2002; BALTIMORE, Aug. 9 /PRNewswire/ -- A group led by the Johns Hopkins University Center for Communication Programs (JHU/CCP) has been awarded $127 million by the U.S. government to implement a five-year global project designed to use strategic communication to fight infectious diseases such as HIV/AIDS, TB, and malaria; i
Flashback: CAGW AIDS Report Uncovers Federal Programs Abuse; New White House and CDC Inquiries Bolster February Report: PRNewswire - August 8, 2002; WASHINGTON, Aug. 8 /PRNewswire/ -- In response to new government inquiries into abuse and mismanagement in federal AIDS programs, Citizens Against Government Waste, the nation s largest taxpayer watchdog, today re-released its February 2002 report, AIDS Programs: An Epidemic of Waste. (See the report at http://www.cagw
Epimmune Reports Second Quarter 2002 Financial Results: PRNewswire - August 8, 2002; SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body s immune system, today announced its financial results for the second quarter ended June 30, 2002. Second quarter
Los Angeles Latino Community, Corporate and Medical Leaders Gather For HIV/AIDS Benefit at House of Blues: PRNewswire - August 8, 2002; WHAT: Una Noche de Esperanza (A Night of Hope), seventh-annual awards dinner and art auction to benefit AltaMed Health Service, a leading organization focusing on growing HIV/AIDS crisis in the Latino community. The concert-style event will also include celebrity appearances and entertainment. WHEN: Sunday, Aug
ViroLogic Announces Data on Increase in HIV Drug Resistance Published In New England Journal of Medicine - Results Strongly Supports Resistance Testing for Newly-Infected Individuals: PRNewswire - August 8, 2002; SOUTH SAN FRANCISCO, Calif., Aug. 8 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the spread of drug-resistant HIV has accelerated rapidly over the last several years according to research using its technology and published in this week s issue of The New England Journal of Medicine. Dru
Calypte Receives Initial Order for Urine HIV Tests From West Africa: PRNewswire - August 7, 2002; ALAMEDA, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approved HIV-1 Antibody tests that can be used on urine samples announced today that it has received its first West African order. The order calls for delivery of t
L.A.'s Latino Community, Corporate and Medical Leaders Gather For HIV/AIDS Benefit at House of Blues - Event Benefits AltaMed, a Leading Organization Focusing On Growing AIDS Crisis in the Latino Community: PRNewswire - August 7, 2002; LOS ANGELES, Aug. 7 /PRNewswire/ -- The devastating affect of HIV/AIDS on the Latino community will be spotlighted at AltaMed s seventh annual fundraiser, Una Noche de Esperanza (A Night of Hope) leadership awards dinner and art auction on Sunday, Aug. 11 at Hollywood s House of Blues. The event begins at 5:30 p.m. Pro
VaxGen Releases Second-Quarter Financial Results; Development Expenses In Line with Company's Expectations: PRNewswire - August 6, 2002; BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- VaxGen , Inc. (Nasdaq: VXGN) today announced a net loss of $6.7 million, or 46 cents per share excluding non-cash charges, for the second quarter ended June 30, 2002, compared with a net loss of $5.9 million, or 42 cents per share excluding non-cash charges, in the sec
ASGA Announces Agreement for YouthAIDS Celebrity Pro-Am Event: PRNewswire - August 6, 2002; ELIZABETH CITY, N.C., Aug. 6 /PRNewswire-FirstCall/ -- ASGA, Inc. (OTC Bulletin Board: ASGA) announced today that its wholly owned subsidiary, ASGA Tour, Inc., has executed an Agreement to conduct an event November 1-3, 2002, with celebrities and golf professionals to benefit Population Services International s YouthAI
Georgia Ag Department Finds Contaminated Bay Leaves: PRNewswire - August 5, 2002; ATLANTA, Aug. 5 /PRNewswire/ -- Commissioner of Agriculture Tommy Irvin announced today that Georgia Department of Agriculture food scientists have found some contamination in a brand of fresh bay leaves pulled from a store sample. A sample of Melissa s Fresh Bay Leaves was found to be contaminated with Listeria monocy
Triangle Pharmaceuticals Names Daniel G. Welch as Chairman and CEO: PRNewswire - August 5, 2002; DURHAM, N.C., Aug. 5 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that Daniel G. Welch has been appointed Chairman and CEO effective August 5, 2002. Mr. Welch succeeds Dr. David Barry, founder and former Chief Executive Officer, who passed away in January of this year. Mr. Wel
Sunesis Achieves Research Breakthrough Using Tethering Lead Discovery Technology - Program Results Highlighted at IBC Drug Discovery Technology 2002 Conference: PRNewswire - August 5, 2002; SOUTH SAN FRANCISCO, Calif., Aug. 5 /PRNewswire/ -- Sunesis Pharmaceuticals, Inc. today announced the discovery of a potent, small molecule inhibitor of Interleukin-2 ( IL-2 ), providing the most advanced proof of principle to date of the Company s Tethering technology. This approach reliably generates small molecule
Groundbreaking Approach to Prevent Transmission of HIV Shows Promise: PRNewswire - August 5, 2002; CHICAGO, Aug. 5 /PRNewswire/ -- New, antiinfective substances that can be developed as gels, creams, foams, films, even impregnated sponges and suppositories may prove to be a ground-breaking approach to preventing the spread of HIV, the virus that causes AIDS, according to an international authority and clinical pharm
Georgia Ag Finds Contaminated Chicken Salad; Take It Back, Says Commissioner Irvin: PRNewswire - August 2, 2002; ATLANTA, Aug. 2 /PRNewswire/ -- Georgia Department of Agriculture food scientists report finding contamination of Reser s White Meat Chicken Salad pulled from a grocery store sample. Commissioner Tommy Irvin urges anyone who has it at home to return it to where they bought it. Georgia s test showing the presence of Lis
California Representatives Cross Party Lines To Back Increase for AIDS Drugs - AIDS Healthcare Foundation Calls on All California Representatives to Join Mary Bono, Henry Waxman, Doug Ose, and Diane Watson in Effort to Boost AIDS Drug Assistance Program (ADAP): PRNewswire - August 2, 2002; LOS ANGELES, Aug. 2 /PRNewswire/ -- California s representatives in Congress today joined across party lines to ask House of Representatives leadership to end waiting lists for AIDS drugs by increasing funds for treatment. With over 1,200 uninsured Americans on waiting lists for life- saving medications, we re proud to
ViroLogic Announces Second Quarter 2002 Financial Results: Company Reports 40 Percent Sales Growth, Improved Gross Margin and Lower Net Loss Over Second Quarter of 2001: PRNewswire - August 1, 2002; SOUTH SAN FRANCISCO, Calif., Aug. 1 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the second quarter ended June 30, 2002. The Company reported revenue of $6.7 million for the second quarter, up 40 percent over revenue of $4.8 million for the same period in 2001. I am plea
Improved HIV Viral Load Test Approved By The FDA - Highly Sensitive Test, Roche AMPLICOR HIV-1 Monitor(R), Now Provides Better Coverage of HIV-1 Viral Subtypes: PRNewswire - July 31, 2002; INDIANAPOLIS, July 31 /PRNewswire/ -- Today Roche Diagnostics announced that on July 26, 2002, it received marketing approval from the U.S. Food and Drug Administration ( FDA ) for the Roche AMPLICOR HIV-1 MONITOR(R) Test, version 1.5. This test is a highly sensitive laboratory test to measure levels of HIV circulating
Elizabeth Glaser Pediatric AIDS Foundation Awarded $100 Million By United States Agency for International Development - Award Will Fund International Programs to Prevent Mother-to-Child Transmission of HIV and Provide Expanded Care and Treatment to Families And Communities: PRNewswire - July 31, 2002; WASHINGTON, July 31 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced today that the United States Agency for International Development (USAID) has awarded a grant of up to $100 million over five years to the Foundation s international Call to Action Project, which is taking immediate action to p
Triangle Pharmaceuticals, Inc. Announces Data Safety Monitoring Board's Recommendation to Unblind Coviracil Pivotal Trial Early - Coviracil(R) Demonstrates Superiority to Zerit(R) in FTC-301; All Patients Offered Rollover to Coviracil Regimen: PRNewswire - July 30, 2002; DURHAM, N.C., July 30, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced positive findings from FTC-301, an ongoing pivotal Phase III trial of Coviracil (emtricitabine), its nucleoside reverse transcriptase inhibitor for the treatment of HIV disease. With these results, the Co
Triangle Pharmaceuticals, Inc. Announces Reacquisition of Product Rights From Abbott Laboratories - Mutual Decision to Benefit R&D Efforts of Both Companies: PRNewswire - July 30, 2002; DURHAM, N.C., July 30, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced that it has reacquired from Abbott Laboratories (NYSE: ABT) full product rights, including rights to all profits, for four drug candidates in clinical development, including Coviracil(R) (emtricitabine) f
Antibodies for Cancer, HIV, RA, Cardiovascular and Autoimmune Disease To Be Featured at Conference & Exposition September 16-18 in New Jersey: PRNewswire - July 30, 2002; LONG BRANCH, N.J., July 30 /PRNewswire/ -- The first of four meetings featured at the World Antibody Summit 2002, Antibody Discovery & Clinical Drug Development will feature the presentation of exciting clinical data in a variety of therapeutic areas on September 16, announces Strategic Research Institute. Alexion,
SuperGen's Orathecin(TM) Receives Orphan-Drug Designation For Treatment of Pediatric AIDS: PRNewswire - July 25, 2002; DUBLIN, Calif., July 25 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that its oral anticancer cancer compound Orathecin(TM) has received orphan-drug designation from the Food and Drug Administration ( FDA ) for the treatment of pediatric patients infected with human immunodeficiency virus (HI
Tucson Media Briefing on Trial Results From Therapeutic HIV Vaccine: PRNewswire - July 25, 2002; Estimates at the recent International AIDS Conference in Barcelona indicate that over 40 million people worldwide are infected with HIV with almost one million of them in the U.S. alone Dr. Fernandez-Cruz and Dr. Moss are presenting data at the 2002 Federation of American Societies for Experimental Biology s (FASEB) Su
Sunesis Receives NIH Grant to Develop New HIV Therapies: PRNewswire - July 24, 2002; SOUTH SAN FRANCISCO, Calif., July 24 /PRNewswire/ -- Sunesis Pharmaceuticals, Inc. announced today that the company has been granted a $600,000, two-year Phase I Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases. The grant was awarded to Sunesis to develop inhibitor
Antibody Discovery & Clinical Development Conference to Feature New Technologies & Therapeutic Applications September 16-18 in New Jersey: PRNewswire - July 24, 2002; LONG BRANCH, N.J., July 24 /PRNewswire/ -- The first of four meetings featured at the World Antibody Summit 2002, Antibody Discovery & Clinical Development will feature the presentation of exciting clinical data in a variety of therapeutic areas on September 16, announces Strategic Research Institute. Alexion, Prot
Statement of Werner Fornos, President of the Population Institute* On the Refusal to Release the Congressional Appropriation For the United Nations Population Fund: PRNewswire - July 22, 2002; WASHINGTON, July 22 /PRNewswire/ -- The following is a statement of Werner Fornos, President of the Population Institute* on the refusal to release the Congressional Appropriation for the United Nations Population Fund: By withholding the $34 million Congress appropriated for United Nations family planning and reproduc
Kucera Hires Fyock for Agency Work: PRNewswire - July 22, 2002; WINSTON-SALEM, N.C., July 22 /PRNewswire/ -- Kucera Pharmaceutical Co., a Winston-Salem-based biotechnology spinoff of Wake Forest University s School of Medicine, has retained Fyock & Associates for media and public relations services. We have enjoyed working closely with Fyock & Associates through its media r
Metropolitan and SABCOHA launch South Africa's first definitive AIDS web portal: PRNewswire - July 22, 2002; Johannesburg - For more than a decade, Metropolitan has been the leader in providing South African business with accurate and cutting-edge information on HIV and AIDS. In 1999, Metropolitan launched its www.redribbon.co.za website, which quickly gained a reputation as the leading HIV/AIDS on-line information resource c
FRC Cheers Born-Alive Bill Passage, Puzzled About White House AIDS Shuffle: PRNewswire - July 19, 2002; WASHINGTON, July 19 /PRNewswire/ -- The pro-life cause registered a significant victory late Thursday when, on a unanimous consent vote, the Senate unexpectedly passed the Born-Alive Infants Protection Act. In other news, a personnel shuffle at the White House over its approach to HIV/AIDS policy, has pro-family conser
Crucell Appoints Dr. Jaap Goudsmit to Executive Committee: PRNewswire - July 19, 2002; LEIDEN, Netherlands , July 19 /PRNewswire-FirstCall/ -- Dutch antibody and vaccine company Crucell N.V. (Nasdaq: CRXL; Euronext) today announced that it has appointed Dr. Jaap Goudsmit to the Executive Committee as Chief Medical Officer and Executive Vice President Vaccine R&D. Dr. Goudsmit will be responsible for
UNICEF Urges Donors to Help Save 6 Million Children at Risk In Southern Africa Crisis: Children Face Tough Odds as Drought, Illness and AIDS Combine - Swift Response to New UN Appeal Is 'Crucial,' Bellamy Says: PRNewswire - July 18, 2002; NEW YORK, July 18 /PRNewswire/ -- The United Nations Children s Fund today urged the world community to help save the lives of more than 6 million children who are at immediate risk of death in southern Africa due to a crippling combination of natural and man-made crises. Speaking in support of an emergency UN appeal f
Achillion Pharmaceuticals Launches HIV/AIDS Clinical Development Program, A Second Indication for Lead Product Candidate: PRNewswire - July 17, 2002; NEW HAVEN, Conn., July 17 /PRNewswire/ -- Achillion Pharmaceuticals today announced receipt of regulatory clearance and the commencement of a Phase 2 clinical study with Company s lead product candidate, ACH-126,443 (Beta-L-Fd4C), in patients with HIV/AIDS. The study is being conducted under Achillion s second Investig
Cell Robotics Retains H.C. Wainwright & Co., Inc. As Its Investment Banker And Announces Additional Lasette Orders For China: PRNewswire - July 15, 2002; ALBUQUERQUE, N.M., July 15 /PRNewswire-FirstCall/ -- Cell Robotics International, Inc. (OTC Bulletin Board: CRII.OB) producer of the laser capillary blood-sampling device announces that it has retained H. C. Wainwright & Co., Inc. to assist in raising near-term operating and expansion capital and to provide other f
FDA Grants Priority Review to PEGASYS(R) (peginterferon alfa-2a) And Ribavirin Combination for Treatment of Hepatitis C : Priority Review Designation Granted to Therapies That Address Unmet Medical Needs: PRNewswire - July 15, 2002; NUTLEY, N.J., July 15 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has granted a six-month Priority Review Status to the Biologics License Application (BLA) and New Drug Application (NDA) for Roche s combination therapy of PEGASYS(R) (peginterferon alfa-2a) and Roche ribavirin tablets, for the treatmen
Amarillo Biosciences, Inc. Licenses Rights to Low Dose Oral Interferon For Hepatitis B in 40 African Countries; and Executes Dietary Supplement Agreement For Korea: PRNewswire - July 15, 2002; AMARILLO, Texas, July 15 /PRNewswire-FirstCall/ -- Amarillo Biosciences, Inc. (OTC Bulletin Board: AMAR) announces the Company has signed a licensing agreement with African Health Solutions, LLC, Greenville, Delaware providing the rights to oral low-dose interferon alpha for the treatment of hepatitis B patients in Afr
Humans found to possess gene defence against HIV: PRNewswire - July 15, 2002; A scientist at King s College London has discovered a unique gene in humans that acts as a defence against attack from human immunodeficiency virus, HIV, the virus that causes AIDS. The gene, CEM15, represents a new type of natural resistance to viral activity that could be exploited to produce new treatments for HIV o
MTV and VH1 to Sponsor 'Sexual Healing', An Event Benefiting Artists Against AIDS Worldwide: Artists Gather at The Spanish Kitchen to Help Raise Awareness to Stop The Spread of AIDS in Africa: PRNewswire - July 11, 2002; LOS ANGELES -- On Thursday, July 18th, the stars will be shining bright in Los Angeles as they turn out to support Artists Against AIDS Worldwide (AAAW). Sponsored by MTV and VH1 and hosted by the much-anticipated new restaurant, The Spanish Kitchen, the event will celebrate Sexual Healing in the artistic community and
Data Show HIV Patients Switched to Bristol-Myers Squibb Investigational Protease Inhibitor May Have Significant Reductions In Cholesterol and Triglyceride Levels: PRNewswire - Thursday, July 11, 2002; BARCELONA, Spain -- Data presented today at the XIV International AIDS Conference demonstrated that patients with HIV (human immunodeficiency virus) experienced significant reductions in blood levels of total cholesterol, low-density lipoprotein (LDL) or bad cholesterol and triglycerides when switched from the protease
Combination Regimen Containing Investigational Once-Daily, Extended Release ZERIT(R) (stavudine) Shows Similar Viral Load Suppression Through 48 Weeks Of Treatment Compared to ZERIT(R) Immediate Release: PRNewswire - Thursday, July 11, 2002; BARCELONA, Spain -- Data presented today at the XIV International AIDS Conference show that the investigational one- capsule, once-daily extended release formulation of Bristol-Myers Squibb s (NYSE: BMY) nucleoside reverse transcriptase inhibitor (NRTI) ZERIT(R) ( stavudine ) ha
IAVI Calls Barcelona Aids 2002 'A Reality Check' For Vaccines, Treatment: PRNewswire - Thursday, July 11, 2002; BARCELONA, Spain -- XIV International AIDS Conference -- Two years after the widespread optimism of the International AIDS Conference in Durban, Barcelona 2002 is a splash of cold water and a reality check on how the world is doing in the fight against AIDS, said Seth F. Berkley, MD, President and CEO of the Internatio
Comparative Study Reveals Regimen Containing SUSTIVA(R) Provides Immunosuppressed HIV/AIDS Patients Effective Treatment Alternative to Protease Inhibitor-Based Therapy: PRNewswire - Thursday, July 11, 2002; BARCELONA, Spain -- Data presented this week at the XIV International AIDS Conference show that a greater proportion of patients on highly active antiretroviral therapy (HAART) containing SUSTIVA(R)( efavirenz ), Bristol-Myers Squibb s (NYSE: BMY) once-daily non- nucleoside reverse transcriptase inhibitor (NNRTI), achi
Women United Against AIDS Drives Action Agenda at the International AIDS Conference: PRNewswire - Thursday, July 11, 2002; BARCELONA, Spain -- Women leaders from around the world will spoke Wednesday evening at the International AIDS Conference on expanding access to effective solutions for women and girls suffering from AIDS. Women United Against AIDS, sponsored by the International AIDS Trust and UNAIDS , i
Zambia's HEART program evaluation shows youth respond positively to AIDS prevention plan promoting abstinence -- HEART program urges abstinence, fidelity or condom use: PRNewswire - Thursday, July 11, 2002; Barcelona, Spain -- Urging young people to abstain from sex in Zambia may not appear to make sense in a country where 75 percent are sexually active, but an AIDS prevention program sponsored by the U.S. Agency for International Development (USAID) shows young Zambians crave support for their decision to abstain and pre
The Immune Response Corporation Announces Oral Presentation of Three Year Clinical Evaluation of REMUNE(R) at XIV World AIDS Conference in Barcelona -- Principal Investigator Reports 'Study Links Strong HIV-Specific Immune Responses With Control of Virus': PRNewswire - Thursday, July 11, 2002; BARCELONA, Spain -- Before a global audience at the XIV International AIDS Conference, The Immune Response Corporation (NASDAQ: IMNR) announced today that data from a Phase II clinical trial (STIR - 2102) of REMUNE(R) was presented by Dr. Eduardo Fernandez-Cruz, head of Department of Clinical Immunology at the Universi
Association Francois-Xavier Bagnoud Projects 100 Million AIDS orphans by 2010 -- Enumerating Children Orphaned by HIV/AIDS: Counting a Human Cost - a study paper on the number of AIDS orphans by 2010, by Neil Monk on behalf of AFXB: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- Whereas official estimates are between 26.4 million and 44 million AIDS orphans by 2010, AFXB projects the breathtaking figure of 100 million AIDS affected children. Based on his scientific expertise, on his own research in Uganda and India and on the experien
Once-Daily HIV Medications Pave Way for Simplified Combination Drug Regimens: PRNewswire - Wednesday, July 10, 2002; PRINCETON, N.J. -- A once-daily drug regimen comprised of three leading anti-HIV medications may allow HIV patients, who previously followed complicated, multi-dose drug regimens, to create a once-daily combination therapy to reduce the frequency of dosing of their HIV treatment. The combination of the once-daily formu
Protest Shuts Down GlaxoSmithKline Booth at AIDS Conference; AIDS Healthcare Foundation Starts "Divest GSK" Drive: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- AIDS Healthcare Foundation (AHF), the largest non-government provider of AIDS medical services in the Unites States, today led a peaceful demonstration at the International AIDS Conference in Barcelona that shut down British-owned GlaxoSmithKline , protesting the pharmaceutical giant s AIDS drug
IAPAC Press Conference From the XIV International AIDS Conference in Barcelona: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- The International Association of Physicians in AIDS Care (IAPAC) today announced two initiatives to significantly enhance healthcare infrastructure in developing countries struggling to fight the AIDS pandemic. The initiatives are an effort to improve the quality of care for people with HIV/AIDS and
The Immune Response Corporation Announces Results of ACTG Clinical Trial Indicating REMUNE(R) Alone Stimulated Stronger Immune Responses Compared With REMUNE(R) Plus IL-2: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- The Immune Response Corporation (NASDAQ: IMNR) announced today that the Adult AIDS Clinical Trials Group of the National Institutes of Health presented new data at the XIV International AIDS Conference from a clinical trial designed to ascertain if the non-specific cytokine, Interleuken two (
Treatment Ready to Go for 35,000 AIDS Patients in Africa and the Caribbean: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- More than 30,000 patients with advanced HIV infections in 15 African and Caribbean countries could be put into an innovative, cost-effective treatment program developed by AIDS Empowerment and Treatment International, according to data presented at the International AIDS Meeting here. The networ
United Nations Foundation Previews 'Apathy is Lethal' HIV/AIDS Campaign: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- A new public service advertising (PSA) campaign aimed at communicating to Americans the breadth of the AIDS pandemic and its effects on the lives of children premiered today at the AIDS 2002 Barcelona XIV International AIDS Conference. The campaign, entitled Apathy is Lethal, highlights the plight o
HIV Patients Taking Investigational Boosted Saquinavir Dosing Regimen Maintained Low Viral Load and Showed Improvements in Triglycerides and Cholesterol: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- Clinical study results presented today indicate that HIV patients who switched their twice-daily protease inhibitor regimen of boosted saquinavir, by increasing the dose of saquinavir and minimizing the booster dose of ritonavir , were able to maintain viral suppression below 400 cop
Head-To-Head HIV Study Showed Significant Benefit for Boosted Saquinavir Over Boosted Indinavir: PRNewswire - Wednesday, July 10, 2002; BARCELONA, Spain -- Data from the MaxCmin1 trial, the first large, randomized study to compare boosted HIV protease inhibitor regimens, showed that boosted saquinavir (saquinavir 1000 mg with ritonavir 100 mg) reduced HIV to undetectable levels (
U.S. Minority Delegates Join Protest of Bush Administration Official at XIV International Conference on AIDS: PRNewire - Tuesday, July 9, 2002; BARCELONA, Spain -- The National Minority AIDS Council delegation to the XIV International Conference on AIDS called on the Bush Administration to rethink its global AIDS funding policy announced recently. The group s call came in response to an address Tuesday to the 15,000 delegates attending the conference by U.S. S
Bill & Melinda Gates Foundation Reaffirms Commitment to HIV Prevention: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain , July 9 /PRNewswire/ -- Helene Gayle, the Bill & Melinda Gates Foundation s program director for HIV/AIDS and TB, today reaffirmed the foundation s commitment to HIV prevention. Dr. Gayle delivered the opening plenary on prevention at the XIV International AIDS Conference in Barcelona, where she i
GlaxoSmithKline Charges 2X Other Drug Companies for Meds in Africa, AIDS Advocates Say: Divest GSK - US' Largest AIDS Organization Launches Dis-Investment Campaign: PRNewswire - Tuesday, July 9, 2002; What: PEACEFUL PROTEST & PRESS CONFERENCE to KICK OFF Divest GSK CAMPAIGN When: Wednesday, July 10th 12:00noon-2pm Where: in front of GSK s Booth International AIDS Conference, Fira de Barcelona Conference Center Building #2 (near the media center) Contact: Ged Kenslea +1.323.791.5526 Who: AIDS ADVOCATES
New Report on Global Impact of HIV/AIDS on Youth: By End of Decade 21.5 Million Young People Ages 15 to 24 Worldwide Expected To Be Living With HIV/AIDS - a More Than 70% Increase From Today: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain -- HIV/AIDS has always been an epidemic of young people, but new projections indicate that if trends persist, the current impact on youth is only the tip of the iceberg, according to a report released today by the Kaiser Family Foundation. Analysis of new U.S. Census Bureau data by the Foundation proje
IAVI Outlines New, Intensive R&D Agenda to Fast-Track Promising AIDS Vaccine Candidates to Final-Stage Human Testing: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain -- XIV International AIDS Conference, -- The International AIDS Vaccine Initiative (IAVI) outlined a new, intensified research and development agenda that the organization and its worldwide partners are undertaking to expedite the development of vaccines to prevent HIV/AIDS, focusing on those tailored
IAVI Launches Neutralizing Antibody Consortium to Accelerate Search For Preventive AIDS Vaccine; Stimulating Antibodies Against HIV Remains a Key but Solvable Challenge; Partners to Ensure Resulting Vaccines Will be Accessible to Developing Countries: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain -- XIV International AIDS Conference -- A new consortium of leading AIDS laboratories, working with the US government s Vaccine Research Center, and brought together by the International AIDS Vaccine Initiative (IAVI), hopes to speed the discovery of a vaccine to prevent HIV/AIDS through collaboration
ViroLogic Announces Positive Data on Its HIV Resistance Tests Presented At International AIDS Conference: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain -- ViroLogic, Inc. (NASDAQ: VLGC) announced today that 11 studies using its proprietary PhenoSense(TM) drug resistance testing technology will be presented here this week at the 14th International AIDS Conference. These studies demonstrate the utility of combined phenotypic-genotypic resistance testing
Study Shows T-20 Administration Has Little Impact On Daily Activities of Patients After Eight Weeks of Treatment - Separate Study Examines Pharmacokinetics and Safety of Weight-Based Dosing of T-20 in Children: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain -- Roche and Trimeris, Inc. (NASDAQ: TRMS) today announced that data collected from a survey of patients in two large, internationally conducted Phase III trials suggest that subcutaneous delivery of T-20 was well-accepted by a majority of patients after the first eight weeks of treatment. These data,
Four Studies Examine Strategy of Combining Saquinavir With Kaletra(TM) in Treatment-Experienced HIV Patients: PRNewswire - Tuesday, July 9, 2002; BARCELONA, Spain -- Roche today announced encouraging results of four new studies examining double boosting -- an investigational treatment strategy which combines a twice-daily regimen of saquinavir (1000 mg) with Kaletra (TM) ( lopinavir 400 mg/ritonavir 100 mg) -- in
Serono Announces Significant Results From Two Clinical Trials Of Serostim(R) at the XIV International Aids Conference: PRNewswire - Tuesday, July 9, 2002; ROCKLAND, Mass. and GENEVA -- Serono S.A. (virt-x: SEO and NYSE: SRA) announced positive results of two major clinical trials of Serostim(R) [somatropin (rDNA origin) for injection] for the treatment of AIDS-related metabolic complications at the XIV International AIDS Conference in Barcelona, Spain . Results
Pfizer CEO Announces Program to Provide Medical Expertise in AIDS Battle; Speech at International AIDS Conference Outlines Company Effort: PRNewswire - July 8, 2002; BARCELONA -- Pfizer Inc Chairman and CEO Hank McKinnell today announced the establishment of the Pfizer Health Fellows Program to provide needed human resources to combat HIV/AIDS in Africa and other hard hit areas. The new program follows other company efforts to increase donations of free medicines and other forms of
PacifiCare Ordered by Court to Turn Over Records to AIDS Healthcare Foundation Showing Whether it Complied With Law for HIV/AIDS Specialty Referrals: PRNewswire - Monday, July 8, 2002; LOS ANGELES -- On July 2, 2002, the California Court of Appeals let stand a decision of the state s trial courts requiring PacifiCare of California ( PacifiCare ) to turn over to AIDS Healthcare Foundation (AHF ) records and documents pertaining to PacifiCare members with HIV/AIDS. The Court implicitly agreed that thes
Sarawak MediChem Pharmaceuticals Initiates Clinical Trial of Calanolide a In Combination Therapy for HIV: PRNewswire - Monday, July 8, 2002; WOODRIDGE, Ill. -- Sarawak MediChem Pharmaceuticals, Inc. announced today that it has begun screening volunteers for a 48 subject, clinical trial of Calanolide A in combination therapy for HIV. This clinical trial will evaluate the therapy s safety and pharmacokinetics. Upon conclusion of this study, Sarawak MediChem P
IAVI Applauds Thailand's Leadership in HIV Vaccine Search: PRNewswire - Monday, July 8, 2002; BARCELONA, Spain -- Seth Berkley, MD, president and chief executive officer of the International AIDS Vaccine Initiative (IAVI), issued the following statement upon learning of Thailand s intention to move forward with the world s largest preventive HIV vaccine trial: From the beginning of this pandemic, Thailand has s
Bill & Melinda Gates Foundation to Premiere Rory Kennedy Film Pandemic: Facing AIDS: PRNewswire - Monday, July 8, 2002; BARCELONA, Spain -- The Bill & Melinda Gates Foundation today announced the premiere of Pandemic: Facing AIDS, the moving and insightful new film by Rory Kennedy and Moxie Firecracker Films. Pandemic, which will premiere at the XIV International AIDS Conference in Barcelona, is a feature-length documentary that tak
AnorMED selects new lead HIV drug candidate: Data on AMD-070 A New CXCR4 HIV Entry Inhibitor Presented at 14th International AIDS Conference, Spain: PRNewswire - Monday, July 8, 2002; VANCOUVER -- AnorMED Inc. announced today that it has identified a new lead drug candidate for HIV called AMD-070. Dr. Gary J. Bridger, Ph.D, AnorMED s Vice President, Research and Chief Scientific Officer, an invited speaker in the New Drugs, New Targets Symposium, presented data today on a new class of HIV Entry Inhi
Panacos Pharmaceuticals Unveils the Leading Compound in a Major New Class of HIV Drug Candidates: Budding Inhibitors: PRNewswire - Monday, July 8, 2002; GAITHERSBURG, Md. -- Panacos Pharmaceuticals, Inc. today made its first public presentation on the Company s innovative HIV drug candidate, PA-457, at the XIV International AIDS Conference in Barcelona, Spain . PA-457 is the first in a new class of drug candidates known as Budding Inhibitors that offer a completely nov
The Immune Response Corporation Announces Presentation of Study Results On REMUNE(R)'s Potential for Treating Chronically Infected HIV-Positive Patients: PRNewswire - Monday, July 8, 2002; BARCELONA, Spain -- The Immune Response Corporation (NASDAQ: IMNR) announced today the presentation of data at the XIV International AIDS Conference which suggest that REMUNE(R) induced helper T-cell immune responses aimed specifically at HIV in chronically infected HIV-positive individuals taking HAART (Highly Active
ViroLogic Study in Journal of the American Medical Association Supports Greater Use of HIV Drug Resistance Testing in Newly Infected Patients; Study Demonstrates HIV Drug Resistance Dramatically Increasing: PRNewswire - Monday, July 8, 2002; BARCELONA, Spain -- ViroLogic, Inc. (NASDAQ: VLGC) announced today that research published in this week s issue of the Journal of the American Medical Association (JAMA) and announced here at the 14th Annual International AIDS Conference indicate that resistance testing should play a greater role in guiding treatment f
Treatment-Experienced Patients Twice as Likely to Achieve Undetectable HIV Levels With T-20 Than Without: PRNewswire - Monday, July 8, 2002; BARCELONA, Spain -- Data from two large, internationally conducted Phase III trials indicate that combination therapy with T-20 reduced HIV to undetectable levels in the blood in at least twice the percentage of patients and provided an improved immune response at 24 weeks, as compared to those who took combination the
Promising Three-Year Data Presented on Viral Suppression, Immune Response And Resistance in Naive Patients Taking a Kaletra(R) (Lopinavir/Ritonavir) Regimen: PRNewswire - Monday, July 8, 2002; BARCELONA, Spain -- Data presented at the 14th International AIDS Conference in Barcelona shows the three-year efficacy and tolerability of a Kaletra-based regimen in 100 patients new to antiretroviral therapy (naive). This promising data demonstrated that a drug regimen including Kaletra provided viral suppression (as
Treatment experienced patients twice as likely to achieve undetectable HIV levels with T-20 (enfuvirtide) than without; T-20 also shows improved immune response: PRNewswire - Sunday, July 7, 2002; Barcelona, Spain - Today world renowned HIV experts unveiled positive results from two large scale international studies with T-20, the furthest in clinical development of a new class of investigational antiretroviral drugs called fusion inhibitors . Phase III results presented for the first time, show that levels of H
Promising Three-Year Data Presented on Viral Suppression, Immune Response And Resistance in Naive Patients Taking a Kaletra(R) (Lopinavir/Ritonavir) Regimen: PRNewswire - Sunday, July 7, 2002; BARCELONA, Spain -- Data presented at the 14th International AIDS Conference in Barcelona shows the three-year efficacy and tolerability of a Kaletra-based regimen in 100 patients new to antiretroviral therapy (naive). This promising data demonstrated that a drug regimen including Kaletra provided viral suppression (as
Thousands March for Treatment at Barcelona AIDS Conference; Conference President Reads 'Barcelona Declaration': PRNewswire - Sunday, July 7, 2002; BARCELONA, Spain -- Thousands of AIDS activists today took to the streets in Barcelona at the International AIDS Conference March for Life demanding AIDS treatment now for the world s HIV-infected, ninety-eight percent of whom do not receive life-saving treatment. You represent the voice of millions seeking help just t
Exposure to Hepatitis C Has No Effect on Antiretroviral Treatment Outcomes in HIV Patients: PRNewswire Saturday, July 6, 2002; WASHINGTON -- A study of HIV-infected patients in Baltimore, Maryland, revealed that individuals seropositive for hepatitis C had similar clinical outcome measures when treated with antiretroviral drug regimens compared to seronegative patients. These findings will be presented at a July 6 press conference at the XIV I
Phase II Study Finds Tipranavir Suppresses HIV/AIDS Virus Resistant To Available Protease Inhibitors - At 48 Weeks, HIV-Positive Patients With Up to Twenty Resistance Mutations Still Maintained Susceptibility to Tipranavir: PRNewswire - July 5, 2002; SEVILLE, Spain -- Study findings demonstrate that a tipranavir-based HIV/AIDS treatment regimen produced a significant reduction in HIV-1 levels in patients who previously had received treatment with multiple protease inhibitor-based (PI) regimens. Data from this trial and an additional in vitro study further character
Global initiative launched to combat HIV drug resistance: Data to be shared and accessible over the Internet: PRNewswire - Thursday July 4 2002; Seville, Spain - A radical new initiative in HIV management was launched today at the XI International HIV Drug Resistance Workshop. The International HIV Resistance Response Database Initiative, or RDI, will combine data from thousands of HIV patients around the world into a freely accessible database that could enhan
Crucell and Genexine Announce Agreement for Hepatitis B Vaccine: PRNewswire - July 3, 2002; LEIDEN, The Netherlands -- Dutch antibody and vaccine company Crucell N.V. (Nasdaq, Euronext: CRXL) and Genexine Co. Ltd., a Korean drug development company, today announced that they have entered into a licensing agreement wherein Crucell s PER.C6(TM) cell line will be used by Genexine for the research, development an
Study Results Demonstrate Safety and Antiviral Activity of T-1249: PRNewswire - July 3, 2002; NUTLEY, N.J. and DURHAM, N.C. -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced final results of a Phase I/II study demonstrating that T-1249, a second-generation fusion inhibitor candidate, was well-tolerated and exhibited antiviral activity in HIV patients. Unlike existing anti-HIV drugs that work inside the
Visible Genetics Identifies Genetic Mutations in HIV That May Cause Resistance to New Drug T-20: PRNewswire - July 3, 2002; TORONTO -- Visible Genetics Inc. (Nasdaq: VGIN) (VGI) scientists have identified a number of new mutations in the HIV genetic code that may be making the virus resistant to T-20, the first of a new class of experimental drugs called fusion inhibitors. The results, which were presented today at the XI International Work
Nastech Announces FDA Approval of Nascobal(R) Labeling Supplement to Include Maintenance of Hematologic Status in Patients With HIV Infection, AIDS, Multiple Sclerosis and Crohn's Disease: PRNewswire - July 2, 2002; BOTHELL, Wash. -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that the U.S. Food and Drug Administration ( FDA ) has approved a labeling supplement to the Nascobal(R) NDA that states that Nascobal can be used in patients with HIV, AIDS, multiple sclerosis, and Crohn s disease, conditions which ca
Activists Charge AIDS Conference Organizers 'Break Faith With Global AIDS Community Turn Meeting Into Drug Company Trade Show' :: PRNewswire - July 2, 2002; BARCELONA, Spain -- Organizers of the July 7 March for Life, representing 500 AIDS organizations across the globe, are protesting the favoritism being shown by the International AIDS Conference to the big drug companies, the only principal sponsors of the conference. Companies pay $1 million to hawk their wares to 14,0
ViroLogic's New Replication Capacity Test to be Highlighted At 11th International HIV Drug Resistance Workshop: Test Could Provide Valuable Information to Help Manage HIV Disease: PRNewswire - July 2, 2002; SOUTH SAN FRANCISCO, Calif. -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that HIV replication capacity (sometimes called viral fitness ) is an important indicator of clinical outcomes at multiple stages of HIV infection, according to several new studies to be presented later this week at the 11th International HIV
City of Berkeley wel ... COMES 'Out of the Closet' : Popular Southern California AIDS Fundraising Chain to Open in East Bay: PRNewswire - July 1, 2002; AIDS Thrift Store Premieres Wednesday, July 3rd - Via 10 AM Ribbon-cutting: Hollywood Lends Hand With Generous Donations Including Set Pieces From Fox-TV s The X-Files, Props From Warner Bros. and a Pool Table From Academy Award-Winning Director Ron Howard WHAT: Grand Opening -- Out of the Closet thrift store WHEN:
AIDS Healthcare Foundation Sues Glaxo for Anti-Trust; AHF Discovers Invalid Patents on AZT & Other HIV Drugs: PRNewswire - July 1, 2002; LOS ANGELES -- The largest AIDS organization in the United States today files a federal lawsuit charging British-owned GlaxoSmithKline with anti-trust violations that could break the manufacturer s monopolistic hold on key AIDS drugs in the United States. AIDS Healthcare Foundation (AHF) -- represented by the law f
Enterprising Youth Leaders From Around the World Receive Awards Through YouthActionNet.org: PRNewswire - July 1, 2002; BALTIMORE -- A 23 year old Namibian leading efforts to help families of those in his community stricken by HIV/AIDS, an 18 year old radio journalist in Vietnam whose stories on environmental and social issues have reached over 30 million people, and a young Peruvian working to provide poor children in the Amazon rainfo
Trinity Medical Group USA Announces Amendment of REMUNE(R) Supply Contracts: PRNewswire - June 28, 2002; RANCHO SANTA MARGARITA, Calif., June 28 /PRNewswire-FirstCall/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) announces that it has amended its REMUNE License and Collaboration contract with The Immune Response Corporation (Nasdaq: IMNR). The amended contract provides for an additional $50.00 per unit to
CIGNA Enhances Accident Insurance Coverage with Several Product Additions, Including Benefits for Health Care Workers Who Accidentally Contract HIV : Other Benefits Include COBRA Coverage, Bereavement Counseling, Rehabilitation, Home or Vehicle Alterations, Child Care: PRNewswire - June 27, 2002; PHILADELPHIA, June 27 /PRNewswire-FirstCall/ -- It happens in the blink of an eye...a medical worker handling a just-used syringe or involved with an injection for a patient with a contagious disease gets nicked in the process. Ordinarily, there is no effect beyond the momentary sting of the pinprick. But those seeming
International Association of Physicians in AIDS Care (IAPAC) Urges Spanish Officials to Ensure Full Participation of Developing World Physicians and Advocates at Upcoming International AIDS Conference: PRNewswire - June 27, 2002; CHICAGO, June 27 /PRNewswire/ -- The International Association of Physicians in AIDS Care (IAPAC) is concerned by recent news indicating that many developing world physicians, allied health professionals, and advocates seeking to participate in the upcoming XIV International AIDS Conference in Barcelona,
New Data on T-20, Most Clinically Advanced HIV Fusion Inhibitor, to Be Featured at International AIDS Conference in Barcelona: PRNewswire - June 26, 2002; NUTLEY, N.J., and DURHAM, N.C., June 26 /PRNewswire-FirstCall/ -- The XIV International AIDS Conference (IAC), the world s largest HIV/AIDS meeting, to be held in Barcelona, Spain , July 7-12, will focus in part on classes of antiretrovirals that attack HIV in a novel way. One developmental class, fusion inhibitors, is
Antibody Discovery & Clinical Development Conference & Exposition to Feature Papers in Cancers, RA, Autoimmune Disease, & HIV September 16-18 in NJ: PRNewswire - June 25, 2002; LONG BRANCH, N.J., June 25 /PRNewswire/ -- The first of four meetings featured at the World Antibody Summit 2002, Antibody Discovery & Clinical Development will feature the presentation of exciting clinical data in a variety of therapeutic areas on September 16, announces Strategic Research Institute. Alexion, Prot
Press Briefing by Gary Edson Aboard Air Force One En Route Phoenix, Arizona: PRNewswire - June 25, 2002; WASHINGTON, June 25 /PRNewswire/ -- The following is a transcript of remarks by Gary Edson: THE WHITE HOUSE Office of the Press Secretary 10:25 A.M. EDT MR. FLEISCHER: Let me turn you over to Mr. Gary Edson. Are you going to do this on the record? MR. EDSON: Any way you want. MR. FLEISCHER: Let s do this on the record,
US' Largest AIDS Organization Praises President's Advisory Council on HIV/AIDS Decision on 'Rapid' HIV Tests: AIDS Healthcare Foundation Sees Recent Action Urging Federal Authorities To Make 'Rapid' HIV Testing Widely Available as Critical Step Toward Reinvigorating HIV Prevention: PRNewswire - June 25, 2002; LOS ANGELES, June 25 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) today praised a recent decision by President Bush s Advisory Council on HIV/AIDS (PACHA) urging federal authorities to make rapid HIV testing widely available. This technology will revolutionize HIV testing in the US, said Clint Trout, spokesman for
Pharmacogenomic Tests Have Important Applications in Cancer and Infectious Disease, According to a New Study from Cambridge Healthtech Institute: PRNewswire - June 24, 2002; NEWTON UPPER FALLS, Mass., June 24 /PRNewswire/ -- Predictive Pharmacogenomics: Revolutionizing Health Care, a new Life Science Report published by Cambridge Healthtech Institute (CHI) examines developing technologies designed to use an individual s genomic profile to predict response to certain drugs, enabling better
Stressgen Biotechnologies and Roche announce global development and Marketing collaboration valued up to $204 million U.S.: HspE7 is the Lead Novel Fusion Product in Stressgen's Immunotherapeutic Pipeline for the Treatment of Human Papillomavirus (HPV): PRNewswire - June 24, 2002; VICTORIA, BC, Canada and SAN DIEGO, CA, USA, June 24 /PRNewswire- FirstCall/ - Stressgen Biotechnologies Corporation (TSX:SSB) and Roche announced today that they have entered into a Collaboration Agreement for the co-development and global commercialization of Stressgen s innovative proprietary heat shock protein (Hsp
Achillion Pharmaceuticals Names John C. Pottage, Jr., MD As Senior Director, Drug Development: PRNewswire - June 24, 2002; NEW HAVEN, Conn., June 24 /PRNewswire/ -- Achillion Pharmaceuticals, today announced that John C. Pottage, Jr., MD has joined the Company as Senior Director, Drug Development. In this position, Dr. Pottage will play a significant role in the pre-clinical and clinical development of Achillion s product candidates design
BET & Rap-it-Up Present 'Unity in the Community' : Downtown Washington, DC on June 27, National AIDS Testing Day: PRNewswire - June 21, 2002; WASHINGTON, June 21 /PRNewswire/ -- When most metro area youth beat ya feet, their sole intention is to show mastery of the latest go-go dance craze. However, when they beat ya feet at BET s Rap-it-Up Unity in the Community Day, they ll be helping to stomp the spread of HIV and AIDS in the metro area. On Thursday, June
500 Groups Endorsing AIDS 'March for Life' : Organizers Expect 10,000 Marchers on July 7 Immediately Preceding International AIDS Conference Opening Ceremonies: Event Demands AIDS Treatment for 2 Million in Poor Countries by 2004: PRNewswire - June 21, 2002; LOS ANGELES, June 21 /PRNewswire/ -- 500 AIDS organizations are endorsing the March for Life, which immediately precedes the July 7 opening ceremonies of the upcoming International AIDS Conference in Barcelona, Spain , according to AIDS Therapeutic Treatment Now (ATTN), a global coalition seeking treatment for at least
Remarks by the President to the 3rd Biennial Leon H. Sullivan Summit Dinner: PRNewswire - June 20, 2002; WASHINGTON, June 20 /PRNewswire/ -- THE PRESIDENT: I m so honored to be with you all to pay tribute to an exceptional man and to further a great cause. Leon Sullivan understood an important principle: If we want to live in a world that is free, we must work for a world that is just. (Applause.) The free people of Ameri
Baltimore's African American Leaders Declare War on HIV/AIDS: PRNewswire - June 20, 2002; BALTIMORE, June 20 /PRNewswire/ -- Leaders of Baltimore s African American community met today with the National Black Leadership Commission on AIDS (BLCA) to develop an action plan to fight HIV/AIDS in Baltimore. Plans the leaders committed to: -- Declare Sunday, Sept. 29, 2002, as HIV/AIDS Awareness Day to encourage
New Social Marketing Campaign to Heighten Syphilis Awareness Among Men Who Have Sex with Men (MSM), Urge Testing for Treatable STD: 'STOP THE SORES' Syphilis Advertising Campaign to Be Unveiled June 20: PRNewswire - June 20, 2002; What: PRESS CONFERENCE Unveiling STOP THE SORES Syphilis Awareness Social Marketing Campaign Who: Sybil Allen, MD, AHF Regional Medical Director, Southern California Celena Holloway, RN, Nurse Manager, AHF Westside Healthcare Center Terri Ford, AHF Director of Prevention Cesar Portillo, AHF Chief of Public Af
Chiron Corporation and Ortho-Clinical Diagnostics Announce Sponsorship of PBS Documentary 'Red Gold: The Epic Story of Blood': PRNewswire - June 20, 2002; EMERYVILLE, Calif. and RARITAN, N.J., June 20 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) and Ortho-Clinical Diagnostics, a Johnson & Johnson company, announced today their joint sponsorship of the PBS documentary Red Gold: The Epic Story of Blood. This four-part mini-series will premier on two consecutive Su
BET to Present Rap-It-Up 'Preservation of Life' Award to Los Angeles-Based Physician During 2ND ANNUAL BET AWARDS: PRNewswire - June 20, 2002; HOLLYWOOD, June 20 /PRNewswire/ -- When the African-American celebrity A-List walks down the red carpet of the Kodak Theatre before the 2ND ANNUAL BET AWARDS on Tuesday, June 25, there will be one face among them far less recognized, but equally as worthy of recognition for his outstanding work. Instead of contributing
GSK Announces Two-Year Price Freeze on HIV/AIDS Medicines: PRNewswire - June 20, 2002; PHILADELPHIA, June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) (NYSE: GSK) today announced that it has implemented a two-year freeze in the U.S. list price(1) of the company s entire portfolio of anti-HIV products through January 2004. GSK will continue to provide its HIV drugs free of charge(2) through its Pati
Abbott Laboratories to Provide Free HIV Test to Assist Mother-To-Child Transmission Prevention Programs in Africa and Developing Countries; Applauds U.S. Government Initiative: PRNewswire - June 19, 2002; ABBOTT PARK, Ill., June 19 /PRNewswire/ -- Abbott Laboratories announced today a donation of its HIV rapid test, Determine(TM) HIV, to programs aimed at preventing mother-to-child transmission (PMTCT) of HIV in the 68 African and Least Developed Countries (LDCs), as defined by the United Nations. The donation is the f
Remarks by the President in Announcement of International Mother and Child HIV Prevention Initiative: PRNewswire - June 19, 2002; WASHINGTON, June 19 /PRNewswire/ -- The following are remarks by the President in announcement of International Mother and Child HIV Prevention Initiative: The Rose Garden 9:04 A.M. EDT THE PRESIDENT: Good morning. The global devastation of HIV/AIDS staggers the imagination and shocks the conscience. The disease has al
ViroLogic Announces Expanded Agreement With Pfizer to Support New HIV Drug Discovery and Development Efforts: PRNewswire - June 18, 2002; SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed an expanded agreement with Pfizer Inc (NYSE: PFE) to use ViroLogic s novel HIV resistance testing technology for Pfizer s HIV drug discovery and development programs. The new agreeme
VaxGen to Provide Primer on AIDS Vaccine Technology Prior to XIV International AIDS Conference: PRNewswire - June 17, 2002; WHAT: VaxGen (Nasdaq: VXGN) will hold a conference call and webcast Wednesday, June 19, to review its AIDS vaccine technology prior to the XIV International AIDS Conference in July. The presentation will give AIDS reporters and conference attendees an in-depth understanding of VaxGen s Phase III clinical tri
Telik's Novel Insulin Receptor Activator Shown to Reverse HIV Protease Inhibitor-Induced Insulin Resistance in Preclinical Tests: Data Presented at American Diabetes Association 62nd Scientific Sessions: PRNewswire - June 17, 2002; SOUTH SAN FRANCISCO, Calif., June 17 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced the presentation of preclinical results demonstrating that one of its insulin receptor activator small molecule drug candidates reversed insulin resistance induced by a human immunodeficiency virus (HIV) protease inhibit
Visible Genetics Launches Trugene.com - New Internet Resource Provides Information on Genotyping in HIV/AIDS -: PRNewswire - June 17, 2002; TORONTO, June 17 /PRNewswire-FirstCall/ -- Visible Genetics Inc. (Nasdaq: VGIN) (VGI) is pleased to announce that it has launched a new internet resource at http://www.trugene.com that provides a comprehensive range of information on the company s TRUGENE genotyping products, services and activities. Today also sees th
Abbott And OraSure Technologies Enter Distribution Agreement For OraQuick(R) Rapid HIV-1 Test In The United States - Abbott To Focus On Hospital And Physician's Office Laboratory Markets; OraSure Also Sublicenses Certain Lateral-Flow Patents -: PRNewswire - June 17, 2002; ABBOTT PARK, Ill., and BETHLEHAM, Pa., June 17 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) and OraSure Technologies (Nasdaq: OSUR) today announced agreements for the co-exclusive distribution of OraSure Technologies OraQuick(R) rapid test for the detection of antibodies to the Human Immunodeficiency Virus
Pharmacor Inc. Receives U.S. Patent for HIV Protease Inhibitor: PRNewswire - June 13, 2002; MONTREAL, June 13 /PRNewswire/ - Pharmacor Inc. has been issued U.S. patent application no. 09/526,209, relating to its antiretroviral program. The small- molecule compounds described in the patent, entitled Amino acid derivatives as HIV aspartyl protease inhibitors , demonstrate inhibitory activity against HIV protea
Epimmune Receives FDA Clearance to Initiate Phase I/II Therapeutic HIV Vaccine Trial: PRNewswire - June 13, 2002; SAN DIEGO, June 13 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body s immune system, today announced that it has received clearance from the U.S. Food and Drug Administration to st
ADVR's Product R Approved in Israel for Phase I Study in Leukemia and Lymphoma Patients: PRNewswire - June 12, 2002; YONKERS, N.Y., June 12 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its immunomodulator-type drug, Product R, has been approved by the supreme medical ethics committee (Helsinki Committee) of the Ministry of Health in Israel for a Phase I clinical trial. The
Recent Survey Shows Majority of Sexually Active Men Are Not Getting Tested for Genital Herpes: In Honor of National Men's Health Week, New Free Brochure Is Available To Raise Awareness of Genital Herpes in Men: PRNewswire - June 11, 2002; RESEARCH TRIANGLE PARK, N.C., June 11 /PRNewswire/ -- A recent four-city survey shows only one-fourth of men (26%) who say they get tested for sexually transmitted diseases (STDs) are getting tested for genital herpes , despite widespread knowledge among the survey participants that genital herpes is a highly contagiou
The Immune Response Corporation Announces Publication of Study Results For AIDS Preventive Vaccine Candidate for Developing Countries: Animal Testing Suggests Cell Mediated Responses to HIV Induced After Vaccination: PRNewswire - June 11, 2002; CARLSBAD, Calif., June 11 /PRNewswire-FirstCall/ -- Following the recent announcement suggesting increased HIV-specific immunity in primates through use of a new HIV combination vaccine, The Immune Response Corporation (Nasdaq: IMNR) today announced results of a study published in the journal Vaccine (20, 2002, 2684-92
Triangle Pharmaceuticals, Inc. Announces Final Settlement of Patent Disputes Involving Its Late Stage Drug Candidate Coviracil(R): President Describes Settlement as 'Important Step': PRNewswire - June 10, 2002; DURHAM, N.C., June 10 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced the final settlement among Emory University (Emory), GlaxoSmithKline and Shire Pharmaceuticals Group plc (Shire) of longstanding patent disputes involving lamivudine and Triangle s drug candidate Coviracil (emt
Land O'Lakes Supports Amendment: Dairy Surplus to HIV/AIDS Relief: PRNewswire - June 7, 2002; ARDEN HILLS, Minn., June 7 /PRNewswire/ -- Land O Lakes, Inc. added its support to an amendment introduced yesterday by U.S. Sen. Paul Wellstone (D-MN) and amended by U.S. Sen. Herb Kohl (D-WI), that would provide 100,000 metric tons of nonfat dry milk to help international relief efforts in the fight to combat HIV/AID
VaxGen Releases Letter Correcting Errors in Scientific American Article: PRNewswire - June 7, 2002; BRISBANE, Calif., June 7 /PRNewswire-FirstCall/ -- In response to inquiries from shareholders, VaxGen , Inc. (Nasdaq: VXGN) is making public a letter from company president Donald P. Francis, M.D., D.Sc., regarding an article published in this month s edition of Scientific American about VaxGen s AIDS vaccine candidate
Today's Findings From the ASGT Annual Meeting: New Research on Non-Malignant Acquired Disorders and Gene Therapy of Cancer: Possible AIDS Treatment: PRNewswire - June 6, 2002; BOSTON (Thursday, June 6, 2002) -- Although highly active antiretroviral therapies have greatly prolonged the lifespan of patients with AIDS, this condition remains a lethal disorder and the adverse effects of chemotherapy are often disabling. According to researchers at the American Society of Gene Therapy Annual Meet
Basketball Great Earvin 'Magic' Johnson to Dedicate AIDS Clinic Named in His Honor: AIDS Healthcare Foundation Facility offers Los Angeles' Residents Improved Access to Quality HIV care, Services: PRNewswire - June 6, 2002; LOS ANGELES, June 6 /PRNewswire/ -- Los Angeles-based AIDS Healthcare Foundation (AHF), the nation s largest HIV/AIDS medical care provider, will welcome Lakers basketball legend Earvin Magic Johnson on Wednesday, June 12 from 11 a.m. - 2 p.m., for the official dedication of the West Adams clinic that bears his name.
ADVR's Product R Approved in Israel for Phase I/II Study In Patients Needing Salvage Therapy For AIDS: PRNewswire - June 6, 2002; YONKERS, N.Y., June 6 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its antiviral immunomodulator, Product R, was approved by the Israeli Ministry of Health for Phase I/II clinical trials in patients who have failed highly active anti-retroviral therapy (HAART)
FIFA and UNICEF Come Together and Dedicate the 2002 World Cup to Children: Three U.S. Soccer Players Join Over 30 International Soccer Stars to Help Highlight UNICEF's Key Goals: PRNewswire - June 4, 2002; NEW YORK, June 4 /PRNewswire/ -- As the games continue, and USA takes on Portugal tomorrow in Korea, UNICEF reminds the world about the positive benefits of sport in a child s life. Last year, FIFA and UNICEF forged a global alliance that promises far-reaching benefits for children; the 2002 World Cup is the partnershi
Local Dairy Producer Advocates Dairy Issues in Washington D.C.: PRNewswire - June 3, 2002; WASHINGTON, June 3 /PRNewswire/ -- John Lasee from Sturgeon Bay, Wis., joined a Land O Lakes delegation of dairy producer-members who spent three days in Washington D.C. last week. With the Farm Security and Rural Investment Act of 2002 now officially law, the group visited Capitol Hill to thank legislators for their s
Antigen Express Announces Patent Award and $301,000 Phase I SBIR Grant for Ii-Key Hybrid MHC Class II Platform Technology: PRNewswire - June 3, 2002; WORCESTER, Mass., June 3 /PRNewswire/ -- Antigen Express, Inc. (AgExp) today announced that the US Patent and Trademark Office has granted a Notice of Allowance of a patent concerning its Ii-Key MHC Class II Platform Technology. Additionally, AgExp has received a $301,000 Phase I Small Business Innovative Research (SBI
ViroLogic Launches First Viral Fitness Assay for HIV Patient Testing New Test Measures HIV 'Replication Capacity' to Help Guide Treatment: PRNewswire - June 3, 2002; SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the launch of the first-ever commercial laboratory test to evaluate the replication capacity (or viral fitness ) of HIV. ViroLogic s new Replication Capacity (RC) assay measures the ability of a patient s virus
U.S.'s Largest AIDS Organization Denounces Glaxo/BMS merger: AIDS Healthcare Foundation Urges Regulators and Investors To Oppose 'Disaster For People With AIDS': PRNewswire - May 31, 2002; LOS ANGELES, May 31 /PRNewswire/ -- AIDS Healthcare Foundation today called the anticipated merger of British pharmaceutical giant Glaxo Smithkline with Bristol Myers Squibb a certain disaster for people with AIDS throughout the world and called on American and European authorities to block the marriage. In contrast to
AIDS Healthcare Foundation (AHF) Protests Lack of Real Inclusion On AIDS Treatment Access Worldwide by International AIDS Conference Organizers: Upcoming July Barcelona AIDS Conference Expected to Draw 14,000 People From Around the World. While 8,500 People Die Every Day from AIDS Worldwide, Official Conference Agenda Offers No Focus on AIDS Treatment Access in The Developing World: PRNewswire - May 31, 2002; LOS ANGELES, and BARCELONA, Spain , May 31 /PRNewswire/ -- Los Angeles-based AIDS Healthcare Foundation (AHF), the largest provider of specialized HIV/AIDS medical care in the United States and the operator of two free AIDS treatment clinics in Africa ( South Africa &
The Immune Response Corporation Releases Results for an AIDS Preventative Vaccine Candidate: Preliminary Animal Testing Suggests Immune Responses Are Induced In CD4+ and CD8+ T Cells Aimed Specifically at HIV: PRNewswire - May 30, 2002; CARLSBAD, Calif., May 30 /PRNewswire-FirstCall/ -- Citing an important step in ongoing research in the ability to trigger immune responses specific to human immunodeficiency virus (HIV), The Immune Response Corporation (Nasdaq: IMNR) announced today preliminary results from a non-human primate study in which CD4+ and C
Novirio Pharmaceuticals Limited Becomes Idenix Pharmaceuticals, Inc.: PRNewswire - May 29, 2002; CAMBRIDGE, Mass., May 29 /PRNewswire/ -- Novirio Pharmaceuticals Limited, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that the company has changed its name to Idenix Pharmaceuticals, Inc. The new name, Iden
Scott Building to Open Doors For Detroit's Homeless: Michigan's Only Center to Offer a Residential 'Safe Haven' Program: PRNewswire - May 28, 2002; DETROIT, May 28 /PRNewswire/ -- The Scott Building opens its doors Wednesday, May 29, 2002, at 9:30 a.m. with a ribbon-cutting ceremony. The facility expands Cass Community Social Services legacy of serving Detroit s homeless, mentally ill and chemically dependent. With its opening, the Scott Center becomes Michigan s
Serono Announces Outcome of Three Clinical Studies: PRNewswire - May 28, 2002; GENEVA, Switzerland and ROCKLAND, Mass., May 28 /PRNewswire/ -- Serono S.A. today announced the outcome of three randomized, double-blind, placebo-controlled clinical trials. Positive results of Serostim(R) in HARS A study of Serostim(R) [somatropin (rDNA origin) for injection] in 228 patients with HIV-Associated Adipo
Joint Statement by President George W. Bush and President Vladimir V. on Putin on U.S.-Russian People-to-People Contacts: PRNewswire - May 24, 2002; The following is a joint statement by President George W. Bush and President Vladimir V. Putin on U.S.-Russian People-to-People Contacts: In keeping with the spirit of cooperation between our two countries, we affirm the importance of strengthening contacts between our societies and citizens. We are confident that dire
HIV/AIDS Experts Meet to Discuss Pandemic Crisis in Haiti: PRNewswire - May 24, 2002; WASHINGTON, May 24 /PRNewswire/ -- Members of the Haitian health community met today with international HIV/AIDS experts to discuss the current status of the HIV/AIDS pandemic in Haiti. The group set out to identify solutions to a socio-economic problem that has reached crisis proportions in recent years. The panel was
Altachem Pharma's Proposed Joint Venture With Erdos Cashmere Group Is In Process Of Regulatory Approval By The Chinese Government Regulatory Authority: PRNewswire - May 23, 2002; EDMONTON, May 23 /PRNewswire-FirstCall/ - Mr. Warren Jackson, President and CEO of Altachem Pharma Ltd., is pleased to announce that the proposed Beijing Erdos Altachem Pharma Ltd. joint venture to be located in Beijing, China between Altachem Pharma Ltd. and Erdos Cashmere Corporation is in the process of regulatory a
Bill and Bono Jam With Investors: PRNewswire - May 23, 2002; HONG KONG, May 23 /PRNewswire/ -- Investors got a call to action from former US President Bill Clinton and rock-star-activist Bono. The two men were guest speakers at the 9th CLSA Investors Forum in Hong Kong , the world s largest gathering of investors in emerging markets. Clinton appealed to the 1,200 institution
Euroscreen Announces CCR5 Licensed to Pfizer: PRNewswire - May 23, 2002; BRUSSELS, Belgium , May 23 /PRNewswire/ -- Euroscreen s.a. has completed a license agreement with Pfizer Inc. of New York for access to Euroscreen s CCR5 patent rights. Financial details of the agreement were not disclosed. The license covers various aspects of the specific G-Protein-Coupled Receptor (GPCR), known as C
Panacos Pharmaceuticals Awarded $125,000 Grant Supporting Development of its HIV Drug Candidate PA-457: PRNewswire - May 23, 2002; GAITHERSBURG, Md., May 23 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has been awarded a Phase I Small Business Innovative Research (SBIR) Grant for $125,000 by the National Institutes of Health (NIH). The award, from the National Institute of Allergy and Infectious Diseases of NIH, will help
Achillion Pharmaceuticals Demonstrates Potent Anti-Hepatitis B Activity of Lead Product Candidate in Humans: PRNewswire - May 22, 2002; NEW HAVEN, Conn., May 22 /PRNewswire/ -- Achillion Pharmaceuticals today reported the successful completion of a Phase 1b/2 clinical trial demonstrating potent antiviral activity of the Company s lead product candidate, ACH-126,443 (Beta-L-Fd4C) in patients with chronic hepatitis B (HBV) infection. ACH-126,443 produced
National Medical Fellowships Announces Partnership With UCSF, Kaiser Permanente: PRNewswire - May 21, 2002; SAN FRANCISCO, May 21 /PRNewswire/ -- A fellowship program designed to increase the number of minority physicians involved in AIDS-related clinical care will be expanded next spring to the University of California, San Francisco, AIDS Research Institute (UCSF-ARI), and Kaiser Permanente. For the past four years, the Ar
AIDS Healthcare Foundation to Bar GlaxoSmithKline Sales Reps From Outpatient Facilities Over Drug Pricing for Developing World: Nation's Largest HIV/AIDS Specialty Medical Provider Says: 'Glaxo: Do the Right Thing - AIDS Drugs for Africa and the World': PRNewswire - May 21, 2002; LOS ANGELES, May 21 /PRNewswire/ -- AIDS Healthcare Foundation (AHF) announced today that it would bar GlaxoSmithKline (GSK) drug sales representatives from its outpatient facilities throughout the U.S. AHF, which is the nation s largest provider of specialized HIV/AIDS medical care, took the unprecedented action to pr
Opera Star Jessye Norman Lifts Her Voice for HIV/AIDS Orphans And Vulnerable Children in New World Vision PSA: PSA Echoes Global Emergency Addressed at United Nations Special Session On Children: PRNewswire - May 21, 2002; SEATTLE, May 21 /PRNewswire/ -- Jessye Norman, one of the world s most celebrated opera singers, is raising her distinguished voice on behalf of more than 13 million children orphaned due to the HIV/AIDS pandemic, recently addressed at the United Nations Special Session on Children. In a newly released PSA for World Vi
ECDC's African Refugee Conference Concludes Successfully, Unifying Resolution to Bring about Positive Change: PRNewswire - May 21, 2002; WASHINGTON, May 21 /PRNewswire/ -- Drawing over 300 participants from across the nation, the Ethiopian Community Development Council s (ECDC) eighth national conference, African Refugees: The Quest for Solutions in a Changing World, held May 13-15 in Washington, D.C., ended with a unanimously approved resolution to aff
Baxter Introduces The BAXJECT Needleless Transfer Device at International Haemophilia Congress: A Safer, Faster and Easier Way to Prepare Medication: PRNewswire - May 21, 2002; SEVILLE, Spain , May 21 /PRNewswire-FirstCall/ -- (World Federation of Haemophilia Congress) -- Baxter BioScience today announced the launch of the BAXJECT needleless transfer device (BAXJECT), a safer, faster and easier way to prepare haemophilia medication without the use of sharp needles or fear of accidental injury
Majority of Sexually Active People Surveyed Are Not Getting Tested for Genital Herpes: Coast-to-Coast Survey Reveals Most Are Not Aware of the Scope of the Genital Herpes Epidemic: PRNewswire - May 21, 2002; NEW YORK, May 21 /PRNewswire/ -- Despite understanding genital herpes is a highly contagious and lifelong sexually transmitted disease (STD), less than one in five people surveyed (16%) say they get tested for the disease. A sample of people in New York, Chicago, Atlanta and San Diego were surveyed to gauge their attit
Data on Investigational Hepatitis C Treatment to Be Presented at Digestive Disease Week Conference: Body of Data Continues to Grow on PEGASYS(R) (peginterferon alfa-2a): PRNewswire - May 20, 2002; SAN FRANCISCO, May 20 /PRNewswire/ -- The Digestive Disease Week (DDW) meeting in San Francisco this week will bring together an assembly of physicians and researchers in the fields of gastroenterology and hepatology. One of the topics at the meeting will be investigational treatments for hepatitis C, a blood-borne vir
Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals -- Company Provides Update on Product Pipeline --: PRNewswire - May 17, 2002; CAMBRIDGE, Mass., May 17 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the results of its Annual Meeting of Stockholders, which was held today. The Company also provided an update on its product pipeline. At the meeting, shareholders re-elected Roger Brimblecombe, Donald Conklin
HIV Vaccine Research is 'Best Hope' for Controlling AIDS Pandemic: Fifth Annual HIV Vaccine Awareness Day to Highlight Progress, Goals for Future: PRNewswire - May 17, 2002; BETHESDA, Md., May 17 /PRNewswire/ -- May 18th marks the Fifth Annual HIV Vaccine Awareness Day, which highlights research advances and the challenges of the HIV/AIDS pandemic, and underscores why developing preventive HIV vaccines offers the best hope for controlling the AIDS pandemic. Thousands of volunteers worldwid
Serono Issues Notification Of Counterfeit Serostim(R): PRNewswire - May 16, 2002; Rockland, MA, May 16, 2002 - Serono, Inc. has recently become aware of a counterfeit lot of Serono s Serostim(R) [somatropin (rDNA origin) for injection]. The counterfeit material has been packaged to appear as drug product lot number S810-1A1. This is not a legitimate Serostim(R) lot number. Serono has notified the ap
Out Wit, Out Play, Out Last ... Out Bid! 'Survivor: Marquesas' Props And Memorabilia to be Sold on eBay to Benefit the Elizabeth Glaser Pediatric AIDS Foundation - Items Available on eBay Sunday, May 19th Through Thursday, May 30th -: PRNewswire - May 16, 2002; LOS ANGELES, May 16 /PRNewswire/ -- Out Wit. Out Play. Out Last ... and Out Bid ... Make the winning bid to out last fellow Survivor fans to become the lucky owner of priceless memorabilia and props from Survivor: Marquesas. Coveted items from the Survivor series will be auctioned on eBay following the
Roche and Trimeris Announce 24-Week Results From Second Pivotal Study of HIV Fusion Inhibitor T-20 - Second of Two Phase III Studies Meets Primary Endpoint; Companies Will Proceed with Filing US and EU Registration Packages In the Second Half of 2002 -: PRNewswire - May 16, 2002; NUTLEY, N.J., and DURHAM, N.C., May 16 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced positive 24-week results from the second pivotal Phase III study of T-20 (TORO 2), just four weeks after reporting similarly positive 24-week results from the first Phase III study of T-20. Together,
Save the Children: South Africa Programme: PRNewswire - Thursday 16 May 2002; Johannesburg - Save the Children today launched a report entitled Childhood Challenged, South Africa s children, HIV/AIDS and the corporate sector. The report summarises research into the extent to which South African companies are engaging with the issue of HIV/AIDS affected children. It makes the case for why compani
Food Technology Service, Inc. Introduces New Brand of Irradiated Foods: PRNewswire - May 15, 2002; MULBERRY, Fla., May 15 /PRNewswire-FirstCall/ -- Food Technology Service, Inc. (Nasdaq: VIFL) (FTSI), the leader in making foods safer through irradiation, announces the introduction of I-Care Foods(TM). I-Care Foods(TM) is a full-line of chicken, turkey, beef, and eggs that are irradiated to remove pathogens such as S
Dimethaid Research completes $37 million purchase agreement for Oxo Chemie AG Company expands product pipeline to include immune-regulating platform drug: PRNewswire - May 15, 2002; TORONTO, May 15 /PRNewswire-FirstCall/ - Dimethaid Research Inc. (TSE:DMX) today announced that it has completed the agreement to acquire Oxo Chemie AG of Switzerland . This US$36.96 million acquisition will expand its existing product pipeline to include a new immune-regulating platform drug, known as WF10, currently
ADVR Names Dr. Mark H. Kaplan to Scientific Advisory Board: Noted AIDS Physician and Research Scientist Joins Experts In Cancer, Immunology and Microbiology: PRNewswire - May 15, 2002; YONKERS, N.Y., May 15 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that Mark H. Kaplan, MD, has joined the Company s Scientific Advisory Board. Dr. Kaplan brings specialized expertise in AIDS treatment and research, including the study of new therapeutic agents, to
Statement of IAVI's Seth Berkley, MD, on Kerry-Frist US Leadership Against HIV/AIDS, TB and Malaria Act of 2002: Applauds Substantial Increase in US Funding for HIV/AIDS, Pairing Existing Prevention and Treatment With R&D for Vaccines: PRNewswire - May 15, 2002; NEW YORK, May 15 /PRNewswire/ -- Seth F. Berkley, MD, President and CEO of the International AIDS Vaccine Initiative (IAVI), released this statement in response to the US Leadership Against HIV/AIDS, Tuberculosis and Malaria Act of 2002. The proposed legislation authorizes an increase in US government funding for inter
California's Largest AIDS Organization Praises Governor's AIDS Budget; Davis Protects Increase to Life-Saving HIV Drugs: PRNewswire - May 14, 2002; SACRAMENTO, Calif., May 14 /PRNewswire/ -- AIDS Healthcare Foundation -- the nation s largest AIDS organization -- today praised Governor Davis brave leadership for keeping his pledge in the face of massive state-wide cuts to protect Californians living with HIV/AIDS. With so much pain in these cuts to so many Californ
Christian Leaders Challenge America's Response To the AIDS Pandemic at Upcoming Forum: 'It's time the Christian community rose to the challenge' : Experts to argue for greater involvement from the U.S. Christian community in fighting the disease; debate the role of gender inequality in virus transmission; and explore the societal impact of an emerging generation of orphaned children: PRNewswire - May 14, 2002; NEW YORK, May 14 /PRNewswire/ -- Leading Christian HIV/AIDS experts from around the world will gather on May 17 and 18 in New York to examine the emerging role the Christian community must play in helping alleviate the growing AIDS pandemic sweeping across the African continent and now into Asia. The time has come to c
Biosyn Announces Positive Clinical Results of Two Phase I/II Trials For Savvy(R) Microbicide Gel: PRNewswire - May 13, 2002; HUNTINGDON VALLEY, Pa., May 13 /PRNewswire/ -- Biosyn, Inc. announced today at the Microbicides 2002 Conference in Antwerp, Belgium , successful results of two clinical studies for Savvy(R) (C31G intra-vaginal gel), currently in development as a contraceptive and for the prevention of sexually transmitted diseases (STD
Illinois Health Advocates Call on the Department of Public Aid to Halt Prior Authorization of Prescription Drugs: PRNewswire - May 13, 2002; CHICAGO, May 13 /PRNewswire/ -- A coalition of advocacy groups today urged the Illinois Department of Public Aid to maintain access to pharmaceuticals for Medicaid patients in Illinois. The IDPA has begun implementation of a plan that would require Medicaid recipients to obtain prior authorization before receiving any
AIDS Fund's GayBINGO Celebrates 6 Years This Month: The Delaware Valley's Most Popular Monthly Fundraiser Has Raised More Than 1 Million for HIV/AIDS Services, Prevention, & Public Awareness: PRNewswire - May 13, 2002; PHILADELPHIA, May 13 /PRNewswire/ -- GayBINGO, the region s wildly popular HIV/AIDS fundraising event will mark its 6th anniversary this Saturday, May 18th at 7 p.m. at the Gershman Y, Pine & Broad Streets in Center City. GayBINGO s success is largely due to the combination of stage entertainment, bingo prizes, and
BioErgonomics Patents Method for Simultaneous Detection of Binding Pair Complexes: PRNewswire - May 13, 2002; ST. PAUL, Minn., May 13 /PRNewswire/ -- St. Paul, Minn. based BioErgonomics, Inc. (BioE) recently received a patent for technology that makes detection and identification of diseases such as Hepatitis C and HIV possible at a much earlier stage of infection. U.S. Patent 6,383,740 protects BioE s method for the simultane
Immunization With REMUNE(R) in Immunocompetent HIV-Infected Patients May Lead To Stronger Immune Responses and Possible Control of Viral Replication: PRNewswire - May 13, 2002; CARLSBAD, Calif., May 13 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today publication of data suggesting that immune responses to therapeutic immunization with REMUNE(R) were more optimal in HIV infected patients with high CD4 cell counts and low virus levels. The article Predict
New HIV Prevention Campaign Launching for HIV Positives: PRNewswire - May 13, 2002; LONG BEACH, Calif., May 13 /PRNewswire/ -- Local HIV positive spokespersons will share their personal stories featured in an innovative HIV prevention campaign launching in Long Beach and Orange County. The regional campaign will join existing activities in Los Angeles, San Francisco and Boston. The HIV STOPS WITH ME c
Nationwide HIV Testing Initiative Offers R&B Tickets - Agouron Pharmaceuticals Intervention Provides Service and Information on Prevention, Testing and Treatment for HIV/AIDS -: PRNewswire - May 13, 2002; SAN DIEGO, May 13 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., a Pfizer Company (NYSE: PFE), today launched Fighting HIV through R&B, a novel HIV testing program that offers free R&B concert tickets for those individuals who get tested for HIV. The program will be available at participating community clinics
What is corporate South Africa really doing about HIV/AIDS?: PRNewswire - Monday 13 May 2002; Johannesburg - As corporate South Africa begins to work together to develop and fund sustainable solutions to HIV/AIDS, Gaby Magomola and Clem Sunter (SABCOHA Governors) invite you to a breakfast presentation of key findings by Deloitte & Touche Human Capital Corporation and SAVE the Children. This is the firs
GlaxoSmithKline Alerts Patients, Pharmacists and Physicians to Watch For Third-Party Tampering that Incorrectly Labels Ziagen(R) as Combivir(R): PRNewswire - May 10, 2002; PHILADELPHIA, May 10 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today that the company has received four reports of suspect bottles containing 60 tablets of Combivir (R) (lamivudine plus zidovudine) that actually contained another medicine, Ziagen
Dr. Richard D. Klausner Named Executive Director of Global Health For Bill & Melinda Gates Foundation: PRNewswire - May 10, 2002; SEATTLE, May 10 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced that Dr. Richard D. Klausner has been named Executive Director of the foundation s global health program. Dr. Klausner is the former Director of the National Cancer Institute (NCI) where he led the nation s cancer program. We are de
Gates Calls on World Leaders to Increase Resources and Leadership To Improve Children's Health Globally: Bill & Melinda Gates Foundation Announces $50 Million Grant to Newly Formed Global Alliance for Improved Nutrition (GAIN): PRNewswire - May 9, 2002; NEW YORK, May 9 /PRNewswire/ -- In a keynote speech today at the United Nations General Assembly Special Session (UNGASS) on Children, Bill Gates, co-founder of the Bill & Melinda Gates Foundation, called for a dramatic increase in leadership and resources from developed countries to improve the health of children
LA Architect Magazine Announces Design Gala And Silent Auction to Benefit Project Angel Food: Frank Gehry Glass Sculpture Will Be on Display to Welcome Patrons To a Silent Auction Benefiting Project Angel Food Featuring Art By Miro, Warhol and Rauschenberg: PRNewswire - May 7, 2002; LOS ANGELES, May 7 /PRNewswire/ -- LA Architect, the only magazine serving the Southern California design community, today announced that its gala benefit on May 18, 2001 from 6 p.m. to 10:00 p.m. at the Southern California Institute of Architecture (SCI-Arc), will include art for a silent auction from notable artists
SHPI Announces U.S. Market Launch of Safety Syringe Needle Product Line by Kendall: PRNewswire - May 7, 2002; BOUNTIFUL, Utah, and MANSFIELD, Mass., May 7 /PRNewswire/ -- Specialized Health Products(R) International, Inc. (OTC Bulletin Board: SHPI) today announced that Kendall, a business unit of Tyco Healthcare, has initiated its U.S. market launch of a proprietary line of safety syringe needles, based upon the FlexLoc(R) saf
Religious Leaders Call on International Community To Meet Children's Basic Needs: Millions of Children Living Under Intolerable Conditions, Religious Communities Uniquely Qualified to Aid Children: PRNewswire - May 7, 2002; NEW YORK, May 7 /PRNewswire/ -- Religious leaders from the world s major faith traditions today decried the intolerable conditions experienced by millions of children worldwide and demanded the international community meet children s basic needs. Leading Buddhist, Christian, Hindu, Indigenous, Jewish and Muslim leaders
New Hopkins Report Details Effective Strategies for Reaching Young People: Programs Urge Youth to Practice Healthier Behaviors Such as HIV/AIDS Prevention: PRNewswire - May 7, 2002; BALTIMORE, May 7 /PRNewswire/ -- As world leaders gather in New York this week to consider how to improve the lives of young people, researchers at the Johns Hopkins University Center for Communication Programs (JHU/CCP) released a new report showing how to reach young people with communication programs designed to enc
Company reveals new aspects of mechanism of action for HspE7 and confirms immunostimulatory capabilities of platform technology for hepatitis B virus: PRNewswire - May 7, 2002; BALTIMORE, MD, May 7 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation today presented new research results which further validate the Company s mechanism of action for its patented heat shock protein (Hsp) fusion platform technology for the treatment of viral infections and cancer, at the 5th Annual Confe
Roche Diagnostics and QIAGEN Partner to Develop and Commercialize An Integrated Diagnostic System for Hepatitis and HIV PCR Testing: PRNewswire - May 7, 2002; PLEASANTON, Calif., INDIANAPOLIS and VENLO, The Netherlands , May 7 /PRNewswire-FirstCall/ -- Roche Molecular Systems, Inc. (RMS), a business area of Roche Diagnostics and Roche Diagnostics Corporation (RDC), the US sales and marketing arm of Roche Diagnostics, and QIAGEN GmbH, a wholly owned subsidiary of QIAGEN N.V.
ViroLogic Launches PhenoScreen(TM) to Help Drug Companies Discover New HIV Drugs: PRNewswire - May 7, 2002; SOUTH SAN FRANCISCO, Calif., May 7 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that it has launched PhenoScreen(TM), a new high throughput screening product designed to help drug companies more quickly and cost-efficiently screen clinical drug candidates for HIV. Developed in response to in
World's Vaccine Experts Meeting in Baltimore to Report New Progress in Vaccine Development: Research Presented on Vaccines Against an Array of Deadly Infectious Agents: PRNewswire - May 6, 2002; BALTIMORE, Md., May 6 /PRNewswire/ -- Leading vaccine scientists from around the world are meeting today in Baltimore for the Fifth Annual Conference on Vaccine Research and will report on the latest research on familiar killers such as pneumococcal, meningococcal, and Group A streptococcal disease, influenza, hepatiti
Female Health Receives British Government Grant to Introduce the Female Condom In India: PRNewswire - May 6, 2002; CHICAGO, May 6 /PRNewswire-FirstCall/ -- The Female Health Company today announced that it has received a grant from the British Government for marketing and manufacturing the Female Condom in India in partnership with Hindustan Latex Limited (HLL). The grant from the Business Linkages Challenge Fund (BLCF) will suppor
Sweden's Bioption, IAVI Partnering to Develop Globally Accessible AIDS Vaccines: Novel Vaccine Candidates to Use Design Developed at the Karolinska Institute; Human Trials Targeted to Begin in Two Years: PRNewswire - May 6, 2002; STOCKHOLM, Sweden , May 6 /PRNewswire/ -- Swedish biotechnology firm Bioption AB is partnering with the International AIDS Vaccine Initiative (IAVI) to develop and test a new approach for vaccines that can train the immune system to protect against HIV/AIDS. The vaccines are being built from a proprietary technology, S
One Million Dollar Grant to Humanitarian Organizations for Africa Emergency: PRNewswire - May 3, 2002; SEATTLE, May 3 /PRNewswire/ -- Save the Children and CARE today announced a $1 million grant from the Bill & Melinda Gates Foundation to provide emergency food aid for more than two million people -- many of them children -- who are suffering from starvation in the southern African country of Malawi .
Trimeris and NEOKIMIA Sign Antiviral Drug Discovery and Development Agreement: Collaboration to Target Discovery and Development Of Small Molecule Fusion Inhibitors of HIV: PRNewswire - May 3, 2002; DURHAM, N.C., and SHERBROOKE, Quebec, May 3 /PRNewswire-FirstCall/ -- Trimeris, Inc. (Nasdaq: TRMS) and NEOKIMIA INC. today announced the execution of a collaborative agreement to discover and develop small molecule fusion inhibitors of the human immunodeficiency virus (HIV). Under the terms of the agreement, Trimeris
AcroMetrix Introduces HIV Drug Resistance Genotype Controls To the Clinical Laboratory Market: PRNewswire - May 3, 2002; BENICIA, Calif. and CLEARWATER, Fla., May 3 /PRNewswire/ -- AcroMetrix Corporation announced today at the 18th Clinical Virology Symposium that it is introducing a new set of quality control products for laboratories conducting genotypic analyses to identify drug resistance mutations of HIV. NAC HIV Drug Resistance Gen
Mama Janet Museveni, First Lady of the Republic of Uganda, To Be Honored With The Global AIDS Leadership Award Monday, May 6th During Washington, DC Reception: PRNewswire - May 3, 2002; Ugandan First Lady Honored for Her Work in the Fight Against HIV/AIDS and Her Tireless Work on Behalf of Ugandan Children Orphaned by AIDS - U.S. Senator Dennis DeConcini (Ret.), U.S. Senator Steve Symms (Ret.), Join International Coalition including AIDS Action, AIDS Healthcare Foundation, AHF Global Immunity and the
New Findings Further Illustrate ONCONASE's Mechanism of Action as a Potential Anti-Viral Agent in HIV-1: Results Published in the April 2002 Issue Of the Journal of Biological Chemistry: PRNewswire - May 2, 2002; BLOOMFIELD, N.J., May 2 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced preclinical results which demonstrate that ONCONASE(R) exerts its anti-viral activity at two stages in the HIV-1 life-cycle. These findings have been published in the April 26, 2002 issue of the Journal of Biological Chemistry. The m
$1 Million in Grants Going to NYC's Community Groups Helping Low-Income Women and Girls: PRNewswire - May 1, 2002; NEW YORK, May 1 /PRNewswire/ -- For the first time in its 15-year history, The New York Women s Foundation will give a total of $1 million in grants to neighborhood non-profit groups helping the City s low-income women and girls. In front of over 2,000 women supporters, 35 women-run organizations will receive grants at
Black and Hispanic HIV Patients Are Less Likely to Get Experimental Medications: PRNewswire - May 3, 2002; ROCKVILLE, Md., May 1 /PRNewswire/ -- A nationwide study sponsored by the Agency for Healthcare Research and Quality (AHRQ), shows that black and Hispanic HIV patients are only about half as likely as non-Hispanic whites to participate in clinical trials of new medications designed to slow the progression of the diseas
Business Leaders Discuss the Future of Corporate Responsibility: Deutsche Bank, BASF, Anglo American and British American Tobacco Assemble To Present Their Visions of Effective Corporate Citizenship: PRNewswire - May 1, 2002; LONDON, May 1 /PRNewswire/ -- Deutsche Bank, BASF, Anglo American and British American Tobacco were just some of the companies delivering clear messages on best practice in corporate responsibility last week at the Ethical Corporation Europe 2002 conference. Hans Michael Holz, Global Head of Sustainable Development at
Genelabs Technologies and the University of Iowa Research Foundation Collaborate on Hepatitis G Virus Research: PRNewswire - May 1, 2002; REDWOOD CITY, Calif., May 1 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that it has entered into a collaboration with the University of Iowa Research Foundation (UIRF) to study the impact of the hepatitis G virus (HGV, also known as GB virus C, or GBV-C) on human immunodeficienc
Roche R&D Day 2002 Innovation Key to Success: Good progress in Roche's R&D pipeline and strong mid-term flow of new products: PRNewswire - April 30, 2002; NUTLEY, N.J. and PLEASANTON, Calif. -- 138 projects in Pharma research and 74 projects in Pharma development -- 48 new molecular entities (NMEs) in pipeline -- 35% increase in the number of NMEs in development portfolio over the past 12 months -- Filing of 17 new drug applications and several additional indications for
Human Genome Sciences Provides Update of Company Progress - Clinical Studies of a Human Monoclonal Antibody to TRAIL Receptor-1 Cleared by the U.S. Food and Drug Administration: PRNewswire - April 30, 2002; - Preliminary Clinical Data for Albutropin(TM) And Albuferon(TM)-alpha Phase 1 presented - Funding Assured, with $1.6 Billion in Cash and Equivalents - ROCKVILLE, Md., April 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today told approximately 200 financial analysts in New York that the compa
AnorMED announces Foznol(TM) NDA submitted to FDA: PRNewswire - April 30, 2002; VANCOUVER - AnorMED Inc. (TSE:AOM) announced today that its licensee, Shire Pharmaceuticals Group plc, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration ( FDA ) for Foznol (likely to be renamed Fosrenol, lanthanum carbonate) as a treatment for elevated blood phosphate levels, in patien
AxCell Biosciences Enters into Second Research Collaboration with Mount Sinai School of Medicine: Collaboration Will Utilize AxCell's Signal Transduction Technology Platform to Identify Molecules Useful for Treating HIV-Associated Nephropathy: PRNewswire - April 30, 2002; NEWTOWN, Pa -- AxCell Biosciences, a subsidiary of Cytogen Corporation (Nasdaq: CYTO), today announced the signing of a research collaboration with Irwin Gelman, Ph.D., of the Mount Sinai School of Medicine (MSSM) to identify molecules useful for treating HIV-associated nephropathy (HIVAN). Under the terms of the agree
Antigen Express Announces Patent Award and $292,000 Phase I SBIR Grant for Ii-Suppression Platform Technology: PRNewswire - April 29, 2002; WORCESTER, Mass., April 29 /PRNewswire/ -- Antigen Express, Inc. (AgExp) today announced that the US Patent and Trademark Office has issued to AgExp a new patent, US 6,368,855, concerning its Ii-Suppression Platform Technology. Additionally, AgExp has received a $292,000 Phase I Small Business Innovative Research (SBIR
Potential Diabetes Treatment, Outcomes of Transplants In HIV+ Patients Among New Research Findings Being Presented By University Of Pittsburgh at American Transplant Congress: PRNewswire - April 29, 2002; WASHINGTON -- Clinical and basic science research findings of more than 60 studies are being presented by researchers from the University of Pittsburgh s Thomas E. Starzl Transplantation Institute at the American Transplant Congress, the joint scientific meeting of the American Society of Transplant Surgeons and the Am
Abbott Laboratories Highlights Year Of Achievements At Annual Meeting - Abbott CEO Stresses Performance And Solid Platform For Growth -: PRNewswire - April 26, 2002; ABBOTT PARK, Ill., April 26 /PRNewswire-FirstCall/ -- At the annual meeting of Abbott Laboratories (NYSE: ABT) shareholders today, Chairman and Chief Executive Officer Miles D. White highlighted the company s scientific efforts; the successful integration of Knoll; and the performance of its two business groups, pharma
Free and Brand Name Prescription Drugs Disclosed in New Book: PRNewswire - April 26, 2002; KERNVILLE, Calif., April 26 /PRNewswire/ -- Senior insurance agent and Certified Senior Advisor (CSA) Harry Thal kept receiving phone calls from clients and other insurance agents regarding the lack of prescription drug coverage provided by Medicare, Senior HMOs and of course, persons with no health insurance. In respo
Epimmune Engages FRB/Weber Shandwick for Comprehensive Investor Relations Program: PRNewswire - April 25, 2002; SAN DIEGO, April 25 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body s immune system, today announced that it is advancing its communications program with the financial community w
UNFPA's Leaky Condoms Poke Holes in Colin Powell's Safe Sex Theory: A Situation Report From PRI: PRNewswire - April 25, 2002; WASHINGTON, April 25 /PRNewswire/ -- More bad news for the world s chief cheerleader and funder of China s one-child policy: The government of Tanzania has rejected a boatload of defective UNFPA condoms, and announced that they will be destroyed. Despite this embarrassment, UNFPA allies in the State Department are work
Protection Results Against Malaria, Herpes and Cancer Reported With CEL-SCI's Newly Discovered Peptide: Results of CEL-SCI Collaborations with the Naval Medical Research Center, Northeastern Ohio Universities (NEOUCOM) and Onyvax Ltd (UK) Presented at Experimental Biology 2002 Meeting: PRNewswire - April 25, 2002; VIENNA, Va., April 25 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) and The Naval Medical Research Center (NMRC) announced today that a newly discovered peptide provided 100% protection against malaria infection in a mouse model. Dr. Yupin Charoenvit of NMRC presented these data at the Experimental Biology
Statement of Seth Berkley, MD, on naming of IAVI Board Member Dr. Richard Feachem as Executive Director of Global AIDS Fund: PRNewswire - April 25, 2002; NEW YORK, April 25 /PRNewswire/ -- Seth F. Berkley, MD, President and CEO of the International AIDS Vaccine Initiative (IAVI) today released this statement in response to the naming of Dr. Richard Feachem, a member of IAVI s Board of Directors, as Executive Director of the new Global Fund to Fight AIDS, Tuberculosis an
FDA Clears Visible Genetics Next Generation HIV Resistance Interpretation Software: PRNewswire - April 25, 2002; TORONTO - Visible Genetics Inc. (Nasdaq: VGIN) (VGI) today received clearance from the U.S. Food and Drug Administration ( FDA ) for the next generation interpretation software for the TRUGENE(TM) HIV-1 Genotyping Test. The GuideLines(TM) 5.0 Rules, which include the latest data on HIV drug resistance, were reviewed wi
VaxGen's AIDS Vaccine Candidates Clear 7th Safety Review; Results From First Phase III Trial Expected in Less Than a Year: PRNewswire - April 24, 2002; BRISBANE, Calif., April 24 /PRNewswire-FirstCall/ -- The independent committee that oversees the only final-stage clinical trials of AIDS vaccine candidates has once again indicated that the vaccine candidates appear safe and that the trials are being conducted appropriately, VaxGen , Inc. (Nasdaq: VXGN) announced toda
Microsoft and Sir Elton John Unite in Battle Against HIV/AIDS: Consumers Test Stock-Picking Skills Against Legendary Pop-Music Icon in MSN Money Celebrity Market Challenge, Benefiting Elton John AIDS Foundation: PRNewswire - April 24, 2002; REDMOND, Wash., April 24 /PRNewswire-FirstCall/ -- To generate awareness and raise money for HIV/AIDS prevention, Microsoft Corp. (Nasdaq: MSFT) today announced the MSN(R) Money Celebrity Market Challenge featuring Sir Elton John. Consumers can log on to CNBC on MSN Money and learn how to improve their stock-picking sk
ViroLogic Announces Expanded Agreement With GlaxoSmithKline to Support Drug Development Efforts: PRNewswire - April 24, 2002; SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Company signed an expanded agreement with GlaxoSmithKline (NYSE: GSK) to use ViroLogic s proprietary HIV resistance testing technology in the Phase III clinical development of an investigational HIV p
Schering-Plough Annual Meeting Reviews Progress in Resolving Manufacturing Issues, Highlights New Products, Strong Research Pipeline: PRNewswire - April 23, 2002; ISELIN, N.J., April 23 /PRNewswire-FirstCall/ -- Richard Jay Kogan, chairman and chief executive officer of Schering-Plough Corporation (NYSE: SGP), told shareholders at the company s annual meeting here today that Schering-Plough has accomplished a great deal on several fronts during the past year: addressing manufac
Scientists From The Johns Hopkins Medical Institutions and CEL-SCI Present Results in Autoimmune Disease Research: Significant Reductions in Myocarditis Disease Symptoms in Mice Reported After Immunization with L.E.A.P.S.(TM) Peptide: PRNewswire - April 23, 2002; VIENNA, Va. and NEW ORLEANS -- Scientists from the laboratory of Dr. Noel Rose in The Johns Hopkins University Department of Pathology and CEL-SCI CORPORATION (Amex: CVM) today presented at the Experimental Biology 2002 meeting, data that could lead to development of a treatment for autoimmune myocarditis, a life threa
Chiron Appoints William G. Green as President, Chiron Blood Testing: New Business Unit Head Brings Depth of Experience to Blood Testing Division: PRNewswire - April 23, 2002; EMERYVILLE, Calif. -- Chiron Corporation (Nasdaq: CHIR) today named William G. Green, 57, as president of Chiron s Blood Testing division. Based in Emeryville, Mr. Green, who has been serving as Chiron s general counsel, will be responsible for the commercial operations of Chiron s blood testing business. He will repor
AnorMED appoints new members of Executive Management Team and Scientific Advisory Board: PRNewswire - April 23, 2002; VANCOUVER - AnorMED Inc. (TSE:AOM) is pleased to announce the appointments of Mr. Paul Brennan as Vice President Business Development; Dr. Renato Skerlj as Vice President Chemistry; and Dr. Robert Schooley as a new member of the Company s Scientific Advisory Board. We are very pleased that Mr. Brennan will be joining o
The Balm In Gilead to Host Annual Black Church HIV/AIDS Institute: The Rev. Al Sharpton, Dr. Lucy Perez and Emanuel Cleaver II Set To Address Hundreds of Clergy and Auxiliary: AIDS Conference for Black Churches in Tarrytown, New York, May 28-31, 2002: PRNewswire - April 23, 2002; NEW YORK -- The Balm In Gilead announces its 4th Annual Black Church HIV/AIDS Training Institute May 28-31, 2002, in its vigorous effort to continue its national and international mission of empowering churches throughout the African Diaspora to become more prominent in the battle against the AIDS epidemic. The Black C
California State University, Sacramento to Host Africamix Collective Volunteer Pledge For Needy Children Festival: PRNewswire - April 22, 2002; SACRAMENTO, Calif. -- Africamix was today delighted to announce that California State University, Sacramento has officially been selected as the first host venue of its touring arts and music festival designed to help combat child abuse and neglect. California State University, Sacramento had keenly accepted the appoin
Donner Corp. International Issues a Speculative Buy Recommendation On Amarillo Biosciences, Inc.: PRNewswire - April 22, 2002; SANTA ANA, Calif. -- Donner Corp. International (DCI) announced today that it released its Speculative Buy Recommendation on Amarillo Biosciences, Inc. (OTC Bulletin Board: AMAR). Donner issued the report at http://www.donnercorp.com stating the favorable research and results in clinical trials of the company s patente
'New Partnership for Haiti' Resolution Calls on Bush Administration To Lift Aid Embargo Against Haiti: Government of Haiti Applauds Congressional Black Caucus for Continued Support In Fight for Release of Humanitarian Assistance Loans: PRNewswire - April 22, 2002; WASHINGTON -- U.S. Representative Barbara Lee (D-CA) and members of the Congressional Black Caucus (CBC) announced on Thursday, April 18, 2002, the introduction of the New Partnership for Haiti resolution at a press conference at the U.S. Capitol. The resolution urges the Bush Administration to end any aid embargo agai
Female Condom Maker Receives Queen's Award for Enterprise: PRNewswire - April 22, 2002; LONDON, -- The Female Health Company (OTC Bulletin Board: FHCO) announced that its subsidiary, The Female Health Company (UK) plc, has received the prestigious Queen s Award for Enterprise, the highest honor that can be bestowed on a UK business. The award, given in the Queen s Golden Jubilee year, has been made in rec
Study Demonstrates New FORTOVASE(R) Dosing Strategy Maintains Low Viral Load While Reducing Triglycerides and Cholesterol: PRNewswire - April 22, 2002; NUTLEY, N.J. -- Roche today announced clinical study results indicating that HIV patients who modified their twice-daily protease inhibitor regimen of FORTOVASE(R) (saquinavir soft gel capsules) with ritonavir (FORTOVASE/r) by increasing the FORTOVASE dose and minimizing the ritonavir dose were able to maintain viral s
Two Years Later, Jubilee Network Celebrates Many Gains in Campaign For Debt Cancellation: US Congress Pushes for Deeper Debt Cancellation; World Bank's Own Report Acknowledges Shortcomings: PRNewswire - April 18, 2002; WASHINGTON, April 18 /PRNewswire/ -- Two years ago, the historic Jubilee 2000 campaign gained international attention with the help of rock star Bono and religious leaders like the Pope and Archbishop Desmond Tutu. Jubilee 2000 has become Jubilee USA Network, and this broad coalition of labor, religious and development
Criticizing Meager Efforts, Shareholders Challenge Abbott Labs on Treatment of AIDS Pandemic: PRNewswire - April 18, 2002; NEW YORK, April 18 /PRNewswire/ -- Calling the company s current AIDS treatment programs meager , religious and union shareholders are challenging Abbott Laboratories to make life-saving HIV/AIDS medicines accessible and affordable in African countries where AIDS is pandemic. Eight institutions are sponsoring a shareho
Roche Adds Promising Compound to Its Strong HIV Treatment Portfolio: Signs Licensing Agreement with Medivir: PRNewswire - April 18, 2002; NUTLEY, N.J. -- Roche announced that it has signed a licensing agreement with Medivir, a Swedish biotechnology company, for MV026048, an innovative treatment in development for HIV. A novel non- nucleoside reverse transcriptase inhibitor (nNRTI), MV026048 is currently in pre-clinical development and is expected to ente
Roche and Trimeris Announce 24-Week Results From First Phase III Study Of HIV Fusion Inhibitor T-20: Pivotal Study Meets Primary Endpoint: PRNewswire - April 18, 2002; NUTLEY, N.J. and DURHAM, N.C., April 18 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. today announced positive 24-week results from the first pivotal Phase III study of T-20, the furthest in clinical development of an investigational class of antiretrovirals called fusion inhibitors. The results from this first st
MTV Responds to Youth Demand for Information on Sexual Health With Fight for Your Rights: Protect Yourself: PRNewswire - April 16, 2002; NEW YORK -- According to new findings from a national survey conducted by the Kaiser Family Foundation for MTV, more young people cite sexual health as a top concern than any other issue, and three in four say they are not getting all the information they need to make informed and responsible sexual health decisions. I
Consensus Pharmaceuticals Awarded Phase I SBIR Grant to Advance Development of AIDS Treatment: PRNewswire - April 16, 2002; MEDFORD, Mass., April 16 /PRNewswire/ -- Privately-held Consensus Pharmaceuticals, Inc. announced today the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health in Bethesda, MD. The grant to Con
SciClone Begins ZADAXIN(R) U.S Phase 3 Hepatitis C Clinical Trials: First Patients Enrolled and Receiving Treatment: PRNewswire - April 15, 2002; SAN MATEO, Calif., April 15 /PRNewswire-FirstCall/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the first patients in its ZADAXIN U.S. phase 3 hepatitis C clinical trials have been enrolled and are receiving treatment. The injection of the first patients in our U.S. phase 3 clinical trials represents the
Newsweek Cover: 'Hepatitis C': Hepatitis C May Kill More People Than AIDS By the End of the Decade: The Virus is Four Times as Widespread as HIV, Affecting Anyone Exposed to Other People's Blood: PRNewswire - April 14, 2002; NEW YORK -- Two decades of mass death have burned the letters HIV deep into our psyches, but few Americans have even heard of the liver-damaging HCV -- the hepatitis C virus. Doctors says the virus now kills 10,000 Americans each year, and the annual toll could reach 30,000 by the end of the decade. That s twice the nu
With Completion of Manufacturing Validation Program, CEL-SCI Significantly Reduces Expenditures: Streamlined Company to Continue Focus on Multikine(TM) Clinical Trials For Cancer Therapeutics: PRNewswire - April 11, 2002; VIENNA, Va. -- CEL-SCI Corporation (Amex: CVM) has aggressively reduced expenditures following the conclusion of the manufacturing validation program for its immunotheraphy product Multikine. During the last quarter of 2001, CEL-SCI spent about $900,000 per month to achieve its goals. By the middle of May of this year,
Millennium Biotechnologies Group, Inc. Announces Product Launch in Nevada: PRNewswire - April 11, 2002; BERNARDSVILLE, N.J. -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) announced today, April 11, 2002 that Resurgex(TM), its multi-component nutritional supplement designed to assist in maintaining lean muscle, decrease oxidative stress,
Nkosi HIV/AIDS Champion; Mbeki??: PRNewswire - 11 April 2002; The United Democratic Movement Youth Vanguard (UDMYV) rejoices with all South Africans that Nkosi Johnson, who died last year, is to be honoured with the World s Children s Prize for the Rights of the Child. We especially would like to thank and honour Ms Gail Johnson, Nkosi s foster-mother, for her diligent and contin
New Data Support Utility of AAV Vectors in AIDS Vaccine Development: PRNewswire - April 11, 2002; KEYSTONE, Colo., April 11 /PRNewswire-FirstCall/ -- Promising data from preclinical studies utilizing an adeno-associated virus (AAV) vector for a novel AIDS vaccine candidate were presented earlier this week by Philip Johnson, MD, President of Columbus Children s Research Institute on the campus of Columbus Children s
New England Journal of Medicine Reports on Treatment For CMV Retinitis, a Leading Cause of Visual Loss in AIDS Patients: First Potent Oral Drug for Treatment of AIDS-Related CMV Retinitis: PRNewswire - April 10, 2002; NUTLEY, N.J., April 10 /PRNewswire/ -- New research published in the April 11th edition of The New England Journal of Medicine shows that VALCYTE(TM) (valganciclovir) tablets are as effective as CYTOVENE(R) (ganciclovir) intravenous (IV) therapy for the treatment of cytomegalovirus (
Viral Genetics, Inc. Regulatory Update: Application for Registration of TNP And Protocol for Expanded Human Clinical Trial Filed With Mexican Department Of Health and Company Begins Preparing USFDA and P.R. China SDA Filings: PRNewswire - April 10, 2002; SOUTH PASADENA, Calif., April 10 /PRNewswire-FirstCall/ -- Viral Genetics (OTC Bulletin Board: VRAL) is pleased to announce that it has received confirmation from its Mexican agents, SAVSA and Labortorios Senosiain, S.A. de C.V., that the final form of the companies joint submission of a New Drug Application ( NDA ) re
Pfizer, Schering-Plough, and Bristol-Myers Squibb Prepare to Vie for HIV Antifungal Market Leadership when Pfizer's Diflucan Patent Expires: PRNewswire - April 10, 2002; BOSTON -- Pfizer s Diflucan (fluconazole) currently dominates the antifungals market, thanks to a good safety profile, relatively few drug-drug interactions, interchangeable oral and intravenous formulations, and a highly successful marketing campaign. As generic competition erodes fluconazole sales, beginning in 2004,
1,100 Riders Registered to Pedal 575 Miles From San Francisco To Los Angeles in California AIDSRide 9, June 2-8, 2002: Funds Raised Will Benefit HIV/AIDS Organizations Throughout The State - From San Diego to Sacramento: PRNewswire - April 10, 2002; LOS ANGELES -- Over one thousand, one hundred compassionate and brave people have now registered to participate in the ninth annual California AIDSRide, an extraordinary journey of kindness and a powerful way for people to put their own sweat and tears into the AIDS crisis. This year s event will take place from June 2
Alfacell's ONCONASE(R) Significantly Inhibits RNA Viruses Including HIV-1; Data Presented at the Congress of the German Society for Virology: PRNewswire - April 10, 2002; BLOOMFIELD, N.J. -- Alfacell Corporation (OTC Bulletin Board: ACEL) today announced that Dr. Martin Michaelis of the Institute of Medicinal Virology at Johann Wolfgang University in Frankfurt, Germany is presenting results confirming that ONCONASE(R) significantly inhibits the replication of the HIV virus (the causativ
Sharon Stone Named Recipient of The Global Conference Institute's Healthcare Humanitarian Award for 2002: Sharon Stone, Champion In the Battle Against AIDS, to Be Honored at Awards Tribute and Dinner Gala as Highlight of 4th World Healthcare Conference, How Policy Is Influencing Healthcare and Medicine, April 22 & 23, 2002 at The University of Chicago: PRNewswire - April 9, 2002; PITTSBURGH -- Actress Sharon Stone, leading healthcare advocate and Chairman of the Campaign for AIDS Research, The American Foundation for AIDS Research, has been named this year s recipient of The Global Conference Institute s Healthcare Humanitarian Award. The Award, which was established in 1998, recognizes one ind
Project Angel Food Receives Emergency Funding From Philip Morris Companies To Continue Successful Home-Delivered Meal Program for Hispanics Response to LA County AIDS Organization Helps Relieve Tremendous Financial Burden Since 9-11: PRNewswire - April 9, 2002; LOS ANGELES, April 9 /PRNewswire/ -- Struggling with the burden of a significant fund-raising shortfall, yet intent on maintaining its commitment to people living with HIV/AIDS, Project Angel Food today announced it has received emergency corporate funding to continue a successful home-delivered meals program for Hispa
Abbott Wins Sole Supplier Contract For Blood Screening Tests: Five-Year Agreement With American Red Cross Covers Abbott's Blood Screening Tests For Hepatitis, HIV And Other Retroviruses: PRNewswire - April 9, 2002; ABBOTT PARK, Ill. -- Abbott Laboratories (NYSE: ABT) announced today it has been awarded a multi-year contract as the exclusive supplier of six infectious disease tests used for screening blood donated to the American Red Cross. The tests consist of markers for hepatitis, HIV and other retroviruses. This agreement
ProdiGene Announces Milestone in NIH Collaboration for AIDS Vaccine - Successful Expression of SIV Sub Unit Vaccine - Important Step to Make a Future Edible AIDS Vaccine -: PRNewswire - April 9, 2002; KEYSTONE, Colo. -- ProdiGene, Inc., a leader in the development and manufacturing of recombinant proteins in transgenic plant systems, announced here today at the Keystone Symposia, that it successfully expressed a sub unit vaccine in maize that is expected to produce an immune response to simian immunodeficiency virus
Nevirapine: Government drags it's feet: PRNewswire - April 9, 2002; The people of this country can only judge its government, based on what they see, hear and experience and it is seems from ANC government s action, or rather lack of action, that it does not take seriously the decision by the Constitutional Court that it provide Nevirapine, in state hospitals with the capacity to do so
Visible Genetics Inc. Announces Preliminary First Quarter Revenue: PRNewswire - April 8, 2002; TORONTO -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN) reported today that it expects 2002 first quarter revenues to be in the range of $4.2 million to $4.4 million, which is within the previously announced range of expected revenues for the quarter. This represents an approximate 35% increase over fourth quarter 2001 r
ActionAid USA's Photo Exhibit/Capitol Reception and Political Rally To Fight AIDS: PRNewswire - April 8, 2002; WASHINGTON, April 8 /PRNewswire/ -- The following was released today by ActionAid USA: WHO: With special guests, Actor Danny Glover, Congresswoman Barbara Lee (D-CA), and Jackie Bataringaya of ActionAid, ActionAid USA, The Global AIDS Alliance, Student Global AIDS Campaign and RESULTS invite you to attend a photo exhib
Roche HIV-1 PCR-Based Blood Screening Assay Cleared for Marketing In Italy: Roche NAT Blood Screening Assays Now Registered in Italy, Australia, France, Germany, Spain and Switzerland: PRNewswire - April 8, 2002; Pleasanton, Calif., Roche Diagnostics announced today that it has received registration for its COBAS AmpliScreenR HIV-1, v1.5 Test within Italy . This assay utilizes Polymerase Chain Reaction (PCR) technology, the worldwide leading Nucleic Acid Amplification Technology (NAT). Roche received this approval from the Mini
The Immune Response Corporation Announces a 1-for-4 Reverse Stock Split: PRNewswire - April 5, 2002; CARLSBAD, Calif. -- The Immune Response Corporation (Nasdaq: IMNR) today announced that its Board of Directors has declared a 1-for-4 reverse stock split relating to its outstanding shares of common stock, subject to approval of the Company s stockholders at the Company s annual meeting to be held on May 23, 2002. The
HelpAge International to Launch Report on State of World's Older People On 8 April: New Report Highlights Discrimination and Disadvantage Faced by Poor Older People in Developing Countries: PRNewswire - April 5, 2002; LONDON -- HelpAge International will launch State of the world s older people 2002 in Madrid on 8 April 2002 to coincide with the opening of the Second World Assembly on Ageing. The report reflects the views and experiences of older people, as expressed in consultations held in developing countries and in east and cent
Harvard's Jeffrey Sachs, One of the World's Leading Economists, Will Head Columbia Earth Institute: PRNewswire - April 5, 2002; NEW YORK -- Harvard University Professor Jeffrey D. Sachs has been named director of the Columbia University Earth Institute, effective July 1, 2002. Sachs, who serves as an economic advisor to governments in Latin America, Eastern Europe, the former Soviet Union, Asia and Africa as well as to the United Nations, is wi
Monique Payton Brings Blues and Basketball Together to Heighten Awareness For AIDS: PRNewswire - April 5, 2002; SEATTLE, April 5 /PRNewswire/ -- Monique Payton, along with some other Seattle Sonic wives and high-profile community women, have teamed up to create Red, White & Blues-an evening of blues music, wine tasting and plenty of Sonic camaraderie to benefit Lifelong AIDS Alliance, a Northwest foundation dedicated to the
AIDS Activists, Danny Glover, Rep. Barbara Lee Rally at Capitol 12:30 PM: Wednesday, April 10, 2002, Demand Congress Donate the Dollars, Treat the People, and Drop The Debt to Fight AIDS Worldwide: PRNewswire - April 4, 2002; WASHINGTON -- 1,000 people with AIDS, public health experts, religious leaders and other activists, joined by actor Danny Glover and Rep. Barbara Lee (D, Oakland), will rally at the Capitol steps Wednesday, April 10, 12:30 PM. The demonstrators will carry a giant alarm clock, declaring that time is up for Congressional
Pair of IAVI-Sponsored AIDS Vaccines for Africa Shows Promise in Initial Human Trials, Progresses to Intermediate Testing in UK: PRNewswire - April 4, 2002; LONDON -- Having successfully completed first-stage human testing, a pair of vaccines designed to mobilize the immune system to protect against HIV and AIDS today advanced to second-stage trials in the UK. The vaccines are the only in human testing that are tailored for variants of HIV common where the infection rate i
The constitutional court has spoken: Nevirapine to the people!: PRNewswire - April 4, 2002; The United Democratic Movement (UDM) welcomes the Constitutional Court s refusal to give government leave to appeal against a Pretoria High Court execution order demanding that it provide the anti-retroviral drug nevirapine in state hospitals with the capacity to do so between now and the outcome of a further court hea
Planned Parenthood of Southeast Michigan Welcomes World-Renowned Author As Luncheon Speaker On May 16: PRNewswire - April 3, 2002; SOUTHFIELD, Mich. -- Planned Parenthood of Southeast Michigan will present Kati Marton, United Nations Chief of Outreach, as the keynote speaker at their annual luncheon on Thursday, May 16, 2002. This eighth annual fundraising luncheon will be held at the Ambassador Hotel in Southfield. The event is typically a huge s
CEL-SCI Corporation Invites You to Join Its Webcast at the American Stock Exchange Online Conference: PRNewswire - April 3, 2002; VIENNA, Va., April 3 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) today announced that it will be presenting at the American Stock Exchange s upcoming online conference, Where Savvy Investors Meet Undiscovered Companies. You are invited to listen to management s slide presentation that will be Webcast live
Therion Biologics Adds to Board of Directors -- Peter R. Wolfe, M.D., Partner and Director of Research at Pacific Oaks Medical Group, and Trudie Resch, Partner of CDP Sofinov --: PRNewswire - April 3, 2002; CAMBRIDGE, Mass. -- Therion Biologics has expanded its Board of Directors with the appointments of Peter R. Wolfe, M.D., Partner and Director of Research at Pacific Oaks Medical Group, and Trudie Resch, Partner of CDP Sofinov. These additions strengthen Therion s Board by bringing to the company Dr. Wolfe s clinical ex
The Immune Response Corporation Announces Result of Special Meeting of Stockholders: PRNewswire - April 3, 2002; CARLSBAD, Calif., April 3 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) is pleased to announce that at the Special Meeting of Stockholders held on April 2, 2002 at the Company s offices, the stockholders of the Company approved the November 2001 financing and subsequent financing proposal.
Ontogen Announces Formation of Oncology Advisory Group: PRNewswire - April 3, 2002; CARLSBAD, Calif., April 3 /PRNewswire/ -- Ontogen Corporation today announced the creation of its Oncology Advisory Group (OAG) that consists of leading experts in basic and clinical oncology research. The OAG will provide scientific and strategic guidance to Ontogen s management team regarding its growing portfolio of
Chugai Pharmaceutical Announces That Gen-Probe, Its Wholly Owned Subsidiary, Has Filed Form 10 With the SEC: PRNewswire - April 2, 2002; TOKYO, April 2 /PRNewswire/ -- Chugai Pharmaceutical Co., Ltd. announced today that its wholly owned subsidiary, Gen-Probe Incorporated, has filed Form 10 with the Securities and Exchange Commission in connection with proposed spin-off from Chugai Pharmaceutical and stock exchange listing in the United States
PA Gov. Schweiker Proclaims April 1-7 `Public Health Week': PRNewswire - April 1, 2002; HARRISBURG, Pa. -- Gov. Mark Schweiker has proclaimed April 1-7 as Public Health Week in Pennsylvania. As state leaders and public health officials, we have no greater responsibility than promoting and protecting the health and safety of Pennsylvanians, Gov. Schweiker said. I commend Health Secretary Robert Zimmerman,
Trinity Medical Group USA Announces Study to Broaden Use of REMUNE(R): PRNewswire - March 31, 2002; RANCHO SANTA MARGARITA, Calif. -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) announced today that the Thai National Ethical Committee, Ministry of Public Health, has approved an advanced study of REMUNE(R), an Immune-Based Therapy to treat HIV-infected individuals. The study, known as IB3101, is intende
Parker Hughes Institute Granted Patent for New Anti-AIDS Drug: Temporarily Closes HIV Clinic in Preparation for Stampidine Clinical Trial: PRNewswire - March 28, 2002; ROSEVILLE, Minn. -- On February 26, 2002 the U.S. Patent and Trademark Office granted Parker Hughes Institute a patent (U.S. patent No. 6,350,736) for Stampidine, a new anti-AIDS drug developed at the institute. Parker Hughes Institute has completed all pre-clinical research and development related to Stampidine and is
FDA Approves Production Of Initial Lots At Nabi Biopharmaceuticals Boca Raton Facility: PRNewswire - March 27, 2002; BOCA RATON, Fla. -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced that the Food and Drug Administration ( FDA ) released for sale the initial production of Nabi-HB(TM) [Hepatitis B Immune Globulin (Human)] manufactured at Nabi Biopharmaceuticals Boca Raton, Florida biopharmaceutical manufacturing facility. Na
VaxGen Biopharmaceutical Manufacturing Joint Venture Appoints Senior Officers and Directors: PRNewswire - March 27, 2002; BRISBANE, Calif. -- Celltrion Inc., a joint venture owned by VaxGen , Inc. (Nasdaq: VXGN) and a group of South Korean investors, announced the appointment of directors and interim senior officers to lead the company in its establishment of facilities for the manufacture of VaxGen s AIDS vaccine candidates. James P.
St. Jude Children's Research Hospital Announces Multicultural Outreach Initiative: PRNewswire - March 27, 2002; MEMPHIS, Tenn. -- St. Jude Children s Research Hospital today announced its Multicultural Outreach Initiative, a program designed to share information with minority communities about the groundbreaking research conducted by St. Jude scientists to treat and cure children who suffer from catastrophic diseases. Some of th
Medical Discoveries, Inc. Signs Euronet International to Initiate Private Stock Placement: MDI to Use Funds for FDA Approvals Push: PRNewswire - March 27, 2002; SALT LAKE CITY -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) announced today that it has entered into an advisory agreement with Euronet International, Inc., a New York City-based business and financial advisory firm. Under the terms of the agreement, Euronet International will seek to initiate a private plac
Regent Group, Inc. Receives HCPCS for Resurgex(TM): PRNewswire - March 27, 2002; BERNARDSVILLE, N.J. -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Regent Group, Inc. (OTC Bulletin Board: RGII), today announced they have received from the Centers for Medicare and Medicaid Services (CMS) a HCPCS coding for their nutritional supplement, Resurgex(TM). HCPCS coding is required for Me
Noted Physician Joins Food Technology Service, Inc.: PRNewswire - March 26, 2002; MULBERRY, Fla. -- Food Technology Service, Inc. (Nasdaq: VIFL), the nation s most experienced food irradiation company, today announced that Robert Windom, M.D. has joined the company as Senior Medical Advisor. Windom served as U.S. Assistant Secretary for Health, the highest-ranking physician in the Federal government
ViroLogic Raises $10 Million Through Private Placement: Cash Position Sufficient to Achieve Breakeven by the End of 2002: PRNewswire - March 26, 2002; SOUTH SAN FRANCISCO, Calif. -- ViroLogic, Inc. (Nasdaq: VLGC) today announced it has closed a transaction to sell newly designated shares of 6% convertible preferred stock to several large investors in a private placement resulting in gross proceeds to the company of $10 million. ViroLogic expects to use the proceeds f
No, to deputy minister on AIDS: PRNewswire - 26 March 2002; The United Democratic Movement (UDM) opposes the proposal that a deputy-minister might be appointed to exclusively deal with the HIV/Aids crisis in South Africa . Such an appointment would only serve as a demotion or downgrading of the very serious issue of HIV/Aids. The management of the issue is supposed to occur at
Dentists: Disease Detectives; Delta Dental Plans Reports Dentists Find Clues to General Health Disorders: PRNewswire - March 26, 2002; OKEMOS, Mich. -- Early detection of serious medical conditions is being made in an unexpected place -- the dental office. Because many other diseases can cause specific signs and symptoms in and around the mouth and jaw, dentists see clues that may point to critical health issues. As a result, increasing numbers of den
Elizabeth Glaser Pediatric AIDS Foundation, The Diana, Princess of Wales HIV Research Foundation, and HIVSA Join UCLA AIDS Institute and Emory Vaccine Research Center as African AIDSTrek Beneficiaries: PRNewswire - March 26, 2002; LOS ANGELES -- Pallotta TeamWorks, charity event organizers, today announced Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), The Diana, Princess of Wales HIV Research Foundation, and HIVSA have signed on as South African beneficiaries of the African AIDSTrek, joining the UCLA AIDS Institute and Emory Vaccine Resear
PROJECT HEALTHY LIVING to Be Held April 6 to May 11 in Metro Detroit: PRNewswire - March 25, 2002; SOUTHFIELD, Mich. -- The 23rd annual PROJECT HEALTHY LIVING, sponsored by WXYZ-TV/Channel 7, Suzuki, Molina Healthcare and the United Health Organization, a United Way agency, will be held Saturday, April 6 through Saturday, May 11, at more than 100 sites in the City of Detroit and the counties of Lapeer, Livingston, M
Oncosis Signs Research Agreement With Univ. of Texas: NIH Grant to Fund Study of the Effects of HIV Virus on Stem-Progenitor Cells In the Progression of AIDS: PRNewswire - March 25, 2002; SAN DIEGO -- Oncosis, Inc., today announced that it has established a sponsored research agreement with Dr. James F. Leary, Ph.D., and the University of Texas Medical Branch (UTMB) in Galveston, Texas. The agreement will feature development of the company s patented Photosis(TM) technology platform, a novel, automated,
Victims of an uncaring government: PRNewswire - 25 March 2002; If it is not enough that our fellow citizens suffer from illnesses like, Cholera, TB and HIV/Aids; more and more South Africans are daily exposed to a government which carry other diseases. lack of care and lack of action. This ANC government refuses to acknowledge its errors when it comes to HIV/Aids; the result is th
UDM welcomes Nevirapine Judgement: PRNewswire - 25 March 2002; The UDM welcomes the Pretoria High Court ruling that Government has to provide nevirapine to HIV-positive pregnant women at all state hospitals with the capacity to do so. This must now end the ANC government s insistence to continue with useless talk and debate, instead of action. Government must lead by example, thus
Johnson & Johnson to Acquire Tibotec-Virco: Acquisition to Expand Johnson & Johnson's Portfolio of Treatments for Infectious Diseases and Add to Research and Development Capability: PRNewswire - March 22, 2002; NEW BRUNSWICK, N.J. -- Johnson & Johnson today announced it has signed a definitive agreement to acquire all of the assets of Tibotec-Virco NV, a privately-held biopharmaceutical company focused on developing anti-viral treatments, with several promising compounds in development for the treatment of infectious dise
City of Hope to Bridge Generations Affected by AIDS/HIV Scourge in Africa: Innovative Living Concept Receives Endorsement and Financial Support From Reverend Franklin Graham: PRNewswire - March 22, 2002; ALEXANDRIA, Va. -- A simple, cost effective living solution pairing children and the elderly, the two groups most vulnerable to the ravages of the African AIDS pandemic, soon will become a reality in Kenya and serve as a prototype for similar initiatives elsewhere. Before the end of the year, the 100-acre City of Hope
New Employer Initiative Addressing Health Care Disparities Announced: PRNewswire - March 21, 2002; WASHINGTON -- The Washington Business Group on Health (WBGH) and Pfizer /PfizerHealth Solutions today announced a pilot project designed to address health care disparities, particularly targeting cardiovascular disease, in a culturally diverse workforce. It is part of the WBGH s initiative entitled, the WBGH Health Di
The New England Journal of Medicine Publishes Landmark Study Highlighting Efficacy of Tracleer(TM) in Life-Threatening Lung Condition: PRNewswire - March 20, 2002; ALLSCHWIL, Switzerland and SOUTH SAN FRANCISCO, Calif. -- A landmark study being published in the March 21, 2002 issue of the renowned New England Journal of Medicine highlights the importance of Tracleer(TM) (bosentan) tablets for the treatment of pulmonary arterial hypertension (PAH). The study, known as BREATHE-1 (B
Zacks.com Featured Expert Issues Recommendations On: TRMS and BTK: PRNewswire - March 20, 2002; CHICAGO -- Nadine Wong s Bioportfolio is up 26.8% in 2002 vs. a -5.6% loss in the Biotech Index demonstrating the importance of specialization in maximizing sector-specific returns. Get one of her top picks with the potential to post bionic performance! For the complete report and more in-depth market commentary, visit
United Nations Association of Greater Boston Announces One-Day Conference on The Global Fund to Fight AIDS, Tuberculosis, and Malaria: Fund to Disburse Between $700-$800 Million in 2002: PRNewswire - March 20, 2002; BOSTON -- The United Nations Association of Greater Boston (UNA-GB) will host a one-day conference, Realizing the Vision: The Global Fund to Fight AIDS, Tuberculosis, and Malaria, on Thursday, May 2, 2002 at the American Academy of Arts and Sciences in Cambridge, Mass. The conference will explore ways to help assure th
ADVR's Product R Granted Patent for Topical Use In Treatment of Skin Diseases, Eye Afflictions: PRNewwire - March 20, 2002; YONKERS, N.Y. -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it has been awarded U.S. Patent No.6,355,226 entitled Topical Treatment of Skin Disease and Eye Afflictions. The patent protects the use of Product R, the non-toxic peptide-nucleic acid immunomodulator developed by Advanced V
Atrix Begins Phase II Clinical Trials for a Low Dose Oral Interferon Product: PRNewswire - March 20, 2002; FORT COLLINS, Colo. -- Atrix Laboratories, Inc. (Nasdaq: ATRX) announced today that it has commenced Phase II clinical trials for a proprietary formulation of a low dose oral interferon-alpha product for the treatment of oral warts caused by human papilloma virus (HPV) in HIV-infected patients. I am pleased with the sw
Dr.Gordon Perkin and Suzanne Cluett of the Bill & Melinda Gates Foundation Participate in 'African AIDSTrek' Journey: 7-Day, 75-Mile Hike Through Cederberg Wilderness in South Africa to Raise Awareness and Money for an AIDS Vaccine From April 2-8: PRNewswire - March 20, 2002; LOS ANGELES -- Two Global Health Program staff members, Dr. Gordon Perkin and Suzanne Cluett, from the Bill & Melinda Gates Foundation join 150 people on an African AIDSTrek, a groundbreaking, 75-mile journey through South Africa as they do their part to make a difference in the fight against AIDS. For seven days,
Gay and Lesbian Fund for Colorado Awards First Grants of 2002 - $148,000 Awarded to 45 Community Nonprofits in 15 Colorado Counties -: PRNewswire - March 19, 2002; COLORADO SPRINGS, Colo. -- The Gay and Lesbian Fund for Colorado, a fund of the Denver-based Gill Foundation, today announced it made more than $148,000 in grants to Colorado nonprofit organizations during its first two granting cycles of 2002. The 45 grants illustrate the support gay and lesbian philanthropists make t
Multikine(TM) Demonstrates Excellent Clinical Responses In HIV-Infected Women With Cervical Dysplasia: PRNewswire - March 19, 2002; VIENNA, Va. -- The Institute of Human Virology (IHV) at the University of Maryland, Baltimore, and CEL-SCI Corporation (Amex: CVM) announce the presentation of clinical data for CEL- SCI s immunotherapy drug, Multikine, at the March 2002 Annual Meeting of the Society of Gynecological Oncologists in Miami, Florida. Thes
SABCOHA to provide information base for business in war against HIV/AIDS: PRNewswire - 19 March 2002; Distributed by PR Newswire South Africa on behalf of SABCOHA The South African Business Coalition on HIV/AIDS (SABCOHA) is to establish a resource centre and website to assist the private sector in the fight against HIV/AIDS. In particular, SABCOHA will gather information on best practice in the field so that companies
The Balm In Gilead Leads Delegation on Five Country African Mission To Help Religious Leaders Combat AIDS Organization Dedicated Exclusively to Organizing African American Churches In US to Fight AIDS Expands its Successful Approaches to Africa: PRNewswire - March 18, 2002; NEW YORK -- Pernessa C. Seele, CEO and Founder of The Balm In Gilead, the leading non-governmental organization dedicated exclusively to mobilizing African American churches in the United States in the fight against HIV/AIDS, will lead a delegation to five African countries beginning April 7 as part of its transatlanti
HIV/AIDS Trailblazers Commemorate the 15th Anniversary of AZT, the First AIDS Drug: Future Expected to Bring Continued HIV/AIDS Treatment, Prevention Advances: PRNewswire - March 18, 2002; RESEARCH TRIANGLE PARK, N.C. -- Physicians, patients and scientists who ve been involved from the beginning will commemorate on March 19 the 15-year anniversary of the FDA s approval of the first AIDS drug -- AZT (Retrovir(R)/zidovudine), manufactured by GlaxoSmithKline -- and reflected on
Progenics' Investigational HIV Entry Inhibitor, PRO 542, Reduced Viral Loads In Patients Failing Conventional Therapy: PRNewswire - March 18, 2002; PRAGUE - Progenics Pharmaceuticals (Nasdaq: PGNX) reported that its novel investigational drug, PRO 542, produced a significant antiviral response in HIV-infected individuals who were no longer responding to currently available antiretroviral medications. In treatment-experienced patients, a single dose of PRO 542 redu
Local Los Angeles Resident to Help Combat AIDS Epidemic By Raising Funds to Help Develop Vaccine: PRNewswire - 15 March 2002; Distributed by PR Newswire South Africa on behalf of Brian Pendleton Neiman Marcus will host a South African wine and hors d oeuvres reception in support of Brian Pendleton s fundraising efforts for the Pallotta Teamworks African AIDSTrek, to be held on April 2 -- 8, 2002. As part of his fundraising efforts, Brian Pend
Great Beer for A Great Cause - Classic City Brew Fest, Athens, GA: PRNewswire - March 14, 2002; ATHENS, Ga. -- The Southeast s largest indoor beer festival, the 7th annual Classic City Brew Fest, will attract 3,000 beer aficionados from several states who will enjoy open sampling of over 160 of the world s greatest beers on Saturday, April 6, 2002 from 2:30 p.m. to 7 p.m. Held in the exhibit hall of Athens downto
Xcyte Therapies, Inc. Announces Issuance of Patent Providing Broad Rights For Its Core T Cell Therapy Technology, 03/05/02: PRNewswire - March 13, 2002; SEATTLE -- Xcyte Therapies, Inc. today announced that the U.S. Patent and Trademark Office (PTO) has issued U.S. patent #6,352,694 covering the Company s core technology used in its products currently in clinical trials in cancer patients. Xcyte Therapies uses this proprietary technology, known as the Xcellerate(TM) Te
Bush Administration Not Making the Grade in the War on AIDS: PRNewswire - March 13, 2002; WASHINGTON -- The polls may show that President Bush is getting good grades for his war on terrorism, but he is not making the grade in the war on HIV/AIDS, according to a national coalition of AIDS organizations from throughout the United States . As the AIDS pandemic enters its third decade, the coalition, in a lette
Epimmune Reports Fourth Quarter and Year-End 2001 Results: PRNewswire - March 13, 2002; SAN DIEGO -- Epimmune Inc. (Nasdaq: EPMN) today announced financial results for the fourth quarter and year ended December 31, 2001. For the fourth quarter 2001, the Company reported revenues of $1.7 million, compared to $0.5 million in the fourth quarter of 2000. Revenues for the year ended December 31, 2001 were $8.2
Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results: PRNewswire - March 13, 2002; TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2001. Revenues for the fourth quarter ended December 31, 2001, totaled $2.7 million compared to $3.5 million for the same quarter in 2000. For the year ended Dec
15 Latinas to Graduate From Popular Planned Parenthood Los Angeles Outreach Program, Promotoras Comunitarias: PRNewswire - March 12, 2002; LOS ANGELES -- Fifteen new Promotoras Comunitarias will celebrate the end of five months of training by Planned Parenthood Los Angeles (PPLA) at a graduation ceremony on Wednesday, March 13 at 11 a.m. at Luminarias Restaurant located at 3500 W. Romona Blvd. in Monterey Park. Following the graduation, the Promotoras wil
Don't Be Afraid to Discuss Sex With Your Children - The Topic Should Not Be Taboo; Ten Tips for Parents From the Scott & White Sex Education Program: PRNewswire - March 12, 2002; TEMPLE, Texas -- A prominent obstetrician/gynecologist at Scott & White Memorial Hospital and Clinic today released 10 Tips on discussing sex with children and teen-agers. Just because you may be a tad embarrassed to talk about sex with your kids doesn t mean your kids don t want to hear from you, said Patricia Sul
amfAR Awards Over $2 Million for New Research on HIV/AIDS; Targeted Initiative Supports Development of New Anti-HIV Drugs: PRNewswire - March 12, 2002; NEW YORK -- The American Foundation for AIDS Research (amfAR) today announced research grant awards totaling over $2 million for new research on HIV/AIDS, including grants to projects specifically aimed at developing new anti-HIV drugs. Since 1985, amfAR has invested nearly $190 million in support for its programs and
Vical to Present Update on Product Development Strategy: PRNewswire - March 12, 2002; BOSTON -- Vical Incorporated (Nasdaq: VICL) announced that Vijay B. Samant, Vical s Chief Executive Officer, will present today a strategic overview of the company s plans to significantly expand its product development efforts. The presentation is scheduled for 9:00 a.m. Eastern Time at SG Cowen Securities Corp. s 22n
AEGiS Launches New Interactive Web Site Tool: 'Ask the Doc' Features Physician Forum to Answer Questions about HIV: PRNewswire - March 12, 2002; NEW YORK -- AEGiS (AIDS Education Global Information System) announced today the formation of Ask the Doc, an interactive program on its web site, http:/www.AEGiS.org/askdoc. The program is designed to provide general information from physicians on a variety of AIDS-related medical topics. AEGiS has been previously cel
Advanced Viral Research Corp. Submits Product R Topical Phase 1 Results to FDA: PRNewswire - March 11, 2002; YONKERS, N.Y. -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it has submitted the results of a Phase 1 study for the topical use of Product R in the treatment of genital warts caused by infection with the human papilloma virus (HPV) to the U.S. Food and Drug Administration (
Ja Rule Event Spokesman for BET and BET.com Rap-It-Up Celebrity Online Charity Event Running March 18 to May 3: Fundraiser to Benefit BET's Campaign to Raise Awareness for HIV/AIDS In the African-American Community With Proceeds to Support LIFEbeat: PRNewswire - March 11, 2002; NEW YORK -- In an effort to raise money and awareness for the fight against HIV/AIDS in the African-American Community, BET and BET.com will team with entertainment industry celebrities to conduct an online auction of signed and/or exclusive memorabilia. The Yahoo auctions event will commence on Monday, March 18th and
AMA Honors Elizabeth Taylor for AIDS Advocacy: PRNewswire - March 11, 2002; LOS ANGELES -- The American Medical Association presented legendary film actress Elizabeth Taylor with an AMA Presidential Citation on Monday for her tireless commitment to advocacy on HIV-AIDS. Calling Taylor s role in addressing AIDS one of her most memorable, AMA President Richard F. Corlin, MD, applauded Taylor for
Constitutional court to decide on Nevirapine: PRNewswire - 11 March 2002; The United disappointment that the Pretoria High Court granted Government leave to appeal against an order that it should provide the Nevirapine to HIV-positive pregnant women at state hospitals and clinics. The actions of the Department of Health and that of Minister Tshabalala-Msimang in particular, bears testimony t
Celgene Clinical and Regulatory Update: THALOMID(R) Multiple Myeloma sNDA Strategy Revised: THALOMID(R) 2002 Guidance Confirmed: REVIMID(TM) Clinical Development Plan Submitted to FDA: PRNewswire - March 7, 2002; WARREN, N.J. -- Celgene Corporation (Nasdaq: CELG) announced today that, based on continuing discussions with the FDA , the Company now intends to seek marketing approval for THALOMID(R) (thalidomide) in early stage multiple myeloma patients. In addition to the data from the four trials that have already been prepared
Genzyme Molecular Oncology Reports 2001 Financial Results - Progress Made in the Clinic and Through Partnerships: PRNewswire - March 7, 2002; FRAMINGHAM, Mass. -- Genzyme Corp. today reported that total revenues for Genzyme Molecular Oncology (Nasdaq: GZMO) for the fourth quarter of 2001 were $2.6 million, an increase from $1.5 million for the fourth quarter of 2000. For the year, total revenues were $6.6 million, up from $5.7 million reported a year ago. Re
URRMA Biopharma Inc. is Pleased to Announce the Appointment of Luc Mainville as Vice President and Chief Financial Officer: PRNewswire - March 7, 2002; MONTREAL - URRMA Biopharma Inc. (http://www.urrma.com) is pleased to announce the appointment of Luc Mainville to the position of Vice President and Chief Financial Officer. Mr. Mainville graduated from the Universite du Quebec a Montreal (UQAM) in Finance and holds an MBA from McGill University. He also holds a certif
URRMA Biopharma Inc. Files Patent on the Discovery of a Modified Subclass of IgG Immunoglobulin (Antibodies): PRNewswire - March 6, 2002; MONTREAL - URRMA Biopharma Inc., (http://www.urrma.com) a private Montreal-based biotech company, is pleased to announce that it has filed a patent on a newly discovered subclass of IgG immunoglobulin with broad diagnostic and therapeutic applications to the diseases caused by HIV and possibly other infectious viruses.
Microbiotix Receives Broad US Patent Covering Its Oral Respiratory Syncytial Virus Drug: PRNewswire - March 5, 2002; WORCESTER, Mass. -- Microbiotix, Inc. announced today that the US Patent and Trademark Office has issued US Patent No. 6,337,390 entitled Compounds Comprising Sulfated Nonulonic Acid Having Antiviral Activity . This composition of matter patent covers a broad class of antiviral compounds that includes Microbiotix s lea
Trimeris Announces Fourth Quarter And Year-End 2001 Results: PRNewswire - March 5, 2002; DURHAM, N.C., March 5 /PRNewswire-FirstCall/ -- Trimeris, Inc. (Nasdaq: TRMS) today announced results for the fourth quarter and fiscal year ended December 31, 2001. For the fourth quarter of 2001, the Company reported a loss of $21.5 million, or $1.24 per share, compared with a loss of $11.1 million ($0.70 per share)
Nabi Changes Name to Nabi Biopharmaceuticals - Reflecting Company's New Business Focus -: PRNewswire - March 5, 2002; BOCA RATON, Fla., March 5 /PRNewswire-FirstCall/ -- Nabi (Nasdaq: NABI) today announced that it has changed its name to Nabi Biopharmaceuticals. This change recognizes the completion of the company s strategic transition to become a vertically integrated biopharmaceutical company. The company s focus is on the developm
EPA Approves BBJ Product For Use Against Hepatitis B Virus: PRNewswire - March 5, 2002; TAMPA, Fla., March 5 /PRNewswire-FirstCall/ -- BBJ Environmental Solutions, Inc. (OTC Bulletin Board: BBJE) is pleased to announce that the U.S. Environmental Protection Agency (EPA) has given its approval for BBJ Spray Disinfectant/Cleaner to be used against Hepatitis B Virus (HBV). Robert Baker, Chairman and CEO of B
Crucell: Preliminary Phase I Data of PER.C6-derived HIV Vaccine Encouraging: PRNewswire - March 5, 2002; LEIDEN, The Netherlands , March 5 /PRNewswire-FirstCall/ -- Dutch antibody and vaccine company Crucell N.V. (Nasdaq, Euronext: CRXL) today said initial data from a Phase I trial involving Merck & Co. Inc s experimental HIV vaccine look encouraging. The HIV vaccine, based on a recombinant adenovirus, is produced on
MedMira Receives FDA GMP Pre-Approval Inspection Notification For Reveal(TM) Rapid HIV Test: PRNewswire - March 4, 2002; HALIFAX, NS, March 4 /PRNewswire-FirstCall/ - MedMira announced today that it has received notification of the date for a comprehensive pre-approval inspection by the United States Food and Drug Administration ( FDA ). This is the final stage of the FDA Pre-Market Approval ( PMA ) process for the approval of MedMira s
M.A.C Cosmetics Reveals Advertising Campaign Starring Elton John, Mary J. Blige and Shirley Manson, the New Spokespeople for VIVA GLAM IV Lipstick and The M.A.C AIDS Fund: PRNewswire - March 4, 2002; NEW YORK, March 4 /PRNewswire/ -- M.A.C Cosmetics, the rule-breaking professional cosmetics company, unveiled today an irreverent advertising campaign shot by David LaChapelle, starring music legend and outspoken AIDS activist Elton John, Grammy Award winner Mary J. Blige and rock icon Shirley Manson of the band Garbag
Trinity Medical Group USA Announces Presentation of REMUNE(R) Study Results Meeting Clinical Endpoint for HIV Treatment: PRNewswire - March 1, 2002; RANCHO SANTA MARGARITA, Calif., March 1 /PRNewswire-FirstCall/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) announces that as part of its New Drug Application for REMUNE(R) filed in Thailand , the Thai Ministry of Public Health has been presented an independent REMUNE study conducted in
Artists for a New South Africa Presents an Event on HIV/AIDS in South Africa: PRNewswire - March 1, 2002; LOS ANGELES, March 1 /PRNewswire/ -- Artists for a New South Africa (ANSA) will present Voices from the Frontline, an evening of art, readings and film about the South African HIV/ADS crisis, Thursday, March 14 from 6 to 9 p.m. at the UCLA Fowler Museum of Cultural History. The event is free and open to the public. Pa
FORTOVASE with Kaletra Shows Encouraging Results Among Protease Inhibitor-Experienced HIV Patients in Initial Study - A second study evaluates viral and immune response of switch to once-daily Fortovase with ritonavir from twice-daily Fortovase -: PRNewswire - March 1, 2002; NUTLEY, N.J., March 1 /PRNewswire/ -- Roche today announced results of two new studies of the HIV protease inhibitor FORTOVASE(R) (saquinavir soft gel capsules). One study evaluated FORTOVASE with Kaletra (TM) ( lopinavir / ritonavir ) in 28 treatme
Data From Phase III Study on ZERIT(R) One-Capsule Once-Daily Extended Release Formulation Suggest Similar Virologic Activity to Current ZERIT(R) Formulation: PRNewswire - March 1, 2002; PRINCETON, N.J., March 1 /PRNewswire-FirstCall/ -- Data presented this week at a major HIV medical meeting suggest that the investigational one- capsule, once-daily extended release formulation of Bristol-Myers Squibb s (NYSE: BMY) anti-HIV drug ZERIT(R) ( stavudine ) had similar virologic activity to the currently
Bristol-Myers Squibb Shows Strong Commitment to Virology R&D at Top HIV/AIDS Meeting: In-House Discovery of New Mechanism to Block HIV Entry Unveiled; Novel Protease-Inhibitor Continues To Show Safety And Efficacy In Clinical Trials: PRNewswire - February 28, 2002; SEATTLE, Feb. 28 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) demonstrated its strong commitment to virology with presentations on research from its discovery, clinical development and Phase IV development programs at a top HIV/AIDS meeting held this week in Seattle, Washington. Of particular note
Men of Color Face Health Crisis: PRNewswire - February 28, 2002; WASHINGTON, Feb. 28 /PRNewswire/ -- Because men from racial and ethnic minority populations face such a high risk of heart disease, diabetes, HIV/AIDS, and other conditions and often lack access to basic care, they are now experiencing a health care crisis, according to a report released today by Community Voices: Heal
Additional Data on REMUNE(R) From Spanish Phase II Trial STIR 2102 Presented At Ninth Conference on Retroviruses and Opportunistic Infections Immunologic Results Demonstrate Statistically Significant Restoration of Key Immune Function in HIV-Infected Patients: PRNewswire - February 28, 2002; CARLSBAD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today new data presented this week at the Ninth Conference on Retroviruses and Opportunistic Infections in Seattle. The results were presented by Dr. Fernandez-Cruz, principal investigator at University General
Achillion Pharmaceuticals Initiates Phase 2 Study of Lead Product Candidate in Hepatitis B Patients: PRNewswire - February 28, 2002; NEW HAVEN, Conn., Feb. 28 /PRNewswire/ -- Achillion Pharmaceuticals, a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative anti-infective agents, today announced the commencement of a Phase 2 clinical study with the Company s lead product candidate, ACH-126,44
Gen-Probe Receives FDA Biologics License Approval in United States for Nucleic Acid Blood Screening Test for HIV-1 and HCV: First Amplified Nucleic Acid Test for Blood Screening Approved in the U.S.: PRNewswire - February 28, 2002; SAN DIEGO, Feb. 28 /PRNewswire/ -- Gen-Probe Incorporated today announced that the U.S. FDA has approved its Biologics License Application (BLA) for its amplified nucleic acid test (NAT) to be used by blood banks to simultaneously detect human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). The comb
Chiron's Procleix(TM) HIV-1/HCV Assay Receives FDA Approval New System Further Ensures Safety of Blood Supply: PRNewswire - February 28, 2002; EMERYVILLE, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the Procleix(TM) HIV-1/HCV Assay for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). The nucleic acid amplification test (NAT)
Economic impact of HIV/AIDS: PRNewswire - February 27, 2002; Distributed by PR Newswire South Africa on behalf of United Democratic Movement The United Democratic Movement (UDM) would add its voice to that of businesses and companies who realise that the scourge of HIV/Aids has, and will exponentially more so, have an effect on the economic status of our country, companies and b
150 Ordinary People Take an Extraordinary 7-Day, 75-Mile Trek Through South Africa to Raise Awareness and Money for an AIDS Vaccine: African AIDSTrek April 2-8 Through Cederberg Wilderness Area in South Africa: PRNewswire - February 27, 2002; LOS ANGELES, Feb. 27 /PRNewswire/ -- African AIDSTrek participants gear up for a groundbreaking, 75-mile journey through South Africa as they do their part to make a difference in the fight against AIDS. For seven days, 150 individuals have dedicated their lives to the forgotten people of Africa, where it is estimated
'Breaking The Silence,' a Collection of Personal Stories by HIV-Positive Latinos and Latinas: AIDS Project Los Angeles Publishes Stories as HIV Prevention Effort: PRNewswire - February 27, 2002; LOS ANGELES, Feb. 27 /PRNewswire/ -- To address HIV disclosure and help prevent the spread of HIV in the Latino community, AIDS Project Los Angeles (APLA) recently published Breaking The Silence... Rompiendo El Silencio. The twenty stories in the booklet are self-authored accounts from Latino and Latina HIV/AIDS surviv
Of the President's Remarks on Abstinence FRC says, 'Well said, Mr. President!': PRNewswire - February 26, 2002; WASHINGTON, Feb. 26 /PRNewswire/ -- In announcing his proposal of $135 million for abstinence education programs, President Bush made the following statement today regarding the government s role in educating children about sex education: Abstinence is the surest way and the only completely effective way to prevent unw
AIDS Healthcare Foundation, America's Largest Provider of Specialized HIV/AIDS Medical Care, Says: 'GlaxoStallingKills!' AIDS Drugs for Africa and the World: GlaxoSmithKline (GSK) Urged to Lower the Price, Cut the Red Tape on Life-Saving AIDS Drugs - Over 8,500 AIDS Deaths Every Day Worldwide: PRNewswire - February 26, 2002; LOS ANGELES, Feb. 26 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest provider of specialized HIV/AIDS medical care, steps up the urgency of its public awareness campaign to try and get GlaxoSmithKline (GSK), one of the largest AIDS drug manufacturers in the world, to lower the prices and cut the
National AIDS Conference Confronts Prevention Politics, Highlights Critical Issues: PRNewswire - February 26, 2002; SAN FRANCISCO, Feb. 26 /PRNewswire/ -- The current controversy regarding the efficacy of HIV prevention programs is just one of the critical issues to be addressed at the 14th annual National HIV/AIDS Update Conference, sponsored by the American Foundation for AIDS Research (amfAR). The conference, to be held March 19-
Animal Study Suggests Intranasal Delivery of HIV-1 Antigen With Adjuvant May Induce Potent Immune Responses Capable of Protection Against Viral Challenge: PRNewswire - February 26, 2002; CARLSBAD, Calif., Feb. 26 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that data presented at the Ninth Conference on Retroviruses and Opportunistic Infections in Seattle on February 25, 2002 suggest that the Company s envelope depleted killed HIV-1 virus when combined with a
Progenics Selects Clinical Candidate for HIV Therapy: Humanized PRO 140 Antibody Blocks Viral Entry - Novel small-molecule inhibitors of CCR5-mediated HIV entry are also identified -: PRNewswire - February 26, 2002; SEATTLE, Feb. 26 /PRNewswire-FirstCall/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) has selected a humanized form of its PRO 140 antibody for clinical testing as a promising new HIV therapy. PRO 140 works by a novel mechanism not exploited by any of the currently approved HIV agents: it blocks CCR5, a receptor on
AnorMED leads in development of new class of small molecule HIV entry inhibitors: New Clinical Data Presented at 9th Retroviral Conference: Genetic Analysis Confirms Anti-HIV Activity of CXCR4 Inhibitor Drug Candidate: PRNewswire - February 25, 2002; VANCOUVER, Feb. 25 /PRNewswire-FirstCall/ - AnorMED Inc. (TSE:AOM) announced today that new clinical data presented at the 9th Retroviral and Opportunistic Infections conference in Seattle on February 25th are the first clinical proof of principle for CXCR4, a chemokine receptor, as a new target in the treatment of HIV
Experts Call for Improved Access to Healthcare for African-Americans With HIV/AIDS: PRNewswire - February 25, 2002; WASHINGTON, Feb. 25 /PRNewswire/ -- Leading healthcare, government and community leaders, today called for a renewed focus on programs which enhance clinical care for African-Americans with HIV/AIDS and increase awareness among clinicians, patients and caregivers about issues as they relate to this community. The most
AcroMetrix Announces First HCV Genotyping Proficiency Program for Molecular Diagnostics Laboratories: PRNewswire - February 25, 2002; ATLANTA, Global Odyssey 2002 International Proficiency Testing Conference, Feb. 25 /PRNewswire/ -- AcroMetrix Corporation announced today the introduction of the first comprehensive Hepatitis C Virus (HCV) Genotyping Proficiency Program available to molecular diagnostics laboratories. This newest addition to AcroMetrix
Sesame Workshop and Johns Hopkins University Center for Communication Programs Partner on Worldwide Health Initiative: PRNewswire - February 25, 2002; NEW YORK, Feb. 25 /PRNewswire/ -- Sesame Workshop, the non-profit organization that has created such beloved children s programs as Sesame Street, Dragon Tales, and Sagwa, The Chinese Siamese Cat, and Johns Hopkins University Center for Communication Programs (JHU/CCP), a pioneer in the field of strategic, research-bas
CytRx's Receives $1 Million Milestone Payment From Merck for TranzFect License: PRNewswire - February 25, 2002; ATLANTA, Feb. 25 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR) today announced that it has received a $1 million milestone payment due from Merck & Co. , Inc. pursuant to Merck s license of CytRx s TranzFect technology. CytRx s TranzFect technology is incorporated in an experimental DNA-based HIV vacci
The Weightman Group Named Agency-of-Record for Prevention Point Philadelphia: Weightman Will Create a Public Awareness Campaign to Encourage People Living With HIV/AIDS and Injection Drug Users to Seek Medical Care And Protect Themselves and One Another: PRNewswire - February 25, 2002; PHILADELPHIA, Feb. 25 /PRNewswire/ -- According to the Centers for Disease Control, injection drug use accounted for 49% of new HIV infections in Philadelphia in 1996. Of the 12,775 AIDS cases reported in the city through May 2000, 42% are injection drug use related, with Philadelphia s minority communities among the h
Panacos Pharmaceuticals Presents Data on Fusion Inhibitor Platform at Retrovirus Conference: PRNewswire - February 25, 2002; GAITHERSBURG, Md., Feb. 25 /PRNewswire/ -- Panacos Pharmaceuticals Inc. today announced that it has found evidence of new targets for HIV fusion inhibitor discovery. Fusion inhibitors block the first step in virus infection of human cells and represent one of the most exciting new areas for antiviral drug development.
AnorMED leads in development of new class of small molecule HIV entry inhibitors: PRNewswire - February 25, 2002; VANCOUVER - AnorMED Inc. (TSE:AOM) announced today that new clinical data presented at the 9th Retroviral and Opportunistic Infections conference in Seattle on February 25th are the first clinical proof of principle for CXCR4, a chemokine receptor, as a new target in the treatment of HIV. Results presented demonstrate
Experts Call for Improved Access to Healthcare for African-Americans With HIV/AIDS: PRNewswire - February 25, 2002; WASHINGTON -- Leading healthcare, government and community leaders, today called for a renewed focus on programs which enhance clinical care for African-Americans with HIV/AIDS and increase awareness among clinicians, patients and caregivers about issues as they relate to this community. The most recent figures availab
Bill Gates Announces Foundation Visit To Africa With The Carter Center To Highlight Need For Increased Financing and Comprehensive Strategies To Fight HIV/AIDS: PRNewswire - February 24, 2002; SEATTLE, Feb. 24 /PRNewswire/ -- Bill Gates announced today, at the Conference on Retroviruses and Opportunistic Infections, an upcoming trip to Africa by the Bill & Melinda Gates Foundation and The Carter Center that is intended to draw attention to the urgent need for comprehensive strategies to fight HIV/AIDS. T
Progenics Initiates Phase IIb Clinical Study of Investigational Drug To Reverse Side Effects of Opioid Pain Therapy - Methylnaltrexone being tested to relieve debilitating constipation in cancer patients: PRNewswire - February 22, 2002; TARRYTOWN, N.Y., Feb. 22 /PRNewswire-FirstCall/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported today that it has initiated a Phase IIb clinical trial of its investigational drug methylnaltrexone (MNTX) for the reversal of narcotic-induced constipation, a debilitating problem for many patients treated with o
Trevor Manuel says nevirapine is too expensive: PRNewswire - 22 February 2002; The United Democratic Movement Youth Vanguard (UDMYV) hopes that the Minister of Finance s, Trevor Manuel, warning that the cost of nationally providing Nevirapine would use up the entire health budget, would not be used as an excuse not to do so at all. The UDMYV recalls offers from international companies and other d
BTG Acquires New Class of Compounds with Potent Activity Against HIV: PMS 601 provides novel approach to fighting HIV with the potential to improve the effects of other existing therapies: PRNewswire - February 21, 2002; WEST CONSHOHOCKEN, Pa., Feb. 21 /PRNewswire-FirstCall/ -- Expanding its development pipeline, BTG (LSE: BGC), the global technology commercialization company, has acquired a new class of drug candidates targeted to treat advanced and chronic HIV infection. Preclinical studies have demonstrated that PMS 601, the lead ca
AIDSRidesUSA Kicks Off 2002 Season By Signing Up Over 4500 Riders Across America - Thousands of People to Raise Money and Awareness For Access to Care and Education for HIV/AIDS -: PRNewswire - February 20, 2002; LOS ANGELES, Feb. 20 /PRNewswire/ -- AIDSRidesUSA event organizers Pallotta TeamWorks today announced that over 4500 people have signed up for the 2002 AIDSRidesUSA events, which raise money and awareness for HIV/AIDS. Since the inaugural fundraising ride in 1994, over 60,000 men and women have participated in 51 event
The Weightman Group Named Agency-of-Record for Prevention Point Philadelphia: Weightman Will Create a Public Awareness Campaign to Encourage People Living With HIV/AIDS and Injection Drug Users to Seek Medical Care And Protect Themselves and One Another: PRNewswire - February 20, 2002; PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to the Centers for Disease Control, injection drug use accounted for 49% of new HIV infections in Philadelphia in 1996. Of the 12,775 AIDS cases reported in the city through May 2000, 42% are injection drug use related, with Philadelphia s minority communities among the h
Pharmacyclics Announces Publication of Preclinical Study Results Indicating Xcytrin May Inhibit HIV: PRNewswire - February 19, 2002; SUNNYVALE, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that preclinical study findings published in this week s issue of the Proceedings of the National Academy of Sciences of the United States of America provide evidence that Xcytrin(R) (motexafin gadolinium, a.k.a., ga
Secretary of State Says Condom Use Saves Lives; Powell Strays From Conservative Dogma and Encourages Sexually Active Youth to Use Condoms: PRNewswire - February 15, 2002; WASHINGTON, Feb. 15 /PRNewswire/ -- The National Youth Advocacy Coalition today praises Secretary of State Colin L. Powell for remarks he made last night to teenagers worldwide supporting the use of condoms in preventing HIV infection among sexually active youth. In my own judgment, condoms are a way to prevent infecti
Comprehensive National Resource Center Launched at AdolescentAIDS.org To Confront Mounting Crisis of HIV/AIDS in Urban Youth - Offers Proven Tools for Providers, Community and Youth on HIV Prevention, Testing, Treatment and Research, Including 3rd Annual Teen Zine, The Deal -: PRNewswire - February 15, 2002; NEW YORK, Feb. 15 /PRNewswire/ -- To draw attention to the growing epidemic of HIV/AIDS in young people, the Adolescent AIDS Program (AAP) at Children s Hospital at Montefiore Medical Center in the Bronx, New York has launched a comprehensive online resource center addressing youth and HIV/AIDS. The online launch coinc
Condoms, a red herring in the HIV/AIDS controversy: PRNewswire - February 14, 2002; Cheryllyn Dudley MP for the African Christian Democratic Party and Member of the Health Portfolio Committee today said, the planned increase in distribution of free condoms, which will cost tax payers 250 million a year, can only be described as a red herring and abuse of public funds. Responding to reports that the He
Antibacterial, Antifungal, & Antiviral Drug Discovery Conferences To Take Place March 11-14, 2002 in Princeton, NJ: PRNewswire - February 14, 2002; PRINCETON, N.J., Feb 14 /PRNewswire/ -- The World Antibacterial, Antifungal, & Antiviral research communities will convene in Princeton, NJ this coming March to attend the 7th Antibacterial Drug Discovery & Development Summit on March 11-12, and the 6th Antifungal Drug Discovery & Development Summit and 3rd
Be Heard: An MTV Global Discussion With Colin Powell: PRNewswire - February 14, 2002; MTV Audiences in the US, India , the Middle East, Italy , UK/ Ireland , Brazil and Russia Ask U.S. Secretary of State Colin Powell Questions About War On Terrorism and Other Global Issues &
Ciphergen Signs CRADA With the NIAID for AIDS Research: PRNewswire - February 14, 2002; FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH) announced today that it has signed a Collaborative Research and Development Agreement (CRADA) with the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases. The CRADA will focus on The Dis
Ciphergen and Aaron Diamond AIDS Research Center Announce Drug Discovery Research Collaboration: PRNewswire February 14, 2002; FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH) announced today that it has signed a Research and License Agreement with the Aaron Diamond AIDS Research Center (ADARC). This agreement contains detailed workplans to pursue projects related to discoveries and samples provided
National Condom Week 2002 - 'A Year of Condoms Sweepstakes': Mayer Laboratories, Inc. Sponsors Pleasure and Protection: PRNewswire - Februayr 14, 2002; SAN FRANCISCO, Feb. 14 /PRNewswire/ -- Aggressive AIDS Prevention, Inc., with the corporate sponsorship of Mayer Laboratories, Inc., is holding a Sweepstakes with prizes of a years supply of Kimono and MAXX brand premium latex male condoms and Aqua Lube personal lubricant during National Condom Week. National Condom We
New Web Site Launches to Combat World Poverty and Improve Delivery of International Aid: PRNewswire - February 13, 2002; WASHINGTON, Feb. 13 /PRNewswire/ -- A new internet platform was launched today that will act as a powerful tool in the fight against world poverty and cut costs and improve targeting of international assistance. DevelopmentSpace, a service of ManyFutures, Inc., was switched on today, opening avenues for effective inter
Top Photojournalists to Digitally Document Africa: Olympus Supports Predominantly Digital 'A Day in the Life of Africa(R)' By Providing Digital Training and Cameras: PRNewswire - February 13, 2002; MELVILLE, New York, Feb. 13 /PRNewswire/ -- On February 28, 2002, 100 of the world s foremost photojournalists, representing 21 countries, will take part in one of the most ambitious photographic projects ever attempted: they will fan out across 53 nations to capture the entire African continent on a single day. The be
Serono Launches SeroJet(TM) Needle-Free Device to Deliver Serostim(R) Human Growth Hormone: SeroJet(TM) eliminates risk of accidental needle-stick injuries and provides patients with an alternative to traditional needles and syringes: PRNewswire - February 12, 2002; ROCKLAND, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Serono, Inc. today announced the US launch of SeroJet(TM)(1), a needle-free option for delivering Serostim(R) [somatropin (rDNA origin) for injection], the company s recombinant human growth hormone (rHGH). Serono (SWX Swiss Exchange: SEO & NYSE: SRA) is the only c
CytRx's Tranzfect Technology Enters Phase I Clinical Trials As Part of Merck's HIV Vaccine Research Program: PRNewswire - February 12, 2002; ATLANTA, Feb. 12 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR) today announced that its TranzFect technology is incorporated in an experimental DNA-based HIV vaccine being developed by Merck & Co. , Inc. (NYSE: MRK) that has now entered Phase I clinical trials. Merck scientists hope the clinical trials
ViroLogic Enters Agreement With Panacos Pharmaceuticals to Evaluate New HIV Drugs: PRNewswire - February 12, 2002; SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced an agreement with Panacos Pharmaceuticals, a privately held pharmaceutical company, to utilize ViroLogic s drug resistance assays in the pre-clinical evaluation of Panacos lead HIV drug candidates. Under the te
Equip for Equality Is New Resource for Illinois Social Security: Beneficiaries Trying to Get Work or Return to Work: Ticket to Work Program Underway: PRNewswire - February 8, 2002; CHICAGO, Feb. 8 /PRNewswire/ -- Equip for Equality (EFE) has launched a new project called Protection and Advocacy for Beneficiaries of Social Security (PABSS), a federally funded initiative to provide advice to Social Security beneficiaries on their rights to obtain or return to work, as well as advocacy services on t
From West Nile Virus to Lyme Disease, from HIV to Anthrax, Science Writer Madeline Drexler Investigates Mother Nature's Deadly Bioweapons: PRNewswire - February 7, 2002; WASHINGTON, Feb. 7 /PRNewswire/ -- Our country s biggest threat isn t bioterrorism, according to science writer Madeline Drexler. Even worse than the possibility of a large-scale bioterrorism attack is the reality of Mother Nature, who brews up daily her own batch of crafty and deadly bioweapons -- West Nile virus, HIV
ViroLogic Announces Agreement With Achillion Pharmaceuticals to Evaluate Novel Next-Generation Anti-Hepatitis and HIV Agents: PRNewswire - February 7, 2002; SOUTH SAN FRANCISCO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- ViroLogic, Inc. today announced an agreement with Achillion Pharmaceuticals, a privately held pharmaceutical company, to utilize ViroLogic s drug resistance assays to evaluate Achillion s lead product candidate, ACH-126,443 (Beta-L-Fd4C), an L-nucleoside in
TheBody.com Spotlights Hidden HIV/AIDS Epidemic in U.S. Women; As AIDS Incidence Triples, Women Experience Unique Difficulties With Treatment: PRNewswire - February 7, 2002; NEW YORK, Feb. 7 /PRNewswire/ -- TheBody.com, the leading HIV/AIDS information resource on the Internet, has released an in-depth assessment of women and HIV in the United States . Overwhelmingly poor, and with 60% caring for at least one child under the age of 16, women with HIV are the fastest-growing population in t
World Leaders Address Dual Challenges of an AIDS Vaccine Acceleration of Science and Development of Access Systems Are Focus of World Economic Forum Workshop: PRNewswire - February 6, 2002; NEW YORK, Feb. 6 /PRNewswire Asia/ -- The global search to develop and distribute a vaccine to prevent AIDS was the focus of a high-level workshop, sponsored by the World Economic Forum s Global Health Initiative (GHI). In attendance were business leaders from such diverse sectors as the pharmaceutical, finance, media
Free Tickets Available to World Premiere Screening of 'living with mimi': Bi-Racial HIV Love Story With a MTV Style Edge to Debut at 4th Annual Hollywood Black Film Festival: PRNewswire - February 5, 2002; SAN DIEGO, Feb. 5 /PRNewswire/ -- Guerilla FilmWorks and The Navajoblack Company are pleased to announce that their first co-production and feature film, living with mimi, will have its world premiere at the Hollywood Black Film Festival 2002 which selected the film as one of 20 feature finalists. Living with mimi will
World Leaders Address Dual Challenges of an AIDS Vaccine Acceleration of Science and Development of Access Systems Are Focus of World Economic Forum Workshop: PRNewswire - February 5, 2002; NEW YORK, Feb. 5 /PRNewswire/ -- The global search to develop and distribute a vaccine to prevent AIDS was the focus of a high-level workshop, sponsored by the World Economic Forum s Global Health Initiative (GHI). In attendance were business leaders from such diverse sectors as the pharmaceutical, finance, media and m
GenVec Signs $10 Million Contract for Development of Preventative AIDS Vaccine: GenVec's Proprietary Adenovector Technology Selected From Nationwide Solicitation: PRNewswire - February 5, 2002; GAITHERSBURG, Md., Feb. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has signed a contract with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under which GenVec will use its proprietary adeno
CMMB Program Opens at St. Mary's Hospital in South Africa for Prevention of Mother-to-Child Transmission of HIV/AIDS: PRNewswire - February 5, 2002; MARIANNHILL, South Africa , Feb. 5 /PRNewswire/ -- Catholic Medical Mission Board (CMMB), a nongovernmental organization which operates healthcare programs and related support in developing nations, expands its fight against AIDS with the official launch here February 11 of the first of at least three clinics in South
$31.5 Billion HUD Budget Expands Homeownership Opportunities, Rental Assistance and Economic Development: PRNewswire - February 4, 2002; WASHINGTON, Feb. 4 /PRNewswire/ -- President Bush s proposed Fiscal Year 2003 budget includes $31.5 billion for the Department of Housing and Urban Development to help more Americans become homeowners, to provide additional rental assistance, to protect vulnerable people, and to stimulate economic development and job g
Bristol-Myers Squibb Announces Approval of New One Tablet, Once-Daily Formulation of SUSTIVA(R): Reduction in Pill Burden in Regimens Containing SUSTIVA Tablets: PRNewswire - February 4, 2002; PRINCETON, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE: BMY) today announced the approval in the US of a new one-tablet 600 mg formulation of its widely used once-daily anti-HIV drug SUSTIVA(R) ( efavirenz ). SUSTIVA is a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used
National Black HIV/AIDS Awareness Day, Thursday, February 7; Studies Show 30% of Young, Black, Gay Men Are HIV-Infected: PRNewswire - February 4, 2002; LOS ANGELES, Feb. 4 /PRNewswire/ -- On National Black HIV/AIDS Awareness Day, Thursday, February 7, AIDS Project Los Angeles will join concerned communities and AIDS advocates across the nation in calling attention to the HIV/AIDS state of emergency in the black community. AIDS is the leading killer of African-American
CEL-SCI Corporation Releases Letter to Shareholders: PRNewswire - February 4, 2002; VIENNA, Va., Feb. 4 /PRNewswire-FirstCall/ -- The following letter is being sent by CEL-SCI CORPORATION (Amex: CVM) to its shareholders as part of the Annual Report: Dear Fellow Shareholders: This past year has provided CEL-SCI Corporation with remarkable new clinical data that could help us become uniquely positioned
Berna Biotech Teams With IAVI, Gallo Lab, Uganda to Test AIDS Vaccine Designed For Developing Countries: Novel Vaccine Candidate Can Be Administered Orally; Expected to be Inexpensive To Manufacture, Easy to Store and Transport: PRNewswire - February 4, 2002; BERNE, Switzerland , and NEW YORK, Feb. 4 /PRNewswire/ -- Swiss vaccine manufacturer Berna Biotech Ltd. has joined a cross-national team to test a new vaccine to prevent HIV infection and AIDS designed specifically for use in developing countries. Berna will produce doses of the vaccine for human trials starting this y
World Economic Forum CEOs Call for Greater Corporate Engagement Against HIV/AIDS, TB and Malaria: PRNewswire - February 2, 2002; NEW YORK, Feb. 2 /PRNewswire/ -- The member companies of the World Economic Forum s Global Health Initiative (GHI) today joined with global health leaders and issued a call to the business leaders of the world to increase their efforts in the fight against HIV/AIDS, TB and malaria. Business leaders Raymond Gilmartin, C
Bill Gates, Bono Call on Leaders at World Economic Forum To Increase Global Health Spending: Bill & Melinda Gates Foundation Announces $50 Million In HIV/AIDS Prevention Grants: PRNewswire - February 2, 2002; NEW YORK, Feb. 2 /PRNewswire/ -- Addressing leaders at the World Economic Forum (WEF) in his capacity as co-founder of the Bill & Melinda Gates Foundation, Bill Gates, joined by pop star Bono of U2, today called on government, industry and not-for-profit organizations to substantially increase and sustain developme
Start of First Clinical Trial With GlaxoSmithKline Biologicals' Novel HIV Vaccine: The First Human Trial With GlaxoSmithKline Biologicals' (GSK Biologicals) Candidate HIV Vaccine Will Test Whether the Vaccine, Which Prevented AIDS In Rhesus Monkeys, is Safe and Immunogenic in Humans: PRNewswire - January 31, 2002; RIXENSART, Belgium , Jan. 31 /PRNewswire-FirstCall/ -- Today, GlaxoSmithKline Biologicals (GSK Biologicals) announces the start of the first trial in humans of its recombinant, adjuvanted candidate HIV vaccine -- NefTat and gp 120 formulated with the proprietary adjuvant AS02. The main objectives are to see if the can
PPD Discovery Regains Rights to Targets for Anti-HIV Drugs: Provides Pipeline of Intellectual Property: PRNewswire - January 30, 2002; WILMINGTON, N.C., Jan. 30 /PRNewswire-FirstCall/ -- PPD Discovery, the drug discovery technology subsidiary of PPD, Inc. (Nasdaq: PPDI), today announced that it has regained full research, development and licensing rights to its targets for therapeutic agents against Human Immunodeficiency Virus (HIV), following a deci
Epimmune Receives Notice of Allowance for Patent to Core Epitope Identification Technology: Patent Covers ImmunoStealth(TM) Technology Which Can Be Used to Identify And Potentially Remove Unwanted Side Effects From Protein-Based Healthcare And Consumer Products: PRNewswire - January 30, 2002; SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering core technology for the identification and enhancement or elimination of epitopes (protein fragments) responsible for activating a class
Journal Articles Highlight Clinical Use of Progenics' Investigational Drug in Reversing Opioid Side Effects - Company Advancing Methylnaltrexone Into Late-Stage Clinical Development: PRNewswire - January 30, 2002; TARRYTOWN, N.Y., Jan. 30 /PRNewswire-FirstCall/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the publication of two scientific articles that underscore the clinical utility of its investigational drug, methylnaltrexone (MNTX), in reversing a wide range of side effects caused by opioid pain therapy.
Keryx Biopharmaceuticals to Initiate Phase II Clinical Trial of KRX-101 for The Treatment of AIDS Related Kidney Disease - HIV Associated Nephropathy (HIVAN): HIVAN is a Life-Threatening Complication of AIDS: PRNewswire - January 29, 2001; CAMBRIDGE, Mass. and JERUSALEM, Israel , Jan. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that it has received approval from the South African Medicines Control Council for the initiation of a Phase II clinical trial of Keryx s investigational drug candidate KRX-101 (sulodexide) for the
Epimmune Provides HIV Vaccine Program Update: PRNewswire - January 29, 2002; SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- Epimmune Inc. today provided an update on the status of its initial HIV vaccine candidate including clinical trial plans. The Company stated that, as additional time is necessary to complete all of the animal safety studies that were contemplated in its pre-IND discussions w
UNICEF Africa Named Beneficiary Of Africamix Traveling Arts and Music Festival: PRNewswire - January 28, 2002; SACRAMENTO, Calif., Jan. 28 /PRNewswire/ -- Africamix, a California-based nonprofit organization announced today that UNICEF Africa will be a primary beneficiary of its traveling arts and music festival organized to help combat child abuse and neglect. The volunteer-organized and oriented festival is scheduled to visit
Achillion Pharmaceuticals Raises $41 Million In A Private Placement Funding to Support Continued Lead Clinical Program, Advancement of Pipeline Compounds and Technology Platform: PRNewswire - January 28, 2002; NEW HAVEN, Conn., Jan. 28 /PRNewswire/ -- Achillion Pharmaceuticals, a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative anti-infective agents, today announced that it has closed a $41 million private round of financing, placing its preferred stock to a sele
AIDS Project Los Angeles Wary of New Leadership and Composition of President Bush's Council on HIV/AIDS: PRNewswire - January 25, 2002; LOS ANGELES, Jan. 25 /PRNewswire/ -- AIDS Project Los Angeles (APLA) reacted with concern about the anticipated appointment of former Representative Tom Coburn (R-Oklahoma) as co-chair of the President s Advisory Council on HIV/AIDS (PACHA). In November, President Bush appointed Patricia Funderburk Ware, another conser
Former FDA Chief, Dr. David A. Kessler to Chair The Elizabeth Glaser Pediatric AIDS Foundation Board of Directors: Prominent Pediatrician Will Lead Foundation's Efforts to Improve the Lives Of Children Worldwide Through Pediatric Research, Training and Advocacy: PRNewswire - January 24, 2002; SANTA MONICA, Calif., Jan. 24 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced the election of former FDA Commissioner David A. Kessler, M.D. to chair its Board of Directors today. Philip A. Pizzo, M.D., another nationally renowned pediatrician, has been named vice chairman. Trained as a ped
Merck Publishes HIV Studies Utilizing CytRx's Tranzfect Technology; Results of Preclinical Studies Appear in the Science Journal Nature: PRNewswire - January 24, 2002; ATLANTA, Jan. 24 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR) today announced that scientists from Merck & Co. , Inc. published results in the science journal Nature on their vaccine research program against HIV which utilized CRL-1005, a component of CytRx s TranzFect technology. In November 2000 Me
Caring Together Is a New Partnership Which Benefits HIV/AIDS Patients: PRNewswire - January 24, 2002; YORK, Pa., Jan. 24 /PRNewswire/ -- Caring Together is a new partnership among WellSpan Health, York Health Corporation, and OPEN (Ordinary People Extraordinary Needs). It provides a coordinated system of care for patients living with HIV and AIDS. John McConville, M.D., chairman, Department of Medicine, York Hospital,
Bill & Melinda Gates Foundation Awards Three-Year Grant to AIDS Vaccine Advocacy Coalition (AVAC): AVAC Announces Appointment of New Executive Director: PRNewswire - January 23, 2002; WASHINGTON, Jan. 23 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced a grant of $600,000 over three years to the AIDS Vaccine Advocacy Coalition (AVAC). Founded in 1995, AVAC is a consumer-based advocacy organization working to speed development and delivery of AIDS vaccines to populations throug
AIDS Project Los Angeles and Pallotta Teamworks Announce Statewide Beneficiaries for Ninth Annual California AIDSRide: PRNewswire - January 22, 2002; LOS ANGELES, Jan. 22 /PRNewswire/ -- AIDS Project Los Angeles (APLA) and Pallotta Teamworks, originator and producer of California AIDSRide, today announced the lead beneficiaries of California AIDSRide 9. For the first time ever, California AIDSRide will benefit HIV/AIDS charities throughout California, opening up fun
VA Launches Four Hepatitis C Centers: PRNewswire - January 18, 2002; WASHINGTON, Jan. 18 /PRNewswire/ -- In its continuing efforts to provide care to more than 80,000 veterans infected with hepatitis C, the Department of Veterans Affairs (VA) on Jan. 1, 2002, funded four new centers to evaluate and improve hepatitis C screening, testing, clinical care and education. These new centers wi
New Research Includes Use of Vical's 'Naked DNA' Technology for HIV Vaccine: PRNewswire - January 18, 2002; SAN DIEGO, Jan. 18 /PRNewswire-FirstCall/ -- Research results published in the scientific journal Nature describe the use of the Vical Incorporated (Nasdaq: VICL) naked DNA technology in the ongoing efforts to develop a vaccine to combat human immunodeficiency virus (HIV). The report in Nature described studies conduct
`Play for Life' Kicks Off in Four African Countries Along With Africa's Largest Sporting Event, The Cup of Nations: HIV/AIDS Prevention Campaign Focuses on Soccer Players, Fans: PRNewswire - January 18, 2002; BALTIMORE, Jan. 18 /PRNewswire/ -- When Africa s equivalent of the Super Bowl kicks off this weekend, millions of young male soccer fans will be urged also to Play for Life and prevent HIV/AIDS infection. The Play for Life/Jouer pour La Vie campaign will be officially launched Saturday as the 23rd African Cup of Nation
Triangle Pharmaceuticals Plans 3rd Quarter 2002 NDA Submission for Coviracil(R) (emtricitabine) and Discontinues Development of Coactinon(R) (emivirine): PRNewswire - January 17, 2002; DURHAM, N.C., Jan. 17, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today provided updated information on the development of two of its HIV compounds, Coviracil and Coactinon. Following recent discussions with the FDA , Triangle now plans to submit a New Drug Application (NDA) early this
Panacos Pharmaceuticals Appoints Dr. David E. Martin as Vice President, Drug Development: PRNewswire - January 17, 2002; GAITHERSBURG, Md., Jan. 17 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced the appointment of David E. Martin, PharmD to the position of Vice President, Drug Development. Dr. Martin joins Panacos from Bristol-Myers Squibb (formerly Dupont Pharmaceuticals) where he worked from 1999, most recently as Direct
African Diaspora HIV/AIDS Summit for Faith Leaders January 16-20, 2002: The Balm in Gilead to Host Historical African Diaspora Faith Leaders HIV/AIDS Summit: PRNewswire - January 15, 2002; NEW YORK, Jan. 15 /PRNewswire/ -- More than 60 religious leaders from Africa, the Caribbean and the United States are attending the first African Diaspora HIV/AIDS Summit this week to discuss the impact of AIDS throughout the African Diaspora. This historical conference will convene the religious heads to examine the c
MTV Channels Around the World Including the United States, India, The Middle East, Italy, UK/Ireland, Brazil and Russia Host Global Forum with U.S. Secretary of State Colin Powell: Young People From Around the World Get to Ask Secretary Powell Questions About War on Terrorism and Other Global Issues: PRNewswire - January 14, 2002; PASADENA, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Judy McGrath, President, MTV Group and Chairman, Interactive Music, MTV: Music Television and Bill Roedy, President, MTV Networks International, announced today that U.S. Secretary of State Colin Powell will participate in an international Global Forum with young adul
Co-op Solutions for More Prosperous & Peaceful World: PRNewswire - January 11, 2002; WASHINGTON, Jan. 11 /PRNewswire/ -- The U.S. Government recently issued a report that implements the Support for Overseas Cooperative Development Act. This report sets a new agenda for overseas cooperative development. The implementation plan is the most significant cooperative development event in forty years, said T
Governor Davis Announces State Budget Proposal; AIDS Project Los Angeles Hopeful About HIV/AIDS Programs: PRNewswire - January 10, 2002; LOS ANGELES, Jan. 10 /PRNewswire/ -- AIDS Project Los Angeles (APLA) applauds Governor Gray Davis commitment to HIV/AIDS programs reflected in his budget proposal for fiscal year (FY) 2002 - 2003. Considering the tough economic situation the State of California faces, this budget offers much hope for people living with
New Trial Seeks to Find a SMARTer Way to Treat HIV: PRNewswire - January 10, 2002; WASHINGTON, Jan. 10 /PRNewswire/ -- The Community Programs for Clinical Research on AIDS (CPCRA) announces the start of the SMART Study (Strategies for Management of Anti-Retroviral Therapy). The study is being carried out by 16 units in the CPCRA, 5 other sites in the United States , and sites in
GenVec, Inc. and National Institute of Allergy and Infectious Diseases To Develop Preventative AIDS Vaccine: Relationship Includes CRADA and Federally Funded Letter Contract: PRNewsire - January 10, 2002; GAITHERSBURG, Md., Jan. 10 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has signed a Letter Contract authorizing it to commence work for the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) using GenVec s propr
Presentation on CEL-SCI's Multikine(TM) Drug to Be Presented At the Society of Gynecologic Oncologists Annual Meeting: PRNewswire - January 9, 2002; VIENNA, Va., Jan. 9 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announces that a presentation on CEL-SCI s immunotherapy drug, Multikine, by scientists from The Institute of Human Virology (IHV) at the University of Maryland, Baltimore, was accepted at the Society of Gynecologic Oncologists (SGO) Annual Meeting in
Dr. Sandra Lehrman Joins Panacos Pharmaceuticals' Board of Directors: PRNewswire - January 9, 2002; GAITHERSBURG, Md., Jan. 9 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced the appointment of Sandra Nusinoff Lehrman, M.D. to its Board of Directors. Dr. Lehrman has more than 18 years experience in senior executive management within the pharmaceutical and biotechnology industries, most recently as Presid
ICN Pharmaceuticals Files Viramidine IND: PRNewswire - January 7, 2002; COSTA MESA, Calif., Jan. 7 /PRNewswire/ -- ICN Pharmaceuticals, Inc. (NYSE: ICN) announced today that an Investigational New Drug Application (IND) has been submitted to the U.S. Food and Drug Administration ( FDA ) to begin clinical testing of ICN s nucleoside analog viramidine for the combination treatment of chronic
Lilly and Vertex Pharmaceuticals Select Novel Oral Anti-Hepatitis C Compound: First Announcement of Hepatitis C Protease Inhibitor Designated as Development Candidate: PRNewswire - January 7, 2001; INDIANAPOLIS, Ind. and CAMBRIDGE, Mass., Jan. 7 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have selected LY570310 (VX-950), a novel small molecule protease inhibitor for the potential treatment of hepatitis C virus (HCV) infection,
CEL-SCI Corporation Releases Letter to Shareholders: PRNewswire - January 7, 2002; VIENNA, Va., Jan. 7 /PRNewswire/ -- Maximilian de Clara, President of CEL-SCI Corporation (Amex: CVM), and Geert Kersten, Chief Executive Officer of CEL-SCI Corporation, sent the following letter to CEL-SCI s shareholders: Recently, we have experienced a remarkable new discovery with our immunotherapy drug, Multikine(T
Data from New Assay Suggest VaxGen's AIDS Vaccine Induces Broad Immune Response to HIV Subtypes: Findings Reported in the Journal Vaccine: PRNewswire - January 7, 2002; BRISBANE, Calif., Jan. 7 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that the journal Vaccine has published findings suggesting that the company s HIV/AIDS vaccine, AIDSVAX B/B, induces antibodies to the five most common HIV subtypes. The article, by Sandra A. Lee et al. at VaxGen (Vaccine 20 (2002) 53
Governor Davis's Administration Announces Proposed Definition of HIV/AIDS Specialist - AIDS Project Los Angeles Statement: PRNewswire - January 6, 2002; LOS ANGELES, Jan. 6 /PRNewswire/ -- AIDS Project Los Angeles (APLA) is pleased with the definition of an HIV Specialist proposed by Governor Gray Davis and the California Department of Managed Health Care today. On October 14, 2001, Governor Gray Davis directed the California Department of Managed Health Care to fully
Stressgen announces issuance of U.S. patent solidifying its heat shock protein-based technology platform: Fusion Patent Relates to Heat Shock Proteins and Methods of Modulating a Patient's Immune Response to Treat Diseases: PRNewswire - January 4, 2002; SAN DIEGO, CA, Jan. 4 /PRNewswire/ - Stressgen Biotechnologies Corporation (TSE:SSB) announced today that the U.S. Patent and Trademark Office had issued Patent Number 6,335,183, for which the Company has an exclusive worldwide license from the Whitehead Institute for Biomedical Research. The patent grants exclusivity
'Survivor: Africa' Joins the Elizabeth Glaser Pediatric Aids Foundation To Highlight the Global HIV/AIDS Pandemic: PRNewswire - January 3, 2002; SANTA MONICA, Calif., Jan. 3 /PRNewswire/ -- Mark Burnett, the executive producer of Survivor: Africa, has partnered with the Elizabeth Glaser Pediatric AIDS Foundation to highlight the global HIV/AIDS epidemic and the work the Foundation is doing to prevent mother-to-child transmission (MTCT) of HIV. This ongoing comm
Lynx Enters AIDS Research Collaboration With Dana-Farber Cancer Institute: PRNewswire - January 3, 2002; HAYWARD, Calif., Jan. 3 /PRNewswire/ -- Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today an AIDS research collaboration with Dana-Farber Cancer Institute (DFCI). The goal of this research collaboration with Wayne A. Marasco, M.D., Ph.D., a leading AIDS researcher, is to identify cellular targets that could be use

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2002. AEGiS.